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ABBREVIATIONS 
CEF  Cyclophosphamide, epirubicine, fluorouracil 
CMF Cyclophosphamide, methotrexate, 
fluorouracil 
DBCG Danish Breast Cancer Cooperative Group 
EORTC European Organization for Research and 
Treatment of Cancer 
EORTC QLQ-C30 EORTC Quality of Life Questionnaire-Core-30 
HADS/HAD Scale Hospital Anxiety and Depression Scale 
HRQL Health-related quality of life 
OS Overall survival 
RFS Recurrence-free survival 
1. BACKGROUND AND INTRODUCTION 
A cancer diagnosis has tremendous consequences for most per-
sons who experience it. In the case of breast cancer the initial 
treatment usually consists of surgery, and after the operation 
many patients are recommended one or more additional treat-
ments including radiotherapy, chemotherapy, and hormonal 
treatment. All these factors may, of course, impact the patients’ 
quality of life.  
This thesis deals with the scientific challenges and clinical results 
of a study aiming at assessing the impact of breast cancer and its 
treatment on the patients’ quality of life.  
Studies of the nature, prevalence, and intensity of problems and 
symptoms experienced by the patients are often referred to as 
health-related quality of life (HRQL) research.  
HRQL research deals with subjective experiences and poses many 
challenging scientific questions. Therefore, in the clinically moti-
vated study reported here much attention was directed towards 
methodological issues. 
1.1  Epidemiology of breast cancer 
Breast cancer is the most common cancer in women and the 
incidence of the disease has been increasing for several years. In 
2003 breast cancer was diagnosed in 4,044 women in Denmark 
[1] and in 2005 breast cancer accounted for the death of 1,255 
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women [2]. A woman living in Denmark has an 8.9% risk of breast 
cancer [3]. Breast cancer is rare in men: the prevalence is less 
than 1/100 of the prevalence in women, corresponding to about 
30 new cases per year [1]. Most women diagnosed with breast 
cancer have ‘locoregional disease’ (as opposed to metastatic 
disease) meaning that the disease is still ‘local’ or ‘regional’; there 
is no evidence of distant metastases. This does not, of course, 
preclude that there may be microscopic metastases.  
This thesis deals with locoregional breast cancer in women.  
1.2  Treatment of breast cancer 
The treatment of primary, locoregional breast cancer consists of 
surgery with or without additional adjuvant therapy. Surgery is 
performed to remove the breast tumour and metastases in local 
lymph nodes, and involves either tumourectomy (also called 
lumpectomy) or mastectomy (removal of the breast). Surgery is 
the most important part of the treatment of breast cancer.  
Adjuvant therapy has the aim of curing some patients who would 
otherwise die from recurrence of breast cancer or delaying such 
recurrence. Clearly, there is no point in giving adjuvant therapy if 
the patient has already been cured via the operation. Therefore, 
the need for adjuvant therapy is elucidated by examination of a 
number of prognostic factors. During the last decades the prog-
nostic factors used most widely have been metastatic spread to 
the axilla, tumour size, the tumour’s content of hormonal recep-
tors, and its malignancy. Patients who based on these variables 
have been classified as being at low risk of recurrence have not 
been offered any adjuvant therapy whereas high-risk patients 
have been offered such treatment. 
Adjuvant therapy includes local radiotherapy against the breast 
area [4] and systemic treatments against (micro)metastases, 
which may have spread in the body. Systemic adjuvant therapy 
includes endocrine therapy (treatments aimed at suppressing the 
effect of oestrogen), chemotherapy (cytotoxic drugs, often given 
in combination) and, relatively recently, monoclonal antibodies 
such as trastuzumab [5-7]. In some instances neo-adjuvant ther-
apy has been used before surgery but usually adjuvant therapy is 
given after the operation. 
A range of clinical and pathological variables are used to guide the 
choice of adjuvant therapy, including the tumour’s hormone 
receptor status, and HER-2 protein, and whether the woman is 
premenopausal or postmenopausal. 
Around 1990, when this study was initiated, the value of combi-
nation chemotherapy was well proven [8]. In Denmark the com-
bination CMF (cyclophosphamide, methotrexate, fluorouracil) 
was considered the standard therapy, mainly for premenopausal 
women at high risk of recurrence [9]. In other parts of the world 
alternative combinations, mainly those including anthracyclines, 
were considered the standard. Postmenopausal women at high 
risk of recurrence were generally offered tamoxifen although sub-
groups were offered chemotherapy.  
Changes in chemotherapy since the initiation of the DBCG 89 
Program [9] will be discussed in the two chapters dealing with 
chemotherapy studies.  
The treatment of primarily metastatic breast cancer and recur-
rent breast cancer is different from that of primary locoregional 
breast cancer and is outside the scope of this thesis.  
1.3  The DBCG 89 studies 
The Danish Breast Cancer Co-operative Group (DBCG) was estab-
lished in 1977. It is one of the first examples of a nationwide 
collaboration between the surgical, medical, oncological, patho-
logical, and radiological hospital departments involved in the 
treatment of a disease [10]. DBCG has developed guidelines and 
protocols for randomised trials, and was one of the first examples 
of the development and successful implementation of national 
guidelines standardising the treatment of a disease [10]. In 1989, 
when DBCG released its DBCG 89 Program, it included guidelines 
for diagnosis and treatment of primary breast cancer as well as 
three randomised trials [9].  
These guidelines included the definitions of the group of patients 
considered low risk, i.e. those who were likely to have been cured 
through surgery, and those considered high risk, i.e. with a risk of 
breast cancer recurrence justifying additional, systemic treatment 
[9]. 
DBCG 89 A was the protocol describing the follow-up program for 
low risk patients not offered any systemic adjuvant therapy. 
Subgroups of the patients were offered local radiotherapy. The 
protocol did not involve randomisation. 
Briefly, the three randomised trials had the following research 
questions. The DBCG 89 B trial randomised premenopausal 
women with receptor-positive tumours between standard CMF 
chemotherapy and ovarian ablation. It had been suggested that 
among premenopausal women with receptor-positive tumours 
the effect of chemotherapy was mediated via its reduction of 
hormone production in the ovaries [11, 12] rather than a cyto-
toxic effect. The research question was mainly whether ovarian 
ablation was as effective as chemotherapy [9].  
The DBCG 89 C trial included postmenopausal women in a trial 
comparing three endocrine regimens. The standard at that time 
was tamoxifen for one year. This standard was compared with 
two years of tamoxifen and with six months of tamoxifen fol-
lowed by six months of megestrol acetate. Thus, this trial com-
pared two durations of tamoxifen therapy and compared the 
combination of two drugs against one drug. 
The DBCG 89 D trial had a 2x2 design, i.e., it had two research 
questions and included a double randomisation resulting in a 
total of four treatment arms. The trial included premenopausal 
and postmenopausal patients who, in general, were at relatively 
higher risk of recurrence than the patients allocated to the two 
other trials. The first research question was whether the standard 
chemotherapy regimen CMF could be improved by exchanging 
one of the three drugs with another, i.e., CEF. The other research 
question was whether the drug pamidronate could reduce the 
risk of or the morbidity from bone metastases.  
The DBCG 89 protocols are described in more detail in the Meth-
ods section.  
1.4  Reasons for assessing HRQL in the DBCG 89 studies 
It was well known that patients diagnosed with and treated for 
breast cancer might experience many different symptoms and 
problems. There were three main reasons for assessing HRQL in 
the DBCG 89 protocols.  
1.4.1  End-points in randomised trials 
As outlined above, DBCG 89 B investigated whether ovarian abla-
tion had the same effect on survival as chemotherapy. The idea 
was that if the treatments had a similar anti-tumour effect then it 
might be preferable for the patient to avoid chemotherapy. On 
the other hand, during the discussions when the HRQL was 
planned it was also suggested that ovarian ablation might be 
worse than chemotherapy: the menopause and sterility induced 
by ovarian ablation was permanent whereas in some patients 
treated with chemotherapy menstruation may persist or return. 
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Although ovarian ablation was briefer and thought to be associ-
ated with fewer side effects, it was argued that these patients 
might for example have a greater risk of depression in the follow-
ing years. These considerations motivated a comparison of the 
HRQL outcomes in the two treatment arms.  
No HRQL studies of tamoxifen or megestrol acetate had been 
conducted (paper I). The evidence concerning tamoxifen was 
about side effects (i.e., not from studies based on patient-report) 
and some was almost at the anecdotal level but nevertheless it 
was frequently mentioned that tamoxifen was associated with 
depression [13, 14]. If the combination of two drugs were shown 
to improve survival, this combination could be a new standard 
recommended to millions of future patients and it would be of 
great interest to know whether a gain in survival probabilities was 
accompanied by better or worse HRQL outcomes. The same could 
be said about the comparison of two durations of tamoxifen. Year 
two of the study where one group had completed tamoxifen 
treatment while the other was still on this treatment gave the 
opportunity to study the HRQL associated with tamoxifen treat-
ment in a randomised trial. Thus, it was of interest to use the 
DBCG 98 c trial to investigate whether there was a difference in 
the HRQL impact between tamoxifen and megestrol acetate, and 
whether the patients randomised to two years of tamoxifen had 
worse HRQL in the second year than those treated for one year 
only. 
Finally, the DBCG 89 d protocol made an HRQL study highly rele-
vant. The trial compared the standard CMF chemotherapy with 
the CEF regimen. It was well known that CEF was more frequently 
associated with alopecia whereas it was unknown whether there 
were other differences in HRQL outcomes. Clearly, if it were 
shown that CEF was more effective than CMF it was important to 
know whether a potential gain in survival was ‘paid for’ by worse 
HRQL. 
Two levels of use of HRQL data in the interpretation of random-
ised clinical trials can be listed. First, and simpler, the researchers 
can use this information in their interpretation of results. If, for 
example, the available research data show no difference in sur-
vival between two treatments with regard to survival but the 
HRQL data show a clear advantage, then researchers can con-
clude that this is an argument in favour of the mildest treatment. 
Second, the availability of HRQL can be used as a means of shar-
ing the total information about treatments with patients and thus 
as a means of providing the patients access to more insight in the 
results forming the basis for treatment decisions. This is because 
the HRQL data may convey information about consequences of 
treatment that would otherwise be part of the doctors’ overall 
evaluation of ‘what is best for you’. In other words, HRQL data 
might be a way of obtaining a better basis for decision-making 
because important information – which otherwise would be 
undocumented – could become accessible for the patient. 
The research questions posed in the three trials of the DBCG 89 
Program thus clearly motivated HRQL assessment but no study of 
HRQL was included when the protocols were designed. Shortly 
after the publication of the DBCG 89 Program I approached the 
DBCG and proposed to assess HRQL in the trials. The proposal 
was received very positively and a parallel ‘add-on-study’ of HRQL 
was launched when funding from the Danish Cancer Society had 
been obtained. 
1.4.2  Descriptive information  
The second category of arguments for assessing HRQL in the 
DBCG 89 Program concerned the opportunity of using it as a 
means of obtaining descriptive information about the longitudinal 
impact of both the disease and its treatment on HRQL. There 
were two main ways to use information about the frequency and 
course of the various symptoms and problems following breast 
cancer diagnosis and treatment:  
A. To be able to inform future patients about the consequences 
of the disease and the various treatments, and  
B. To give health care professionals insights which could be 
used to alleviate or prevent symptoms and problems (this 
also includes the potential use in continuous quality devel-
opment).  
Not only the randomised trials but also the very detailed guide-
lines standardising the treatment procedures across the country 
served to improve the opportunities for obtaining useful informa-
tion. 
Another important point is that knowledge about the patient-
experienced consequences of treatments (and relevant treatment 
alternatives) is a necessary basis for the informed consent re-
quired by Danish law (Patientrettighedsloven, Lov om patienters 
retsstilling, lov nr. 482 af 01/07/1998; Sundhedsloven, Lov nr. 546 
af 24/06/2005, www.retsinfo.dk accessed June 2007).  
Further, knowledge about likely consequences of treatments may 
make the patient feel safe because she knows what is going to 
happen and can prepare herself for this. By this it is not meant 
that all patients should always be given the maximal amount of 
information – this may neither be desirable nor practically possi-
ble – but the information given to each patient should be based 
on knowledge that is as scientifically sound as possible.  
Thus, HRQL data might improve information to patients, might 
facilitate greater patient involvement in treatment decisions 
(‘empowerment’ via access to information), and might serve as a 
basis for better prevention or alleviation of symptoms and prob-
lems.  
1.4.3  Investigation of the psychosocial consequences of cancer 
At a more general level, a longitudinal study of a large group of 
breast cancer patients using relevant questionnaires was antici-
pated to be able to elucidate questions of general scientific and 
clinical interest. Relatively little was known about the course of 
the various consequences of the disease and treatment over 
time. Little was known about differences between sub-groups of 
patients (e.g., younger versus older, more or less affluent pa-
tients, and between patients differing with regard to social net-
work). Comparisons of sub-groups could clarify which patients 
managed the situation the best and the worst and information 
could be used to identify groups of patients in need of additional 
care. 
Another, more basic research question, which could be elucidated 
via HRQL data, was whether there was any association between 
psychological distress and the risk of death from cancer. At the 
time of initiation of this study there was evidence of an associa-
tion between self-rated health and survival in general population 
studies [15, 16]. Furthermore, Spiegel’s randomised study pub-
lished in 1989 [17], which indicated that metastatic breast cancer 
patients taking part in support groups had better survival, had 
generated renewed interest in the possible relationships between 
psychological distress and breast cancer survival. 
In sum, there were strong arguments for assessment of HRQL in 
the DBCG 89 protocols.  
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1.5  Breast cancer from the patient perspective and HRQL 
evaluation 
Seen from the patient’s perspective, a diagnosis of breast cancer 
may have multiple implications. It may be viewed as a sudden, 
unexpected threat to life, may cause acute hospitalisation, usually 
involves surgery with the removal of a breast or part of a breast, 
creates a need for medical decisions, may necessitate additional 
treatments, and may give rise to symptoms and practical prob-
lems. These and many other factors may cause an acute and 
severe disruption of the patient’s daily life [18]. All this creates a 
strong need for mental adaptation, which it is hoped will lead to 
successful readjustment to a new situation. Thus, for many pa-
tients a diagnosis of cancer is a turning point in their life: habits 
and daily life activities are reviewed and are possibly changed. All 
these aspects may be investigated in various research projects 
but clearly a single study may elucidate only parts of the experi-
ence of breast cancer. 
The present study falls within the category of ‘health-related 
quality of life’ (HRQL) research. Initially, the term ‘quality of life 
research’ was used when describing medical studies of patients’ 
experiences of disease and treatment but recognising that many 
aspects of quality of life are unrelated to health, the term HRQL 
became preferred [19, 20]. 
There is no single, universally accepted definition of HRQL as-
sessment but ‘… there seems to be an emerging consensus that 
generic HRQL takes into account levels of physical, mental, social, 
and role functioning, and includes abilities, relationships, percep-
tions, life satisfaction, and well being.’ [20]. HRQL assessment is 
thus based on the WHO definition of health [19]. A fundamental 
characteristic of HRQL assessment (in contrast to ‘toxicity rating’ 
carried out by physicians) is that it is preferably based on patient 
self-report [21, 22].  
When this study was initiated it was viewed as controversial 
whether the subjective experience resulting from breast cancer 
and breast cancer treatment could be investigated via question-
naires in a way that was sufficiently robust seen from a scientific 
point of view to allow such results to influence decision-making 
and clinical practice. I was often challenged when reading the 
scientific literature, following the debate in the field, and when 
presenting the project to colleagues and research partners. Some 
of the objections were: 
• All patients react differently to cancer; their reactions are 
subjective and fluctuating; it is impossible to investigate this 
scientifically (clinicians). 
• A questionnaire does not produce anything that can be used 
scientifically; we all know that when completing a question-
naire we tick some boxes but we could equally well have 
ticked other responses – much of it happens arbitrarily or at 
random, and the process is subject to all kinds of different 
and uncontrollable bias. A questionnaire cannot produce 
valid data (clinicians). 
• Quantitative research methods such as questionnaires are 
not suitable for assessment of subjective experiences or, 
more generally, quality of life. Qualitative methods are 
needed; theoretical frameworks must be developed. Other-
wise, results will be useless and potentially misleading (psy-
chologists, etc.). 
• It is practically impossible – with the resources potentially 
available to such a project – to carry out a longitudinal ques-
tionnaire study involving large numbers of patients across 
the entire country; it will not be feasible to identify the pa-
tients at the right time, to get their consent, or to organise 
the collection of questionnaires at the right time (various col-
leagues). 
• The current methodology applied to analysis of question-
naires is misleading and outdated; instead, newer statistical 
methods (which at that time were virtually unknown to al-
most all leading scientists in the field) have to be used (stat-
isticians). 
Given the many arguments in favour of conducting a large study 
of HRQL in the DBCG 89 Program, I took the objections seriously 
and discussed them and the methodological challenges with 
advisors and colleagues. The resulting research plan was an at-
tempt at establishing a study that could provide results that were 
useful in relation to the research questions, that overcame the 
practical obstacles, and that at the same time investigated the 
scientific quality of the results, i.e. their validity and reliability.  
When initiating the study the problems around delineation of the 
field of enquiry (i.e., that it could rightly be argued that it was 
impossible to assess a huge and ill-defined concept such as ‘qual-
ity of life’) led to the following definition of aims in the clinical 
research protocol: ‘… to describe how, how much, and for how 
long the quality of life is affected by each kind of adjuvant treat-
ment…’  [23](p. 8). A quality of life study was defined as ‘a map-
ping of treatment-related physical and psychological symptoms 
and effects on social, sexual, and work-related matters’ [23](p. 8). 
It was added that ‘The term ‘quality of life’ is thus used in a rela-
tively narrow meaning. General investigation of the quality of life 
concept is not central to the research project. It is concerned with 
the assessment of a number of matters that are significant to 
quality of life’ (p. 8). 
As stated above, the concept HRQL became widely used at a later 
stage with the same motivation, i.e. to use a more specific and 
less pretentious term than ‘quality of life’ [24, 25]. As stated by 
Ferrans in a recent review, ‘… the term HRQL draws a line be-
tween those facets of life that are primarily health related and 
those that are not.’ [24](p. 14-15). Thus, the initial conceptualisa-
tion made in the present study was in line with the subsequent 
development in the research field. 
The study has resulted in publications investigating HRQL in a 
general population sample (paper V), a paper studying psycho-
logical distress in breast cancer patients compared to the general 
population (paper VI), and papers on the impact of chemotherapy 
compared to no adjuvant therapy (paper VII) or versus ovarian 
ablation on HRQL (paper VIII). It was also investigated whether 
psychological distress in newly diagnosed breast cancer patients 
was related to survival (paper IX). Based on this study an article 
investigating whether operation type (mastectomy or lumpec-
tomy) was related to social class [26], a book chapter investigat-
ing whether there were social differences in the reactions to 
breast cancer chemotherapy [27], and a methodological article 
partly based on this study [28] were written; these publications 
are not included in the thesis. The same is the case, of course, for 
a Master’s thesis [29] and a PhD thesis [30] using data from the 
study. The methodological parts of the study, which were added 
after the clinical HRQL study had been implemented, are intro-
duced in the following sections. 
1.6  Validity and reliability in HRQL research 
This section briefly reviews some of the concepts related to valid-
ity and reliability in HRQL research. The concepts were explored 
in more detail in my PhD thesis [31] and are extensively described 
in the literature [25].  
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Validity refers to the truth of scientific results or statements. All 
scientific fields have their approaches to assessment of validity 
and reliability. In HRQL a typical definition is ’Validation of in-
struments is the process of determining whether there are 
grounds for believing that the instrument measures what it is 
intended to measure, and that is useful for its intended purpose.’ 
[32](p.45). Validity can be viewed as absence of systematic error. 
In contrast, reliability refers to absence of unsystematic error. 
This means that while validity problems will influence the results 
of a scientific study irrespective of its sample size, suboptimal 
reliability can be compensated for by a sufficient sample size.  
Many different terms are used to categorise the approaches used 
to validate questionnaires in HRQL research. Useful overall cate-
gories are content, construct, and criterion validity [25]. These 
terms are defined and discussed in detail in my PhD thesis [31]. 
1.6.1  Content validity 
Content validity refers to the extent to which the questionnaire 
has the content needed to elucidate the research question. This 
implies that content validity (like other aspects of validity) is not 
an ability that a questionnaire can possess (it is often stated in the 
literature that ‘this questionnaire has proven validity and reliabil-
ity’); instead, content validity is related to a specific application of 
a questionnaire. For example, a questionnaire may have a high 
degree of content validity when used to assess the symptoms 
resulting from one chemotherapy regimen while it may have poor 
content validity when used to evaluate another chemotherapy 
regimen if it misses the main problem resulting from that chemo-
therapy regimen, e.g., neurotoxicity, as discussed in relation to 
palliative care trials [33].  
The work aimed at assuring the content validity of a question-
naire usually includes a literature review combined with inter-
views with patients and health care professionals. The overall 
research question for the study should be used as the delineation 
of the literature review and as the basis for the questions asked in 
the interviews, for example ‘which consequences do patients 
experience as a result of the disease or treatment?’ Many conse-
quences may be identified, and to select which of these to include 
in the questionnaire it is often desirable to obtain ratings of the 
relevance and importance of the issues from relevant patients. 
Paper I reports the work aimed at developing a content valid 
questionnaire for this study. 
1.6.2  Construct validity 
Construct validity concerns the constructs (concepts) used in the 
study or the research field. It is thus a theoretical way of ap-
proaching the validity discussion. However, in practice the theo-
retical questions are often not formulated and instead, standard 
statistical manoeuvres are often carried out and interpreted as 
numbers without proper acknowledgement of their meaning and 
theoretical justification.  
Construct validity may concern important aspects related to the 
construction of multi-item scales. There are three main reasons 
for making multi-item scales: (a) to reduce measurement error 
(i.e., increase reliability), (b) to reduce the number of variables in 
the statistical analysis (often a careful attempt at obtaining good 
content validity results in a large number of items, which may 
result in an excessive number of results and problems resulting 
from multiple hypothesis testing), or (c) because the concept in 
question is best measured via multiple questions (e.g., one may 
want to capture various aspects of depression).  
Irrespective of the reasons for construction of multi-item scales 
and the many advantages they may produce, there is a consider-
able risk that multi-item scales may lead to loss or distortion of 
information obtained by the items. It is problematic if important 
information about the research question disappears or is modi-
fied during the transition from items to scales. If, for example, we 
want to know the consequences of a new kind of chemotherapy 
and an item on dizziness shows that patients experience this 
problem, then it is problematic if this symptom is overlooked 
because we have analysed the dizziness item as part of a ‘symp-
tom scale’ where the effect on dizziness is diluted and we there-
fore incorrectly conclude that the treatment is not associated 
with any symptoms.  
There are several other potential problems associated with the 
creation and use of multi-item scales and still such multi-items 
scales are usually necessary. One of the newer approaches to the 
validation of multi-item scales is analysis for differential item 
functioning (DIF), previously called item bias analysis. In contrast 
to the traditional approach to construct validation, where one or 
more separate ‘validation studies’ are performed and are later 
referred to as proper justification of ‘construct validity’ or ‘psy-
chometric robustness’ of the questionnaire, DIF analyses have the 
advantage of being able to examine the multi-item scales specifi-
cally in relation to particular research questions.  
Paper II is an application of DIF analysis to one of the question-
naires used in this study and examines the ability of the question-
naire to compare groups varying with regard to treatment and 
age. DIF analysis was also used in the studies reported in papers 
VI, VII, and VIII. The results were not included in the published 
papers due to space restrictions but are included in this thesis. 
An entirely different way of approaching construct validity testing 
was also used in this study. While the researcher can make sure 
that the relevant items are included in the questionnaire and can 
make sure that multi-item scales do not distort the information 
obtained in the individual items, an additional, important ques-
tion may be raised: do patients give the right answers when they 
complete the questionnaire?  
Answers to questions about subjective matters do not exist be-
fore the question is asked; they are constructed by the individual 
through complicated processes [34]. Patients may misunderstand 
the questions asked, they may misunderstand the response cate-
gories or the way they relate to the question, or they may in error 
tick the wrong response options. Furthermore, patients may 
understand the questions and response options differently from 
that intended – not due to errors or misunderstandings, but 
simply because their reality is different from that of a healthy, 
academically trained researcher who has thought and read about 
the issues for months or years.  
These considerations could be summarised into a basic question 
of whether questionnaire items are a valid way of obtaining in-
formation about the topics they are supposed to measure. Does 
our item on sleeplessness give valid insight into breast cancer 
patients’ problems with sleeplessness? It is easy to imagine nu-
merous sources of error. Paper III describes a method developed 
to elucidate whether patients understand questionnaire items in 
the same way as do the researchers conducting the study. If this 
were the case, it would be unlikely that major errors occurred 
during patient completion of the questionnaire. Additional results 
not included in Paper III are included in this thesis. 
 DANISH MEDICAL BULLETIN   6 
1.6.3  Criterion validity 
Criterion validity is usually the third way of approaching the valid-
ity of HRQL questionnaires. The idea is that if an external criterion 
is available then the validity of the questionnaire can be meas-
ured directly against this criterion. However, when the question-
naire is used to measure symptoms and experiences such criteria 
are rarely available. However, if for example a questionnaire is 
used to determine whether patients are depressed, an interview 
with a psychiatrist can be used as a criterion.  
Criterion validity in the traditional sense was not evaluated in this 
research project but the study comparing patients’ responses to 
the questionnaire against data based on an interview (i.e., using 
the interview results as the criteria) can be viewed as an assess-
ment of criterion validity. 
1.7  Problems related to lack of a priori hypotheses and multiple 
significance testing 
One of the basic principles of statistics is that the statistical 
methods should be used to test hypotheses – not to trawl the 
data searching for ‘significant’ associations. It follows from this 
that hypotheses should be formulated a priori, i.e., before the 
data is collected. A closely related principle is to limit the number 
of statistical tests carried out in a data set. Otherwise, problems 
of multiple hypothesis testing may occur (see also paper IV). 
The present study is an example of the difficulties one may en-
counter when implementing statistical principles in clinical re-
search. Many of the planned comparisons of groups had never 
been done before and therefore the basis for formulating a priori 
hypotheses was sparse. Furthermore, a questionnaire aiming at 
covering as many of the relevant symptoms and problems as 
possible would naturally contain a large number of variables. And 
on top of this, it was planned to follow patients over time, so six 
measurements of each variable would be available. 
Two different approaches to these problems were applied in this 
study. Concerning one of the main research questions of the 
study – which aspects of HRQL are affected by chemotherapy? – 
there was considerable literature available and thus it was possi-
ble to use this literature to formulate hypotheses (papers I and 
IV). These hypotheses were not formulated in the original proto-
col as usually required in order to be a priori hypotheses, but 
were subsequently extracted from the literature review used to 
compose the questionnaire (paper I). Thus, they were a priori 
formulated in the sense that they were based on data collected 
before the study.  
Another solution was explored in relation to some of the other 
planned comparisons. Given that there were no published studies 
having compared for example chemotherapy to ovarian ablation, 
it was difficult to formulate well-motivated hypotheses. A staff 
survey was conducted to elucidate whether health care profes-
sionals treating breast cancer patients had expectations that 
could be used to formulate hypotheses that could guide the 
statistical analysis (paper IV). 
2.  AIMS 
The overall aims of this study were to evaluate the impact of early 
breast cancer and adjuvant therapy on health-related quality of 
life (HRQL) and to assess whether psychological distress had 
prognostic significance. This involved the following specific aims: 
1) To compose a questionnaire measuring the impact of early 
breast cancer and adjuvant therapy on health-related quality 
of life (paper I) and to employ this questionnaire longitudi-
nally in breast cancer patients.  
2) To investigate whether the multi-item scales included in the 
questionnaire were adequate representations of the infor-
mation collected through their items (paper II). 
3) To investigate whether patients understood and responded 
to the items of the questionnaire in the same way as did the 
researchers (paper III).  
4) To investigate whether the views and experiences of health 
care professionals are useful in handling problems related to 
hypothesis testing in the analysis and interpretation of 
health-related quality of life data (paper IV).  
5) To facilitate the interpretation of results from breast cancer 
patients: to use the same questionnaire(s) to investigate the 
HRQL of a sample of women from the general population 
(papers V and VI). 
6) To investigate the prevalence of anxiety and depression in 
newly diagnosed breast cancer patients as compared to 
women selected randomly from the general population (pa-
per VI). 
7) To investigate whether there are differences in HRQL be-
tween premenopausal low-risk patients not offered any sys-
temic therapy and patients on chemotherapy (paper VII). 
8) To investigate whether there are differences in HRQL be-
tween premenopausal patients with receptor-positive tu-
mours randomised to chemotherapy or ovarian ablation 
(paper VIII). 
9) To investigate whether psychological distress and other 
HRQL variables carry prognostic information independent of 
biological variables (paper IX). 
3.  PATIENTS AND METHODS 
3.1  Design 
This was a prospective, longitudinal questionnaire-based study of 
(1) consecutive patients included in the DBCG 89 A protocol for 
follow-up of low-risk patients, and (2) consecutive patients ran-
domised in the trials in DBCG 89 protocols B, C, D [9]. A cross-
sectional study of Danish women randomly selected from the 
general population and a small, cross-sectional survey of health-
care professionals were also included.  
3.2  The DBCG-89 Protocols 
The DBCG 89 Program for Treatment and Follow-Up of Patients 
with Primary, Operable Breast Cancer [9] contains guidelines for 
the surgical, medical, and oncological therapy of breast cancer. It 
also includes guidelines for follow-up, for pathological proce-
dures, and a detailed description of the various tests and exami-
nations involved in the diagnosis of early breast cancer.  
3.2.1  Inclusion criteria 
The protocol had the following general inclusion criteria [9, 10]: 
1) Female less than 75 years 
2) Primary, unilateral, histologically proven breast cancer, 
excluding in situ carcinomas and inflammatory cancer, 
treated with lumpectomy or mastectomy and axillary dissec-
tion 
3) No prior neoplastic disease (except cutaneous cancer and 
cervical cancer in situ). 
For patients fulfilling the general inclusion criteria, the DBCG 89 
Program provided a decision-sheet to determine risk of recur-
rence and the adjuvant systemic therapy. Using this sheet any 
patient could be placed in one of four categories. Protocols A, B, 
 DANISH MEDICAL BULLETIN   7 
C, and D determined the treatment and follow-up of these pa-
tients.  
In contrast to systemic therapy, local treatment did not depend 
on protocol allocation but was determined by common guide-
lines. Local radiotherapy against the residual breast was offered 
to patients who had undergone lumpectomy (breast-conserving 
therapy with removal of the tumour). Local radiotherapy was 
additionally offered to patients who were up to 45 years old and 
had four or more positive lymph nodes, and to all patients whose 
tumour had not been radically removed. 
Patients allocated to protocol A were viewed as low-risk patients 
and were not offered any systemic therapy. These patients had 
tumour-negative axillary nodes and tumours up to 50 mm. Most 
hospitals also required that premenopausal women had histologi-
cal grade I (low-grade malignancy) tumours. Of the 59 hospitals 
reporting patients to DBCG, 50 agreed to inform patients about 
the present study and only Protocol A patients from these hospi-
tals were included in the HRQL study. 
 
Each of the three other protocols described the standard systemic 
adjuvant therapy for the particular sub-group of breast cancer 
patients and included a randomised trial comparing this standard 
therapy to one or more other treatment regimens. Patients allo-
cated to one of these protocols were informed about the ran-
domised trial at the department taking care of adjuvant therapy. 
The patients accepting randomisation were subsequently ran-
domised by telephoning the DBCG Secretariat. Patients not ac-
cepting randomisation were offered the standard therapy.  
 
In addition to the general inclusion criteria, the specific inclusion 
criteria for the protocols were: 
DBCG 89: Premenopausal, node-positive, and receptor-positive 
DBCG 89 C: Postmenopausal, node-positive, and receptor-
positive/unknown 
DBCG 89 D: Premenopausal, node-positive, and receptor-
negative/unknown, premenopausal, node-negative, and histo-
logical grade II-III (medium-high grade malignancy) (most hospi-
tals), or postmenopausal, node-positive, and receptor-negative. 
3.2.2  Treatments 
The randomised trials in the three protocols [9] were:  
DBCG 89 B: (1) Standard CMF (cyclophosphamide, methotrexate, 
fluorouracil) chemotherapy versus (2) ovarian ablation. CMF was 
given as nine cycles of intravenous cyclophosphamide 600 
mg/m2, methotrexate 40 mg/m2, 5-fluorouracile 600 mg/m2 
every three weeks. Ovarian ablation was irradiation (five doses of 
three Gy against the pelvic region) or (rarely) surgical oophorec-
tomy 
DBCG 89 C: (1) Standard tamoxifen 30 mg daily for one year ver-
sus (2) tamoxifen for 2 years versus (3) tamoxifen for 6 months 
followed by megestrol acetate 160 mg daily for 6 months 
DBCG 89 D: (1) Standard CMF (cyclophosphamide, methotrexate, 
fluorouracil) chemotherapy versus (2) CEF (cyclophosphamide, 
epirubicine, fluorouracil) chemotherapy. The CMF regimen was 
the same as in Protocol b. CEF was given as CMF with meth-
otrexate substituted by epirubicine 60 mg/m2. In addition, this 
protocol randomised patients between no additional therapy (1 
or 2) versus oral pamidronate 150 mg twice daily for four years 
(arms 3 or 4).  
3.3  Relationship between study populations and the nine papers 
The relationship between the nine papers included in this thesis 
and the study populations is shown in Fig. 1. Thus, papers II (DIF 
analyses), III (validation), and IX (survival) were based on patients 
from all DBCG 89 protocols. Paper VI (low-risk patients versus 
general population sample) included breast cancer patients from 
Protocol A. Paper VII (CMF chemotherapy versus no chemother-
apy) included premenopausal patients from Protocol A (control 
group) and premenopausal patients randomised to CMF chemo-
therapy in Protocols B and D. Finally, paper VIII included patients 
from Protocol B. 
3.4  Development, composition, and pilot testing of question-
naire 
The development of the questionnaire to be used in this study is 
the subject of paper I, which includes a detailed description. The 
development took place as summarised below.  
3.4.1  Literature review 
The literature was searched for publications describing the quality 
of life impact of breast cancer adjuvant therapy. The review was 
based on MEDLINE searches, reference lists of identified articles, 
and other sources. Papers dealing with chemotherapy, endocrine 
therapy, and ovarian ablation were identified. From each article, 
data about patient-reported negative effects of the treatments 
were extracted, and a list summarising the results was made. 
Because no articles dealing with ovarian ablation or endocrine 
therapies were identified in the literature review a gynaecologist 
was consulted about whether any likely effects of these treat-
ments were missing from the list of issues made from the litera-
ture review. 
In order to avoid unimportant issues, the list resulting from the 
literature review was examined in the interviews described be-
low, and issues not considered severe or frequent were removed. 
The literature review also included a review of existing question-
naires that could be used for breast cancer patients.  
3.4.2  Interviews with patients 
A convenience sample of 14 breast cancer patients attending the 
outpatient clinic at the Department of Oncology, State University 
Hospital (Rigshospitalet) was interviewed. The interviews con-
sisted of two parts. First, in an open (qualitative) part, interview-
ees were asked about how they experienced adjuvant therapy 
and how it affected their daily lives. After having completed this 
description, they were asked to nominate the three most impor-
tant negative effects of adjuvant therapy. In a second, structured 
part of the interview, interviewees were asked to what extent 
they had been bothered by each of the issues on the list devel-
oped in the literature review. Finally, 8 of the 14 patients who 
had filled in the preliminary version of the questionnaire (de-
scribed below) were interviewed about the acceptability of the 
questionnaire. 
3.4.3  Construction of questionnaire 
The construction of the questionnaire was based on the review of 
the HRQL impact of adjuvant therapy as well as the interviews. 
The existing questionnaires were reviewed and new items were 
developed. When constructing the items the same simple and 
brief structure as used in the EORTC QLQ-C30 was used when 
possible. However, changes to the structure or the response 
categories were made if this was thought to improve the items. It 
quickly became clear that the questionnaire would become rela-
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tively long, and therefore, each issue was represented with one 
item only, except if it was judged that more items were needed to 
measure the concept adequately. 
3.4.4  Pilot study 
The preliminary questionnaire was pilot tested in 84 breast can-
cer patients at the outpatient clinic at the Department of Oncol-
ogy, State University Hospital (Rigshospitalet). All patients with a 
planned visit within a one-week pilot study period were eligible. 
Terminal patients, patients visiting the clinic for the first time, and 
patients above 75 years of age were, however, not included. In 
addition to the 74 patients fulfilling these criteria, 8 patients from 
the clinic, who were interviewed later, were also included. The 
questionnaire was sent to the patients by post with an accompa-
nying letter asking them to complete the questionnaire at home 
and bring it with them to their visit to the clinic a few days later. 
The questionnaire also included a ‘debriefing form’ containing 
questions about the questionnaire. 
 The pilot study was also used as the basis for a small ‘known-
groups comparison’ [25, 35] in order to test whether the ques-
tionnaire could detect differences between patients in chemo-
therapy (N=23) and patients not receiving any treatment (N = 23).  
3.4.5  Sociodemographic variables 
In addition to the HRQL questionnaire described above a brief 
questionnaire was constructed to collect information on marital 
and cohabitation status, number of children, and education. The 
social class classification developed by the Danish Social Research 
Institute was used, and items to collect the relevant information 
for this were made [36]. Based on these data social class was 
assigned ‘manually’ to each participant in the breast cancer and 
the general population (see below) studies. The social class classi-
fication has five levels ranging from V (unskilled worker) to I (the 
most affluent; includes academics and groups of self-employed 
and employed persons) [36, 37]. In the coding, the ‘family social 
class’ (as recommended in [36](p. 15)) was used for married, 
cohabiting, or widowed women: social class was determined both 
for the woman and for her husband/cohabitant. Each woman was 
then assigned the higher of the two values [36](p. 14).  
3.4.6  Adaptation of the questionnaire to the general population 
study 
The basis for the general population study was the questionnaire 
developed for breast cancer patients. However, items that were 
obviously related to cancer treatment and might give the respon-
dents an impression that they were suspected of having a disease 
were omitted. 
3.5  The questionnaire study in DBCG 89 
3.5.1  Inclusion of patients 
The present study included consecutive patients registered in 
protocol A, as well as consecutive women randomised in the 
three protocols 89 B, 89 C, and 89 D. Accrual to the questionnaire 
study was initiated on 1 June 1991 and the goal was to include 
100-150 fully evaluable patients in each of the 11 protocol arms 
[23, 31].  
It could be problematic to send a letter with a questionnaire to a 
patient who was not prepared for this and who might be worried 
about how the information about her disease and treatments had 
become available to researchers at the University of Copenhagen. 
To prevent this problem, I contacted all surgical, medical, and 
oncological departments in Denmark who were involved in 
treatment of patients with primary breast cancer and asked them 
to hand out a written information sheet to all patients diagnosed 
with breast cancer. The departments involved in adjuvant therapy 
did this by adding the information about the questionnaire study 
to the standard information used to give information about the 
relevant DBCG protocol. The surgical departments, which were 
the vast majority, organised to hand out the information sheet as 
part of their routine. A total of 59 departments reported patients 
to the DBCG during the study period and 50 of these agreed to 
distribute this information, and Protocol A patients from these 
departments were included.  
The ‘initial information letter’ explained that a questionnaire 
study was going on and that some patients would receive a letter 
with more details about this. It emphasised that the patient was 
not asked to make a decision as to whether she would participate 
at that time – the letter was informing about the possibility that 
the patient could be contacted only. The letter included the ad-
dress of the office of the HRQL study and the information that if 
the patient did not want to receive the more detailed letter about 
the study she could indicate this and would thus not be con-
tacted. 
Every weekday during the inclusion phase, the DBCG Secretariat 
mailed a list of all patients registered in Protocol A or randomised 
in one of the three protocols to the office of the HRQL study at 
the Department of Social Medicine, University of Copenhagen.  
The design of the study determined that in order to get compara-
ble results across the different protocols and treatment arms, 
Table 1  
 
Relationship between study population and the nine papers. 
 
Paper DBCG 89 protocol and treatment arm 
 
 A pre A post B1 B2 C1 C2 C3 D1 D2 D3 D4 
General 
population 
Convenience 
sample 
Nurses, 
doctors 
I             •  
II • • • • • • • • • • •    
III • • • • • • • • • • •    
IV              • 
V            •   
VI • •          •   
VII •  •     •       
VIII   • •           
IX • • • • • • • • • • •    
Pre: premenopausal; Post: postmenopausal 
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questionnaires had to be completed by the patients at the same 
point in time, measured from the date of diagnosis, irrespective 
of protocol. Therefore, patients registered by the DBCG Secre-
tariat later than the planned date for the first questionnaire, i.e., 
7 weeks postoperatively, were excluded from the HRQL study.  
3.5.2  Questionnaire administration 
Information letter 
The questionnaire was sent to the patients by post. A patient 
information sheet explaining the purpose of the study, emphasis-
ing that participation was voluntary, that the patient could with-
draw at any time without any consequences, and that the infor-
mation they provided would be kept confidential, accompanied 
the first questionnaire. It was also stated that no information 
would be released from the questionnaire to the hospitals in-
volved in the treatment and care of patients. Finally, the letter 
contained instructions about when the questionnaire was to be 
completed (see below). A stamped, addressed response envelope 
was enclosed.  
Timing of questionnaires 
The questionnaires were sent to the patients to be completed at 
1, 3, 5, 9, 15, and 24 months after the date of randomisation. The 
questionnaires to patients in protocol A, who were not random-
ised, were sent at the same points in time, measured from the 
operation. To do this, the average time from operation to ran-
domisation in protocols B, C, and D was determined.  
The patients in chemotherapy were asked to complete the ques-
tionnaires seven days after they had their chemotherapy. The 
letters were sent out a few days before the estimated date of 
completion. All other patients were asked to complete the ques-
tionnaire as soon as possible. As a result, all patients in the study 
completed the questionnaires at the same number of days after 
their operation irrespective of which protocol they were allo-
cated.  
In the beginning of the study, the questionnaires were sent out 
based on preliminary estimations. After about two months and 
again 2-3 months later the schedule was reviewed by examining 
the data for all patients entered. The preliminary schedule was 
found to be very accurate in achieving ‘simultaneous’ completion 
of questionnaires across protocols, but a few, small revisions 
were made to optimise the schedule. 
Reminders 
Patients who did not return the questionnaires were sent re-
minders after two, four, and six weeks. The reminders were care-
fully written to emphasise that study participation was voluntary, 
and to take into account that some chemotherapy patients would 
have to wait for some time before completing the questionnaire. 
A questionnaire and a response envelope was enclosed with the 
first and third reminders. 
Ethical committee approval 
The Danish ethics committees approved the HRQL study 
(V.200.1873/90, V.200.2067/91).  
3.6  General population study 
3.6.1  Identification of study sample 
A random sample of women living in Denmark was obtained from 
the Danish Central Population Register (CPR). All women who 
were born on a particular date in all odd years from 1913 to 1971 
were identified. As described in paper V, a colleague conducted a 
parallel study, and the women identified from the CPR were 
randomly distributed between the two studies. Up to 200 pa-
tients in each 10-year age stratum were included in the present 
study. 
3.6.2  Questionnaire administration 
The women were contacted by post in April 1992 following the 
same procedures as for the breast cancer study (see above) ex-
cept that they were sent only one questionnaire. Of course, the 
information was different and emphasised that we did not con-
tact them because we thought they were ill. However, the 
women were encouraged to participate even if they were ill. 
3.7  Analysis for differential item functioning (DIF) 
The multi-item scales of the EORTC QLQ-C30 were analysed for 
DIF in relation to age and treatment (chemotherapy) using three-
way contingency tables (paper II). A table was made for each 
combination of item and exogenous variable, controlling for scale 
score. The null-hypothesis of no association between item and 
exogenous variable after control for scale score was tested by 
calculation of the partial gamma [38]. The two-sided test prob-
ability for partial gamma equal to zero was found via Monte Carlo 
simulation (1000 simulations) using a computer program [39]. 
The same approach to DIF testing was used in each of the papers 
comparing groups of patients differing as to treatment (papers VI-
VIII). The grouping variable used in each study was used as ex-
ogenous variable. In addition, age was also included as exogenous 
variable in paper VI. However, due to space restrictions these 
results were removed from the papers during the peer-review 
process. The results are summarised in this thesis (Appendix A). 
3.8  Testing whether patients and researchers understand ques-
tionnaire items in the same way 
The method was developed for this and a parallel study [40-43] in 
response to our concerns about the validity of patient-completed 
questionnaires (paper III). The principle was to compare patient 
responses to the questionnaire against an observer’s rating of the 
same patients’ open-ended responses to the same questions. The 
observer was the researcher who had composed the question-
naire. A high extent of agreement between the patient responses 
to the questionnaire given before the interview and the observer 
ratings would indicate that, in general, patients had understood 
the items in the same way as the observer and thus that the items 
were not to a large extent misunderstood or erroneously com-
pleted. 
The study was carried out in collaboration between two studies, 
the present study and one including gynaecological cancer pa-
tients conducted by Marianne Klee. From the present study 57 
patients, who had already completed one or two of the six se-
quential questionnaires were randomly selected. In addition, 88 
gynaecological cancer patients were invited to take part. The 
EORTC QLQ-C30 was used in both studies, and all patients could 
therefore be used in the analysis of this questionnaire (paper III). 
In contrast, the HAD Scale and the DBCG 89 Questionnaire were 
used in breast cancer patients only (Appendix B). 
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Between 1 and 24 hours after having completed the question-
naire at home (and having put the questionnaire in a sealed enve-
lope) the participants were interviewed by a nurse via telephone. 
The interviewer asked the same questions as in the questionnaire 
but the patients were asked to respond using their own words 
and to avoid using the response categories used in the question-
naire. The interviews were tape-recorded and were subsequently 
rated by an observer (M. Groenvold for the breast cancer pa-
tients, M. Klee for the gynaecological cancer patients). The ob-
server made qualitative comments during the rating. 
The questionnaires completed by the patients before the inter-
view were compared to the observer rating based on the inter-
view. For each item, the overall agreement (i.e., the proportion of 
cases where the patient and the observer had given identical 
responses) and the (weighted) kappa were estimated. A priori it 
was decided that kappa values equal to or below 0.40 indicated 
potential validity problems, values up to 0.60 also deserved atten-
tion, whereas values of 0.61-1.00 indicated acceptable results 
[44]. A detailed description of the methodology is provided in 
paper III. 
3.9  Staff survey 
3.9.1  Identification of study sample 
Almost all patients in DBCG 89 protocols B, C, and D were treated 
at one of the five comprehensive cancer centres or at one of four 
regional oncological departments. We contacted 46 health care 
professionals working at these nine centres/departments, 19 
physicians and 27 nurses (paper IV). These included the consult-
ant and head nurse in charge of breast cancer treatment, who 
were asked to identify their most experienced colleagues. 
3.9.2  Questionnaire 
A staff questionnaire was constructed by selecting 18 HRQL di-
mensions from the patient questionnaire. We selected the di-
mensions we thought were most likely to be affected by adjuvant 
therapy and were most important, as based on the pilot study 
and literature review. The staff questionnaire consisted of six 
almost identical parts. Each concerned a comparison of two 
groups selected from the DBCG 89 protocols. For each of the 18 
HRQL dimensions it was asked: ‘Which group – all things being 
equal – has the problem/symptom to the largest extent?’ 
3.9.3  Questionnaire administration 
Each health care professional received a package consisting of a 
staff questionnaire, a patient questionnaire, an information let-
ter, and a stamped return envelope.  
3.10  Comparison of participants and non-participants  
In the clinical studies (papers VI-VIII) the characteristics of the 
final groups of participants in the study were compared against 
larger subsets of the target populations to determine whether the 
patients actually included were similar to the target groups (de-
tails in each paper). Age and tumour size were compared using 
Wilcoxon's rank sum test; proportions defined by other clinical 
variables were compared using Fisher's exact test or χ2 test. The 
same was done to compare participants and non-participants in 
the validation study (paper III) and to compare the groups within 
papers VII and VIII. In paper VI the demographic characteristics of 
breast cancer patients and the general population sample were 
compared using ordinal logistic regression controlling for age. 
3.11  Analysis of HRQL data 
3.11.1  Scoring of questionnaires 
The EORTC QLQ-C30 was scored according to the Scoring Manual 
[45]. A high score on one of the five functional scales or on the 
global health status/quality of life scale indicates a good function, 
whereas a high score on one of the three symptom scales or the 
six single items indicates a high level of symptoms/problems. Two 
of the early papers used simpler methods. In paper I the scores 
were dichotomised. In paper II a linear transformation of EORTC 
QLQ-C30 scores was used but the scores were not transformed to 
0-100 (footnote to Table 2 in paper II).  
The HADS was scored according to guidelines: scores for each of 
the two sub-scales were constructed by summation of its seven 
items [46] when at least 6 of the 7 items were not missing.  
The DBCG 89 Questionnaire was analyzed as single items. Items 
using the same four response as in the EORTC QLQ-C30 were 
transformed to 0-100 scales as for EORTC items [45], except in 
paper I where the scores were dichotomised. 
3.11.2  Group comparisons 
In paper I the proportions experiencing symptoms in the two 
‘known’ groups were compared using Fisher’s exact test. In pa-
pers II, III, V, VII, and VIII scores were compared between groups 
using Mann-Whitney (Wilcoxon) rank sum test (two-tailed) [47]. 
In paper VI the HADS scores were compared using age as covari-
ate in an analysis of covariance (ANCOVA) model. The same com-
parisons were carried using the non-parametric partial gamma 
[38, 48] with age grouped in 10-year intervals, and this method 
was also used to compare the proportions of HADS cases. The 
level of significance was 0.05 in all the analyses listed, except in 
paper VII where it was 0.01 and where at least two significant 
findings in the treatment period were required to confirm a hy-
pothesis. The SAS statistical analysis program (SAS Institute Inc., 
Cary, NC, USA [49]; versions 6 to 9.1) was used for all analyses 
unless otherwise specified. 
3.12  Prognostic factor analysis 
In addition to a range of clinical and biological variables (paper 
IX), six ’HRQL’ variables were selected for analysis. The EORTC 
QLQ-C30 emotional function scale and global quality of life item 
and the anxiety and depression subscales of the HADS were se-
lected as indicators of psychological distress. The EORTC QLQ-C30 
physical function and fatigue scales and the global health item 
were selected as indicators of physical health. Social class was 
included to control for possible confounding (social class may be 
related to HRQL as well as to prognosis). 
Patients were followed until 1 March 2005 resulting in a median 
follow-up time of 12.9 years. 
The multivariate Cox proportional hazards regression analysis was 
used to predict recurrence-free survival (RFS) and overall survival 
(OS). The categorisation of clinical and biological variables was 
described in the article (paper IX). To avoid over-estimation of 
effect resulting from categorisations derived from exploratory 
analyses of the data, all patient-rated variables were dichoto-
mised at the median. In addition, to take the clinical definitions of 
‘case’ vs. ‘non-case’ into account, the HADS subscales were ana-
lysed using the recommended cut-points 7/8 and 10/11 [46]. 
The analysis took place in three steps. First, multivariate ‘biologi-
cal models’ for RFS and OS were made based on the clinical and 
pathological variables. Second, each of the patient-rated variables 
and social class were added to the biological models, and the risk 
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ratios for that variable in combination with all variables in the 
biological models were estimated. Third, all the ‘self-rated’ vari-
ables and social class were added to the biological model and a 
stepwise selection (p < 0.05) was carried out, keeping all biologi-
cal variables.  
In addition, we carried out the final multivariate analysis resulting 
from the procedure described above in low-risk patients (Protocol 
A), only (N=432). These patients had not received any systemic 
adjuvant therapy but some had radiotherapy; this variable was 
included in the model. 
When the proportional hazards assumption was not fully satisfied 
we compared the results using the variable against an analysis 
stratified by that variable. Two-sided p-values based on the Wald 
test statistic were estimated. The SAS software package version 
9.1 was used. 
4  RESULTS & DISCUSSION 
4.1  Questionnaire development, composition, and pilot testing 
(paper I) 
Based on the literature review a list of issues was made. Because 
no articles dealing with ovarian ablation or endocrine therapies 
were identified in the literature review a gynaecologist was con-
sulted and asked whether any likely effects of these treatments 
were missing in the list. Two issues were added in order to assess 
consequences of low levels of oestrogen; ‘vaginal dryness’ and 
‘urinary incontinence’. Based on recommendations in the litera-
ture [50], the issues about sexuality were supplemented with 
‘sexual satisfaction’. A number of issues were removed from the 
list because they were not considered severe or frequent or were 
difficult to operationalize.  
As a result of the review of available instruments, two question-
naires, which were widely used internationally, were selected for 
this study. The EORTC QLQ-C30 [35, 45, 51], a 30-item question-
naire developed by the European Organisation for Research and 
Treatment of Cancer Quality of Life Group [52] was selected 
because it covered many of the issues identified in the literature 
review, because it was considered to be well-structured (consist-
ing of brief multi-item scales as well as single items), because of 
its format with simple questions and response options, and be-
cause it was developed in a cross-cultural, mainly European con-
text.  
To assess anxiety and depression, the two psychological con-
structs reported most frequently in the literature, the Hospital 
Anxiety and Depression Scale (HAD Scale) [46] was selected. This 
questionnaire was widely used [22, 53-56] and was recom-
mended for cancer studies [57, 58]. It consists of 14 items consti-
tuting two seven-item scales for anxiety and depression, respec-
tively. 
To assess social network/contact, four items from the Danish 
Glostrup Population Studies were selected [59]. 
In addition, 19 items, including one open-ended item for supple-
mentary comments, were developed.  
The 14 interviews with patients generally confirmed the decisions 
made during the choice of issues for the questionnaire, and the 
pilot testing with 58 patients confirmed that the questionnaire 
was acceptable. However, a few revisions of questionnaire devel-
oped for the study were made. Three items about vaginal dis-
charge, weight gain, and wearing wig and two ‘administrative’ 
items about dates for treatment and questionnaire completion 
were added. Two items on consequences of surgery were re-
moved because they were considered out of focus, and one item 
on cohabitation was moved to the questionnaire on demograph-
ics. The wordings of a few of the newly developed items were 
modified.  
Thus, the 69-item questionnaire used in this study consisted of 
the EORTC QLQ-C30 (30 items), 21 items developed for the study, 
four items on social network/contact, and the HAD Scale (14 
items).  
In the analysis for papers VII and VIII not all of the items were 
reported. The four items on social network/contact had been 
included in order to be used as covariates in analyses, not as 
outcome variables. The item on sexual satisfaction was excluded 
due to ambiguous interpretation. Finally, the two ‘administrative’ 
items and the item for comments were not used as outcome 
variables. In papers VII and VIII the 17 remaining items developed 
for this study have been named the DBCG 89 Questionnaire (the 
English translation is shown in the Appendix of paper VIII). 
In the general population study we used the same questionnaire 
except that eight obviously cancer-related items (e.g., the items 
on hair loss) were removed (paper V). 
4.2  The questionnaire(s) used in this study compared to other 
questionnaires 
How does the content of the questionnaire combination used in 
this study compare with questionnaires used in other studies? 
Table 4 (section 4.9.6) shows the content of the three question-
naires used in this study. Table 4 also includes findings about 
chemotherapy in this and other studies, organised according to 
the structure of our questionnaire as further discussed in section 
4.9.6. Obviously, other studies have used other questionnaire 
combinations. The results, which could not be organised accord-
ing to the content of our questionnaire(s), are summarised in 
Table 5.  
Thus, taken together, Tables 4 and 5 illustrate the extent of suffi-
ciency of the questionnaires used in the literature as measured 
according to their ability to reflect the HRQL of breast cancer 
patients in adjuvant chemotherapy. The two tables show that the 
questionnaire combination used in the present study is the most 
complete. This is further discussed in section 4.9.6. 
The two standard questionnaires, the EORTC QLQ-C30 and the 
HAD Scale, have become widely used. The EORTC QLQ-C30 has 
been used in thousands of studies and is the most frequently 
used instrument in European and Canadian HRQL studies in on-
cology [60]. The HADS has also been used extensively [61, 62]. 
Thus, our choice of these two instruments turned out to be con-
gruent with decisions made in many subsequent studies. There-
fore, a considerable part of our results have become comparable 
with a large part of the literature. The DBCG 89 results are not 
comparable to other studies, but our study (paper VII) showed 
that a questionnaire with at least part of that content is neces-
sary. Questionnaires are also discussed in section 4.9.6. 
4.3  Study participation  
4.3.1  Inclusion of patients  
The inclusion periods for the protocols are listed in Table 2. The 
table shows that the planned number of patients (100-150 fully 
evaluable participants per protocol arm) was reached quickly in 
protocols A and C, whereas protocols D and particularly B had 
slower accrual. The age limits for protocols A and C were in-
creased shortly after the study was initiated and therefore inclu-
sion of patients in the oldest old groups started a few months 
later. 
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During the inclusion periods a total of 1,950 patients were regis-
tered and contacted about the quality of life study. Of these, 
DBCG later determined that 50 did not fulfil all inclusion criteria; 
two were contacted outside the inclusion periods. These patients 
were excluded leaving 1,898 eligible patients (Table 2).  
 
Table 2  
 
Inclusion periods for each of the DBCG 89 protocols and the number of 
patients included. For protocol A the dates refer to dates of operation, 
for the other protocols the dates are randomisation dates. 
 
Protocol Inclusion started 
Inclusion 
stopped 
Patients 
included 
A1 1 June  
1991 
31 October 
1992 
 
A2  
(< 70 years) 
1 June  
1991 
31 March 1992  
A2 
(70-74 years) 
1 December 
 1991 
30 September 
1992 
538 
B 1 June 
 1991 
6 February  
1996 
 
317 
C 
 (< 70 years) 
1 June  
1991 
31 October 
1992 
 
C  
(70-74 years) 
1 October  
1991 
31 December 
1992 
469 
D 1 June  
1991 
8 June 
1995 
 
574 
 
Total 
   
1,898 
 
4.3.2  Patient participation 
Of the 1,898 patients, 1,713 (90.3%) filled in the first of the six 
questionnaires (Table 3). The table shows that the number of 
patients participating declined modestly over time; the figures are 
not adjusted for the fact that some of the missing patients at the 
later assessments had died. 
 
Table 3  
 
Number of patients completing each of the six questionnaires of the 
study. 
 
 Month 
 1 2 3 4 5 6 
Participants 1,713 1,644 1,599 1,561 1,502 1,404 
Per cent 90.3% 86.6% 84.2% 82.2% 79.1% 74.0% 
 
4.4  Testing multi-item scales for differential item functioning 
4.4.1  Results concerning all treatment arms (paper II) 
The analyses of the nine multi-item scales of the EORTC QLQ-C30 
using data from the first 1,189 patients completing the question-
naire showed DIF in three scales (paper II). DIF in the physical 
function scale was found in relation to both age and treatment 
(+/- chemotherapy) for the item ‘Do you have to stay in a bed or a 
chair for most of the day?’ After control for the physical function 
scale score, higher proportions of younger patients and patients 
in chemotherapy answered ‘Yes’ to this item. There was a rela-
tively strong association between scores on this item and the 
‘vomiting’ item. Our interpretation was that in addition to being a 
measure of physical function this item is a measure of nau-
sea/vomiting: some patients who had severe nausea after chemo-
therapy had to stay in bed (paper II).  
The results of paper II led to two conclusions. First, it confirmed 
the potential relevance of DIF analyses. Second, at the methodo-
logical level, we found support for a relatively strict significance 
criterion of p<0.001, which reduces the number of ‘DIF cases’ 
identified. Therefore, this approach was used in the analyses 
related to papers VI-VIII.  
4.4.2  Results concerning anxiety and depression in breast cancer 
patients compared to the general population (Appendix A) 
The main finding was that there was DIF in relation to group in 
the depression scale mainly for item 10: 'I have lost interest in my 
appearance'; at a given level of depression there were much 
higher scores on this item in the general population than in the 
breast cancer patients (Appendix A). This item therefore influ-
enced comparisons between the two groups: depression scores in 
the general population sample were biased upward. If this item 
was removed from the HAD depression scale, the magnitude of 
the difference in mean scores between the two groups (described 
in section 4.8.2) was diminished, but still significant.  
An analysis of the wordings of the items of the depression scale 
exhibiting DIF suggested an explanation. The item, 'I have lost 
interest in my appearance', has response categories including 'I 
take just as much care as ever' (corresponding to '0' depression). 
The analysis indicated that – at a given level of depression – 
women from the population sample had a much greater likeli-
hood of being 'depressed' on this item. The context of response 
may explain this bias. A cancer patient may perceive this item as 
relating to her disease (‘I have lost interest in my appearance’ - 
since I became ill). On the other hand, a woman from the general 
population sample had no clear point in time or event with which 
to compare her 'interest in ... appearance' and may have re-
sponded by comparing her actual 'interest' to some prior level, 
e.g. when she was younger. If this difference in perception actu-
ally took place, it might explain why – when controlling for de-
pression score – the score on this item was higher in the general 
population sample.  
The HADS was developed for and validated in hospital patients 
[46]. We must therefore assume that the cancer patients' percep-
tion of this item better reflects the intended meaning. If the 
interpretation of the DIF is correct, this item overestimates de-
pression in population samples. As stated above, correcting for 
this bias by excluding the item from the scale score diminished 
the difference between groups but did not change the conclusion 
of significantly higher depression scores in the general population 
sample than in the patient sample.  
However, similar DIF may affect scores on four other depression 
(but no anxiety) items, which have such diffuse references to 
prior states. Unfortunately, as the test for DIF examines one item 
at a time in relation to the other items of a scale, it cannot detect 
effects that affect the majority of items in a scale. The analyses 
thus suggested, but could not demonstrate, that the problem of 
'diffuse back reference' affects additional items in the depression 
sub-scale. It was not possible to correct fully for this bias.  
The depression sub-scale also showed DIF with regard to age for ‘I 
feel as if I am slowed down’ (item 8) and ‘I look forward with 
enjoyment to things’ (item 12) (Appendix A). This DIF does not 
directly affect the outcome of the comparison of the two samples 
as the analysis was age-stratified, but it explains at least part of 
the apparent increase in depression score with age. It is interest-
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ing that the validation study found independent evidence for the 
age-bias in item 8 and thus supports the interpretation above 
(section 4.5.2). 
In conclusion, the DIF analyses suggest that the HAD depression 
sub-scale over-estimates depression in a general population 
sample and – of less importance here – in older women com-
pared to younger women.  
The results of the DIF analyses had to be omitted to shorten 
paper VI but the interpretations of the DIF results were used in 
the paper where they appear as ‘speculations’ rather than results. 
An Australian study carried out DIF analyses in a similar project 
comparing breast cancer patients to a general population sample 
using the HAD Scale [63]. That study found the same overall re-
sults (lower anxiety and depression in breast cancer patients than 
in the general population sample). They explicitly tested our 
interpretation of the findings, particularly the hypothesis that 
‘diffuse back references’ as discussed above for item 10 and other 
items might contribute to the counter-intuitive findings discussed 
in section 4.5.3. Using different methods to test for DIF the Aus-
tralian study found the same DIF for item 10 as described above. 
For the depression scale all DIF findings were compatible with the 
hypothesis that items having ‘diffuse back references’ tend to 
underestimate depression in breast cancer patients relative to 
women from the general population. However, in contrast to our 
study DIF was found for anxiety items as well, and the overall 
conclusion by Osborne et al. was that the finding of lower levels 
of anxiety and depression in breast cancer patients could not be 
explained by DIF [63]. This may be correct but as discussed above 
the main problem may be that the DIF analysis method is not well 
suited for bias affecting several items in a scale.  
4.4.3  Results concerning chemotherapy versus no chemotherapy 
and chemotherapy versus ovarian ablation (Appendix A) 
The DIF found in paper II was not found in the data reported in 
papers VII and VIII even though the data were overlapping. How-
ever, DIF of similar magnitude and direction, but not meeting the 
p < 0.001 significance criterion, was found in the data reported in 
both papers. The two studies found that patients in chemother-
apy had poorer cognitive function than patients not in chemo-
therapy (paper VII, Table 2 and Fig. 1) and than patients who had 
undergone ovarian ablation (paper VIII, Fig. 2). The DIF implies 
that in these cases the cognitive function scale score was inap-
propriate as a description of the effect of chemotherapy: chemo-
therapy had a relatively strong effect on concentration and a 
much weaker effect on memory.  
4.4.4  Discussion 
Our article (paper II) was the first publication presenting and 
applying DIF analyses to HRQL research. Is this new ‘technology’ 
relevant and worthwhile?  
The results discussed above suggest that it may indeed be 
worthwhile to carry out DIF analyses: the results of DIF analyses 
contributed to the detection of possible problems associated with 
the use of the HAD Scale. If undetected, these problems could 
have led to misinterpretations.  
In the subsequent analyses we used the relatively strict criterion 
of p<0.001 (Bonferoni-correction) based on paper II and did not 
find any DIF. With the relatively small samples in particularly 
paper VIII it is clear that the power to detect DIF was limited. The 
replication of the findings of DIF in the cognitive function scale 
suggests that this DIF was indeed missed in both studies due to 
the strict significance criterion (i.e., a type II error). Therefore, 
one could consider being less restrictive in smaller studies but of 
course this will increase the number of ‘false positive’ findings 
(type I errors). We reviewed the remaining DIF results related to 
the studies reported in papers VII and VIII, which did not meet our 
criterion for significance. There were 15-20 findings and most 
were difficult to interpret and were probably random fluctua-
tions, or were at least without clinical importance.  
In later research we continued using the Bonferoni adjusted 
significance level and based on Bjorner’s study [64] we added a 
further requirement to reduce the number of findings: that the 
partial gamma coefficient had to be numerically larger than 0.30 
(the criterion was later adapted to logistic regression analysis) 
[65, 66].  
As previously discussed, an Australian study found DIF in the HAD 
depression scale supporting our interpretation (i.e., bias due to 
‘diffuse back references’) but concluded that DIF could not ex-
plain the unexpected finding of lower levels of anxiety and de-
pression in breast cancer patients compared to the general popu-
lation. This highlights an important limitation of the DIF method: 
that it cannot detect or correct for effects affecting several items 
in a scale in the same way. Theoretically, this limitation can be 
avoided if the total scale score, which is used to control for the 
level of the attribute, is replaced with an unbiased variable meas-
uring the same attribute [67]. However, in practice this is often 
not possible because such a variable is not available (question-
naires are kept as brief as possible and measuring the same di-
mensions twice or more is not feasible). Instead, it is sometimes 
recommended to substitute the total score with a score based on 
item response theory (IRT) scoring of the same scale [68-70]. This 
may, however, not be relevant for the EORTC QLQ-C30, as our 
later research showed that there was little difference between 
traditional and IRT scoring of these scales [71]. In our recent study 
comparing translations of the EORTC QLQ-C30, DIF analyses using 
IRT scoring were compared to those based on traditional scoring: 
DIF results were similar [72]. 
DIF analyses were uncommon in the HRQL field (whereas they 
have been widely used in educational testing for many years [73]) 
until quite recently. Now they have become relatively widely 
used: according to a PubMed search (January, 2007) 108 out of 
approximately 180 articles mentioning DIF were published in 
2004-2006.  
This increasing use makes it even more important to critically 
discuss the usefulness of DIF analyses. Our results in this thesis 
and in recent papers showing that DIF analyses are effective in 
detecting problems in the translation of multi-item scales as well 
as in examining for cultural differences [66, 74] illustrate the 
relevance of the method. Many other examples are found in 
recent applications in HRQL research.  
However, despite the potential relevance of the method it should 
also be evaluated in the light of its ‘side effects’. DIF analyses cost 
time, complicate the reporting of results, and can be seen as a 
‘problem generation mechanism’, which delays the research 
process. Do the benefits outweigh the costs? Are DIF analyses 
necessary in routine analyses of HRQL data?  
We recently reviewed the use of DIF analyses, particularly in the 
analysis of clinical trials, in a book chapter. Given that it is not 
always feasible to carry out DIF analyses we made the following 
recommendations about when DIF analysis is of particular impor-
tance [67]: 
• ‘In analyses of great clinical importance (to make sure that 
the conclusions as to content are correct) 
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• If the unidimensionality of the scale is questionable, e.g. 
scales covering broad domains of HRQL 
• If DIF has previously been detected in the scale in relation to 
the variable 
• In analyses focusing on variables, which may be associated 
with DIF, e.g. ethnicity or sociodemographic variables such 
as sex and age 
• In studies using questionnaire versions in more than one 
language.’ 
4.4.5  Conclusions 
• Several cases of DIF were found in the multi-item scales of 
the EORTC QLQ-C30 and HADS. 
• DIF analyses are relevant when important analyses of multi-
item scales are made. 
• The usefulness and interpretability of DIF analyses may be 
increased through parallel investigations using qualitative or 
cognitive interviewing techniques, as seen by the congru-
ence of findings in this and the next chapter (section 4.5). 
4.5  Testing whether patients and researchers understand ques-
tionnaire items in the same way 
4.5.1  EORTC QLQ-C30 (paper III) 
Of the 57 breast cancer patients, 46 (81%) were successfully 
interviewed. Of 88 gynaecological cancer patients, 49 (56%) were 
successfully interviewed. The overall participation was 66% (pa-
per III). 
In general, the agreement between patients’ responses to the 
EORTC QLQ-C30 questionnaire before the interview and the 
observer’s rating based on the interview was remarkably high. 
The mean scores did not differ between patients and observers. 
The median overall agreement for the 30 items was 0.85 (range 
0.47-1.00). It was above 0.80 for 21 of the 30 items. The median 
kappa/weighted kappa was also 0.85 (range 0.49-1.00). No items 
had kappa values at or below the a priori chosen threshold 0.40, 
and only three items were in the range 0.41-0.60 (paper III).  
While the overall result was that the agreement was very high, 
the analysis of both the quantitative and qualitative data sug-
gested some potential problems. The most important of these 
problems was what we labelled ‘selective reporting’: patient 
replies such as ‘Yes, I had the symptom but it was due to some-
thing else’ were observed for the item about pain and other 
symptoms. We had not instructed the patients to report only 
symptoms caused by the breast cancer or its treatment. Despite 
this, several patients clearly wanted to prevent symptoms caused 
by other factors, e.g. arthritis, being misclassified by the re-
searchers as results of breast cancer. Therefore, they reported 
selectively, carefully distinguishing between causes of symptoms. 
 Selective reporting may invalidate comparisons of groups of 
persons who differ as to their perception of the research aims. 
This was particularly relevant to the present study where great 
effort had been put into establishing an optimal control group 
based on a general population sample. For example, we must 
expect that equal proportions of breast cancer patients and 
women from the general population suffer from pain due to 
arthritis. However, if the breast cancer patients reported only 
parts of this pain, whereas participants from the general popula-
tion sample reported their arthritis symptoms more completely, 
then the comparison of pain is biased. 
In addition, a specific problem in a single item was detected. 
Some patients seemed to overlook the word ‘difficulties’ in the 
item ‘Has your physical condition or medical treatment caused 
you financial difficulties?’ Instead they answered whether the 
disease or treatment had had any economic consequences. This 
item may therefore lead to over-reporting. 
4.5.2  HAD Scale (Appendix B) 
The quantitative results from the breast cancer patients are 
shown in Table B1 (Appendix B). The median overall agreement 
was 0.80 (range 0.61-0.91). The median weighted kappa was 0.79 
(range 0.65-0.95).  
Thus, the median values were slightly lower than for the EORTC 
QLQ-C30, but in contrast to the results for the EORTC QLQ-C30, all 
items were above the a priori defined threshold for acceptable 
results (0.61). The plan (paper III) was to use the qualitative data 
in the cases where the agreement indicated potential problems 
((kappa up to 0.40) or was in the intermediate range (0.41-0.60). 
The agreement was higher than these limits but the qualitative 
data will still be briefly examined.  
The comments are listed in Table B2 (Appendix B), and showed 
the following: 
The comments to items 1 and 12 can be viewed as corrections to 
the negative way items in symptom questionnaires are generally 
phrased. These patients report positive effects (changes) due to 
breast cancer. This ‘positive adaptation/adjustment’ [75-78] is 
discussed in paper VI. 
The answers to item 3 showed that it was understood by some 
patients as concerning fear of breast cancer recurrence and 
death. The same point was made for item 5. This finding supports 
the hypothesis of selective reporting discussed above (section 
4.5.1 and paper III): some breast cancer patients specifically un-
derstood these items as dealing with breast cancer-related wor-
ries; therefore, they may have left out some problems that were 
unrelated cancer. 
Patients who understand the item in this way may feel that the 
response categories are inappropriate. A patient experiencing a 
moderate extent of fear of recurrence is likely to feel that ‘Very 
definitely and quite badly’ is not suitable, but the two following 
options ‘Yes, but not too badly’ and ‘A little, but it doesn’t worry 
me’ may also be unsuitable: there seems to be a contradiction 
between the seriousness of the question and the response cate-
gories. 
The two comments to item 8 suggest that this item about being 
‘slowed down’ may capture an effect of ageing in addition to 
being a measure of depression. This finding was also made based 
on the DIF analyses reported in section 4.4.2, and the qualitative 
results thus corroborate the statistical findings. The effect of this 
possible age bias is that depression in older persons is over-
estimated compared to younger individuals having the same level 
of depression. 
Other comments address difficulties in discriminating between 
adjacent response categories (item 5) and minor technical or 
specific issues. 
An overall view of the qualitative comments does not suggest 
major validity problems affecting the sub-scale scores to a large 
extent. Despite this, the following results are important: 
 The finding that some patients lacked positive response options 
emphasises that it is too simple to expect that disease and treat-
ment have negative consequences only. 
Selective reporting was found, confirming results from the EORTC 
QLQ-C30. 
Possible age-bias was found in some depression items confirming 
DIF analysis results. 
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Specific problems were found in some response categories.  
Most of these problems (except selective reporting) could proba-
bly be handled through relatively small modifications of particu-
larly the response categories. However, one of the virtues of 
standard questionnaires is that they are seldom changed (thus 
making results comparable across studies) so it is doubtful 
whether this will be done. 
The interpretation of the results for the HAD Scale is somewhat 
different compared to the EORTC QLQ-C30 and the DBCG 89 
Questionnaire items in the sense that our estimates of agreement 
on individual items may be less important: the HAD Scale is linked 
to the relatively well-established concepts, anxiety and depres-
sion. It was developed as a screening questionnaire and can be 
deemed valid if it accurately predicts these diagnoses. Numerous 
validation studies have, in general, shown that the HAD Scale is in 
agreement with professionals’ diagnoses (summarised by Bjelland 
[62]). However, the very high level of agreement observed in this 
validation study is encouraging as it confirms that items are gen-
erally understood as intended. In addition, relevant findings that 
can be used to nuance the interpretation of HAD Scale results 
were made from the qualitative data. This study thus adds impor-
tant information to the literature about the validity of the HAD 
Scale. 
 4.5.3  The DBCG 89 Questionnaire (Appendix B) 
The results concerning agreement are shown in Table B3 (Appen-
dix B). The median overall agreement was 0.91 (range 0.48-1.00). 
The median weighted kappa was 0.92 (range 0.51-1.00). The 
observer rated mouth soreness significantly higher and rated 
desire for intercourse significantly lower but both differences 
were relatively small. Thus, agreement was generally excellent. 
The one exception exhibiting ‘moderate agreement’ [44] only was 
the item ‘satisfaction with appearance’, which used a seven-point 
scale, and had overall agreement 0.48 and weighted kappa 0.51. 
There was no difference in mean scores for this item. 
The qualitative data are shown in Table B4 (Appendix B). The two 
comments related to the ‘satisfaction with appearance’ item both 
concerned the ambiguity these patients had felt: they were 
strongly affected by their recent breast operation but did not 
know whether to take this into consideration because it was not 
visible to others. More generally, these observations indicate that 
the item is relatively broad and unspecific, and this – together 
with the many response options – results in less agreement. In 
fact the overall agreement for this item was almost identical to 
that observed for the two ‘overall items’ 29 and 30 in the EORTC 
QLQ-C30 (Table 2, paper III), which use seven similar response 
categories, whereas the kappa was somewhat lower. It is usually 
advisable to be specific in item formulation (when possible) in 
order to limit ambiguity but on the other hand, as for this and the 
two similar EORTC items, one may want an overall evaluation. In 
summary, the results indicate that the responses to this item may 
vary more strongly with the individual patient’s perception than 
do more specific items. However, there is no evidence that the 
item was misunderstood, and scores for patients and observers 
were similar.  
Even though the agreement for the remaining DBCG 89 items was 
excellent, some potentially important issues appeared in the 
qualitative data (Table B4, Appendix B). Concerning the item 
‘interest in sexual intercourse’ the standard response categories 
(taken from the EORTC QLQ-C30) appear suboptimal. The usual 
EORTC QLQ-C30 interpretation of the response categories would 
correspond to a range from complete loss of libido (‘not at all’) to 
no loss of libido (‘very much’). However, the results showed that 
some patients perceived ‘a little’/‘quite a bit’ as expressions of 
‘normal’ sexual desire. This observation may also explain that 
observers rated this item slightly lower than patients. The item 
appears valid in the sense that patients understood the content 
correctly, but when results of the item are interpreted it should 
be kept in mind that ‘normality’ is not equal to ‘very much’. The 
item might probably be improved through response categories 
better matching the question. 
Concerning the item on work (‘… worked outside your home…’), 
two weaknesses were detected. First, respondents having paid 
work at home are not eligible to report their work with this item. 
Second, child minders in Denmark usually have working hours 
above the usual level, and an answer result such as ‘40 hours’ 
(about 20% reduced time) may therefore be misinterpreted as full 
time work. However, the significance of these weaknesses ap-
pears to be minor. 
4.5.4  Discussion 
As outlined above, the present validation study was designed 
mainly to validate the EORTC QLQ-C30 and the DBCG 89 Ques-
tionnaire items, not the HAD Scale, which could be (and had 
been) validated against clinical diagnoses. The validation study 
was designed to elucidate whether the patients’ open-ended 
responses were in agreement with the wordings of items as un-
derstood by the researcher.  
The main finding of this validation study was that the agreement 
was very good, and considerably higher than expected, thus 
indicating that despite the scepticism one may (and should) have 
towards questionnaires, breast cancer patients’ completion of 
these questionnaires seems to be valid to a remarkably high 
extent.  
The levels of agreement were much higher than usually observed 
in inter-rater studies where patients’ responses have been com-
pared to health care professionals’ or significant others’ evalua-
tions [79, 80]. Although not fully comparable due to different 
statistics, it is also remarkable that the values observed here for 
the EORTC QLQ-C30 do not appear to be lower than test-retest 
correlations ranging 0.70-0.90 in a Norwegian study [81]. In other 
words, there does not seem to be more discrepancy between 
patients and observers than between patients’ own assessments 
separated by a few days. 
The most important problem found was that of selective report-
ing, which is probably a phenomenon affecting all or at least most 
HRQL questionnaires that do not specifically ask the patients to 
indicate whether the symptoms are caused by the disease or 
treatment. Additional analyses of other data based on the same 
method have confirmed that selective reporting is found in other 
questionnaires as well [82]. There can be little doubt that the 
phenomenon is real and that it may affect comparisons of groups 
who have different perceptions of the study.  
The magnitude of effect of selective reporting could be elucidated 
experimentally if patients were first given the usual instructions, 
and then, after completion of the questionnaire, were informed 
that it was important that they reported all symptoms including 
those caused by factors other than cancer. They could then com-
plete the questionnaire again after the instructions, and the 
results could be compared. Alternatively, cancer patients who 
had completed a questionnaire could be interviewed about what 
they had reported. 
As described later, paper VI showed unexpected results indicating 
that breast cancer patients had less psychological morbidity than 
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the women from the general population sample. It seems likely 
that selective reporting was part of the explanation of this proba-
bly incorrect result. As described above, some breast cancer 
patients perceived questions in the HAD Scale as relating to 
whether they were worried or sad due to the cancer. They may 
thus have excluded ‘everyday worries or sadness’ from their 
replies. However, other factors may also have contributed (sec-
tion 4.8.3). 
Concerning selective reporting it is important to note that in 
many studies the groups compared will not have different per-
ceptions of the study, and therefore selective reporting does not 
influence the outcome of a comparison. Selective reporting is 
described and discussed in the recent version of Fayers & Ma-
chin’s textbook [25] (p. 438-441), where it is concluded that it 
may be a general mechanism that may lead to under-estimation 
of symptoms/problems. 
The finding of a phenomenon such as selective reporting, which is 
interesting and important but is probably still in most cases a 
limited source of bias, should not distract attention from the 
answer to the overall research question posed in this validation 
study: do patients understand the items in the way they are 
intended? The remarkable result of this study was the generally 
very high level of agreement found for the two standard ques-
tionnaires as well as for the newly developed DBCG 89 Question-
naire. 
The present validation method was also used to validate newly 
developed items in the questionnaire used in the parallel study of 
gynaecological patients [82, 83]. The level of agreement found for 
the two parts of the questionnaire was similar to those found 
here, median weighted kappas were 0.88 (range 0.71-1.00) [82] 
and 0.80 (range 0.52-1.00) [83]. Selective reporting was observed 
in the questionnaire measuring urological and gynaecological 
morbidity [82]. 
During the recent years a new scientific field, cognitive aspects of 
survey methodology (CASM), which is highly relevant to HRQL 
questionnaire validation, has evolved [34, 84, 85] (see also sec-
tion 7.1.2). In a review of the use of cognitive techniques Willis et 
al. described the present study as ‘…an interesting example of 
cognitive techniques… Such an approach points the way for other 
cancer-related HRQOL researchers to evaluate their instruments.’ 
[34] (p. 616). 
4.5.5  Conclusions 
• This new method for validation of questionnaires showed 
high levels of agreement between patients’ written answers 
and observers who had listened to an open-ended interview. 
This indicates that, in general, patients respond to the ques-
tions as intended. This finding supports the validity of the 
EORTC QLQ-C30, the HAD Scale, and the DBCG 89 Question-
naire. 
• A mechanism we termed selective reporting was identified 
via the qualitative comments. Selective reporting may lead 
to under-estimation of the levels of symptoms and problems 
and may lead to bias if groups of respondents who are in dif-
ferent circumstances and therefore perceive the questions 
differently are compared. Selective reporting is likely to be a 
general, methodological problem, which is not specific for 
the questionnaires investigated here. 
• The identification of the selective reporting mechanism 
probably contributed to avoiding misinterpretations of re-
sults in other parts of this study (particularly in the compari-
son of breast cancer patients to women from the general 
population). 
• The method also proved useful in providing other insights 
into the complex process of questionnaire completion, and 
appears to be a widely applicable questionnaire validation 
technique that can be used in and adapted to all kinds of 
questionnaire. 
• In the recent years extensive worked based on cognitive 
psychology has taken place mainly in the USA, and this 
method can now be seen as one of many ‘cognitive inter-
viewing techniques’.  
4.6  The staff survey (paper IV) 
4.6.1  Participation 
Of the 46 health care professionals contacted, 36 (78%) re-
sponded.  
4.6.2  Staff survey results for the comparison chemotherapy ver-
sus ovarian ablation (Appendix C) 
The staff survey data were removed from the final version of 
paper VIII to reduce the length of the paper and because it was 
difficult to integrate it into the text without complicating the 
structure.  
Table C1 shows the staff survey data for the comparison of pa-
tients on chemotherapy versus ovarian ablation. A priori we 
decided that if at least half the staff members expected that a 
quality of life issue would be more affected by one of the treat-
ments, this was a ‘staff hypothesis’. The majority of professionals 
expected more nausea and vomiting, hair loss and fatigue in 
patients receiving chemotherapy (Table C1, top). As shown in 
paper VIII and in section 4.10.2 of this thesis, this was found in 
the patients’ responses.  
A majority of staff respondents expected more hot flushes and 
more irregularity of bleedings/menostasia in patients having 
undergone ovarian ablation (Table C1, bottom). Again, this was 
seen in the quality of life data (paper VIII), section 4.10.2.  
Thus, for these five quality of life issues, we can regard the staff 
expectations as independent hypotheses confirmed in the data. 
For the remaining issues, the majority of staff members either did 
not expect a difference or the picture was mixed. This means that 
the data could not be used as a basis for formulating and testing 
hypotheses.  
If we look at the patient data and compare these to the staff’s 
expectations (i.e., taking the same point of view as in the next 
section, 4.6.3), there are surprising discrepancies: significant 
minorities of physicians and nurses did not expect that nausea 
and vomiting, hair loss, and fatigue were more prevalent in pa-
tients receiving chemotherapy.  
 4.6.3  Staff survey results for the comparison chemotherapy 
versus control 
The staff survey was not carried out with the comparison of con-
trol patients and patients on chemotherapy in mind (paper IV, 
page 484). When initiating the HRQL study, a relatively large 
amount of literature was available and the literature review (in 
paper I) could in fact be seen as a compilation of the hypotheses 
available in the research field at that time. Therefore, when re-
porting the results of the comparison of control patients and 
patients on chemotherapy in paper VII we did not use the data 
from the staff survey to generate hypotheses. Instead, the origi-
nal literature review (in paper I) was used to generate such hy-
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potheses. Thus, the staff survey was used in a way that was not 
anticipated when designing the study: the results were seen as a 
description of the level of knowledge about HRQL consequences 
of chemotherapy in the staff treating the patients.  
 
As elaborated in section 4.9.8 and paper VII, the staff study sug-
gested that the information given to patients about HRQL conse-
quences of chemotherapy was insufficient.  
4.6.4  Discussion  
The staff survey was used as intended in relation to the DBCG 89 
trial comparing chemotherapy and ovarian ablation (paper VIII) 
and as a way of elucidating staff knowledge about patient-
experienced consequences of chemotherapy (paper VII). 
Concerning the comparison of chemotherapy and ovarian abla-
tion (paper VIII) five hypotheses could be extracted from the staff 
survey data and these were confirmed in the patient data. Thus, it 
proved possible to use the staff survey data as intended. How-
ever, these data were not included in the published paper (sec-
tion 4.6.2). If they had been incorporated in the paper, would this 
manoeuvre have led to the anticipated increase in the scientific 
credibility of the results? The five hypotheses concern findings 
that are not surprising. Three of them are extremely well known 
consequences of chemotherapy: nausea and vomiting, hair loss 
and fatigue. Our reporting that these symptoms/problems were 
more frequent in patients on chemotherapy has high credibility 
even without the ‘support from the staff survey’. The same is the 
cases for hot flushes and irregularity of bleedings/menostasia. In 
other words, the staff survey allowed us to generate hypotheses 
only in areas where we did not need the support of such hy-
potheses. 
 One could have hoped that the staff had picked up previously 
unknown consequences of one of the treatments; such findings 
could have been used to form hypotheses, and the patient data 
could have confirmed the hypotheses, but this was not the case. 
In fact, the finding that even HRQL consequences of chemother-
apy, which should be widely known by the staff, were not ex-
pected, suggests that the likelihood that staff surveys can be used 
to pick up such problems is limited.  
Later research seems to support this interpretation: even in a 
palliative care setting where the attention towards patients’ 
symptomatology should be very high, we showed that many 
symptoms and problems were not detected by doctors [86] or 
nurses [87]. This is in line with other studies [88]. And related to 
this, we found little agreement between patients and doctors on 
the assessment of the patients’ HRQL [89].  
In this thesis, the staff survey data have been used as intended in 
relation to one trial only (paper VIII). However, preliminary analy-
ses of the data concerning the other comparisons seem to give 
the same picture: only the most evident and pronounced HRQL 
consequences of treatments were expected by the majority of 
staff members. And as these effects are also convincingly demon-
strated in the patient data, the staff surveys had little added 
value. 
In contrast, the ‘alternative’ use of the staff survey data to eluci-
date the staff knowledge and thus (indirectly) their information to 
patients (paper VII) was useful as it suggested serious deficits and 
highlighted a need for additional research (and probably also for 
quality improvement) in this area.  
More generally, the staff survey was an attempt to address both 
the problems resulting from the fact that a priori hypotheses 
were not formulated and the problems of multiple hypothesis 
testing resulting from the large questionnaire and the repeated 
measurements. As such, the staff survey could be seen as an 
example of ‘methods triangulation’, i.e. the widely recommended 
parallel use of more than one scientific method. Ideally, with the 
addition of a simple, low-cost study, evidence with increased 
scientific robustness would have come out from the first study 
reporting newly detected HRQL consequences. However, that was 
not the case here. 
An alternative solution to the problem of multiple hypothesis 
testing was that used in paper VII, i.e. the generation of hypothe-
ses from a literature review. This was done after the original 
protocol was written, and thus it cannot be termed true a priori 
hypotheses, but because the basis was data collected prior to the 
study, it can still be defended. In paper VII the issue of multiple 
hypothesis testing was also handled through a decision rule (to 
confirm a hypothesis, a between-groups difference had to be 
found at least twice during the first three assessments) and 
through a reduction of the significance level to 1%. This approach 
seemed to work well. However, as no literature was available 
concerning chemotherapy vs. ovarian ablation, this method could 
not be used there. 
There are at least four other solutions to the problem of multiple 
hypothesis testing, which were carefully considered but rejected. 
First, one could have limited the number of statistical tests by 
reducing the number of variables through the creation of overall 
endpoints. This would mean that instead of having more than 30 
outcome variables, one would combine these to e.g. a single 
summary score, which could be called an ‘HRQL score’, or maybe 
two or three summary scores, e.g. for physical symptoms, psycho-
logical distress, and functional impact. It is not unusual to see 
such overall scores in the literature. For example, for the widely 
used 36-item SF-36 questionnaire [90] the two Physical and Men-
tal Component Scores may be used instead of separate scores for 
physical function, bodily pain, vitality, etc. [91]. Similarly, a so-
called Trial Outcome Index (TOI) composed of 23 items has been 
developed from the FACT-B breast cancer questionnaire [92]. 
However, such overall outcome variables were not suitable for 
the present study because they would not have produced a de-
tailed picture of the HRQL in the different groups. Furthermore, 
as demonstrated in DIF analyses, there may be significant DIF 
(and thus loss or distortion of information) even in brief scales 
addressing relatively well-defined concepts. It is likely that the DIF 
problems would increase if so-called higher-order summary vari-
ables were created. This implies that important information about 
group differences might be lost.  
Second, even if one refuses to reduce the number of outcome 
variables, the six measurement points during the two-year study 
period needed not to be used as separate outcomes. An alterna-
tive would be to base the comparison of groups on one overall 
test for each variable summarising the information from the six 
points in time. Such an overall test could be made in numerous 
ways ranging from simple tests (e.g. based on the mean value of 
six observations or the area under the curve) to sophisticated, 
statistical models, e.g. growth curve models [93], multilevel mod-
els, etc. [25, 94]. Such procedures could have added precision to 
the estimates and could thereby have increased the likelihood of 
detecting between-group differences. As the overall concern in 
the present study was to conserve the complexity of the original 
data, it was found valuable to determine the temporal patterns of 
the various symptoms and problems (e.g., ‘how long is anticipa-
tory nausea a problem?’). Therefore, in the longitudinal studies 
(papers VII and VIII) the decision was to carry out separate tests 
for the separate points in time. 
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Third, the problem of multiple hypothesis testing could be han-
dled by adjusting the level of significance, e.g. via the Bonferoni 
method: the level of significance is adjusted by dividing the p 
value by the number of tests carried out [95] (see also paper IV). 
The problem resulting from such adjustment is that it reduces the 
power of the study to detect between-group differences [96, 97]. 
Therefore, in this study with its many variables and a relatively 
modest sample size, a full Bonferoni adjustment would mean that 
many of the findings of differences between groups would not be 
detected. Variations of the Bonferoni method, which take into 
account that the variables are not independent, reduce but do 
not eliminate this problem. In paper VIII the level of significance 
was kept at the traditional 5% but this was accompanied by 
‘warnings’ in the text and with a graphical presentation of the 
level of significance, which made it possible to see from the fig-
ures how the results would have been if other levels of signifi-
cance had been used. A partial adjustment of the level of signifi-
cance was made in paper VII.  
A fourth approach is to carry out an overall test for a number of 
variables followed by analyses of the individual variables only if 
the overall test is positive. A recent example of this was a com-
parison of two adjuvant chemotherapy regimens in early breast 
cancer using the EORTC QLQ-C30 and the breast cancer module 
QLQ-BR23 [98]. First, O’Brien’s global rank procedure [99] was 
used. An overall difference was found for the EORTC QLQ-BR23, 
and subsequent analyses of the individual subscales showed 
differences in ‘systemic side effects’ and ‘upset by hair loss’ [98]. 
This technique reduces the risk of false positive findings but an 
important assumption is that similar effect is seen across the 
variables [100]. Differences seen in a few variables only may be 
missed. Thus, this approach has some of the same advantages 
and disadvantages as the use of overall endpoints. It is therefore 
not surprising that the study found few differences [98]. 
4.6.5  Conclusions  
• It is a generally acknowledged statistical principle that a 
priori hypotheses should be formulated whenever possible. 
This approach may also limit problems of multiple hypothe-
sis testing. When a priori hypotheses are not available, there 
are different options that can be used. The formal use of a 
literature review to establish hypotheses is one example 
(paper VII).  
• The idea of staff surveys to support the analyses of HRQL 
data is basically sound. However, the case was not proven 
here. The staff survey did not add significantly to the analysis 
of HRQL results. Staff surveys may be useful in other con-
texts, particularly when it is important to be able to make 
relatively definitive conclusions from a single study in a new 
area.  
• More traditional ways of tackling the problem of multiple 
hypothesis testing (e.g., to collapse variables into overall 
summary scores, to combine information from longitudinal 
assessments into a single variable, or to adjust the p-value 
for the number of tests) are justified in some cases but the 
risk of loss of information should be considered. 
• The staff survey proved useful in an unexpected way. Many 
staff members seemed to be unaware of common HRQL 
consequences of treatments. This indicates that there may 
have been deficits in the information given to patients, and 
calls for research concerning the sufficiency of information 
given to cancer patients today.  
4.7  The  general population study 
4.7.1  Participation  
The participation in the two parts of the general population study 
(which were part of the present study and a parallel study investi-
gating gynaecological cancer, respectively) was strongly different. 
Of the 872 women contacted as part of the present study, 608 
(70%) responded (Table 1, paper V)  (unfortunately, in the table 
‘872’ was erroneously replaced with ‘860’ and ‘70%’ with ‘71%’.) 
The table also shows the participation for the different age strata; 
there was no significant association with age (Chi-square=0.96, 
p=0.34).  
In contrast, the participation in the parallel study intended to 
produce reference values for gynaecological cancer patients was 
much lower (49%) (paper V); therefore, the data from the two 
studies were not merged in the reporting. Paper V therefore 
includes EORTC QLQ-C30 data from the participants selected to 
produce a control group for the present breast cancer study only, 
and only this part of the general population study is discussed 
here. 
4.7.2  Results for EORTC QLQ-C30 (paper V) 
The mean scores (overall and age-stratified) for each of the 30 
items of the EORTC QLQ-C30 are shown in Fig. 1 of paper V. Fig. 2 
of paper V shows means scores for the 9 multi-item scales. The 
study showed that women in the general population sample 
reported functional limitations as well as symptoms. For example, 
the mean score for emotional function was 77 (i.e., 23 points 
lower than ‘best possible emotional function’), and the score for 
pain was 21 (no pain=0).  
Scores on the first two items of the physical function scale 
(strenuous activities, taking a long walk) clearly declined with age 
corresponding to increasing limitations in older women. The large 
differences in these two items translated into an overall age 
association for the five-item physical function scale. A similar 
tendency was seen for the role function scale (particularly item 6, 
limited in work) although a more positive score was seen in the 
oldest age group. However, the latter was probably an artefact 
reflecting that these women did not experience work-related 
limitations because they were above the retirement age. Other 
items showing increasing problems with age included item 10 
(need to rest), item 25 (difficulty remembering), and the pain 
items 9 and 19.  
In contrast, the emotional function scale (items 21-24) showed a 
trend towards increasing (better) scores with age. 
4.7.3  Results for HAD Scale (paper VI) 
Results for the Hospital Anxiety and Depression Scale are shown 
in Table 1 of paper VI. The overall mean score for anxiety was 6.0. 
According to the authors’ criteria [46], only 68.9% had scores 
classified as ‘non-cases’, 18.7% were classified as ‘doubtful cases’, 
and 12.4% as ‘definite cases’. In other words, almost a third were 
classified as having possible psychological morbidity. 
The depression scores were lower. The mean score was 3.4, and 
8.0% were classified as ‘doubtful cases’, and 3.5% as ‘definite 
cases’. 
Figure 1 in paper VI shows that the associations with age were 
not perfectly linear. However, statistically significant, opposite 
trends were seen for anxiety and depression; anxiety tended to 
decrease with age, whereas depression increased, at least in 
women above 40 years of age. 
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4.7.4  Results for DBCG 89 Questionnaire (Appendix D) 
Mean values for 12 items of the DBCG 89 Questionnaire are 
shown in Table D1 (Appendix D). Items referring to chemotherapy 
(e.g., hair loss) and surgery (e.g., current level of energy com-
pared to before the operation) were not used in the general 
population study, as they were not meaningful. 
As for the two other questionnaires the study showed at least 
some symptomatology and/or functional limitation for all items. 
The menopause-related items such as hot flushes, presence of 
menstrual bleedings, regularity of bleedings, incontinence, and 
vaginal dryness showed clear relationships with menopause. The 
same is the case for the two items on sexuality. Employment 
declined with age. 
4.7.5  Discussion 
One may view a general population sample as ‘healthy controls’ 
and might thus anticipate absence of problems. However, as 
illustrated in these data, quite significant levels of symptoms and 
functional limitations were seen.  
This is of course not surprising. The Danish health and Morbidity 
Survey 2000 showed that 49% of the population reported at least 
one disease [101]. In Swedish and Norwegian general population 
studies, using other measures of disease, only 23% and 32% of 
the participants, respectively, did not report any health problems 
[102, 103].  
Therefore, also participants in studies of e.g. breast cancer are 
likely to have health problems other than cancer and this empha-
sises that general population studies are indeed needed in order 
to interpret results from studies of specific groups of patients. 
Otherwise, all symptomatology reported by the patients might be 
interpreted as if caused by the disease or its treatment.  
Our study was the first to collect responses to the EORTC QLQ-
C30 from a general population sample. Since then similar studies 
have been carried out in Norway [102, 104], Sweden [103, 105], 
Germany [106], and Korea [107]. 
The participation in the Danish sample (70%) was relatively high; 
slightly higher than in studies using the EORTC QLQ-C30 in Nor-
way (68%) [104] and Germany (67%) [106] but lower than the 
impressive participation obtained in Sweden (78%) [105] (the 
participation in the Korean study was not described). A value of 
70% is probably satisfactory for a general population study, al-
though it is markedly lower than the extremely high participation 
seen among breast cancer patients in this study. It is not surpris-
ing that a clinical study asking about the patient’s wellbeing in the 
context of breast cancer may appear more relevant than a gen-
eral population study. A subsequent Danish study using a differ-
ent questionnaire was carried out in exactly the same way, and 
had a slightly lower response rate of 67% [108]. 
This relatively high level of participation reduces the risk of selec-
tion bias. However, it is still possible that there is insufficient 
representation of individuals who do not read and write well, are 
severely ill or handicapped, have psychiatric disease, etc. On 
average, individuals in these groups probably have poorer quality 
of life than the participants. While opposite effects (e.g., the most 
healthy are busy with other things and might not prioritise par-
ticipation in a survey like this) might also be present, it seems 
likely that more non-participants experience quality of life below 
the average, and that general population surveys such as this 
therefore over-estimate quality of life.  
Fayers compared the Danish, Norwegian, Swedish, and German 
general population studies using the EORTC QLQ-C30, and found 
notable differences [109]. Whereas the Scandinavian data were 
fairly similar, he noted a markedly stronger decline with age in 
global quality of life in Germans than in Scandinavians. Similarly, 
fatigue scores increased more with age in Germans. The same 
tendencies could be seen in international reference data for the 
SF-36 questionnaire thus confirming the finding [109]. The Korean 
data [107] are not directly comparable due to adjustment for a 
number of background values.  
General population studies have also been conducted for the HAD 
Scale in Sweden [110], the Netherlands [111], Germany [112], the 
United Kingdom [113], and Australia [63]. The anxiety mean 
scores were 6.0 in our study against 4.8 in Sweden, 5.1 in the 
Netherlands, 5.0 in Germany, 6.1 in the UK, and 8.2 in Australia. 
For depression the corresponding scores were 3.4 against 3.8 in 
Sweden, 3.4 in the Netherlands, 4.7 in Germany, 3.7 in the UK, 
and 4.2 in Australia. However, differences in sampling methods, 
age distributions, and in the reporting of results make it difficult 
to compare the results directly. However, anxiety scores seem to 
exhibit larger international differences than depression scores, 
which are remarkably similar. The Danish anxiety score is similar 
to or lower than the two English-speaking countries and higher 
than the other countries. In contrast the Danish depression score 
is one of the lowest. The important point – which will be further 
discussed in section 4.8.3, which compares the data against 
breast cancer patients’ scores – is that the Danish general popula-
tion scores appear to be similar to those from other countries. 
Comparing the age-relations in the Danish data it is notable that 
while the EORTC emotional function scale shows a trend towards 
increasing emotional function with age, the HAD anxiety scale 
showed a similar decrease in anxiety with age, whereas the de-
pression score increased with age. One interpretation of this 
could be that the EORTC emotional function scale is functionally 
closer to anxiety than depression. Another interpretation, which 
probably explains part of the increase with age, is the age bias in 
the HAD depression subscale discussed in section 4.4.2. 
4.7.6  Conclusions 
• The general population study was carried out with a rela-
tively high level of participation (70%). This high participation 
limits but does not exclude the possibility of selection bias. 
• Both the two standard questionnaires and the newly devel-
oped DBCG 89 Questionnaire showed considerable ‘morbid-
ity’ (functional limitations and symptoms) in women ran-
domly selected from the general population. In broad terms, 
the results are similar to those from the subsequent interna-
tional studies using the EORTC QLQ-C30 and the HAD Scale. 
• These results, which show that parts of the symptomatology 
reported by cancer patients may have causes other than 
cancer and cancer treatment, constitute a good justification 
for the use of general population samples in the interpreta-
tion of data from cancer patients. 
• As shown in the next section, the interpretation of HRQL 
data from general population ‘control groups’ may be more 
difficult than anticipated. 
4.8  Anxiety and depression in low-risk breast cancer patients 
compared to a general population sample (paper VI) 
4.8.1  Participation 
Patients (pre- and postmenopausal women in DBCG 89 protocol 
A) 
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The selection of patients is described in paper VI. Of the 538 
patients invited to participate, 468 (87.0%) completed the ques-
tionnaire (89.2% in the age group 30-39 years, 77.9% in patients 
aged 70-75 years).  
General population sample 
The participation in the general population sample was described 
in section 4.7.1. The women in the general population sample and 
the breast cancer patients were not significantly different with 
regard to marital status, number of children, employment status 
or social class (paper VI). 
4.8.2  Results 
The surprising main finding was that the scores for anxiety and 
depression were significantly higher in the general population 
sample than among low-risk breast cancer patients.  
DIF analysis identified DIF in one depression item. Correction of 
this DIF diminished the difference but it was still significant (Ap-
pendix A and section 4.4.2). The interpretation of the DIF analyses 
suggested that similar bias may affect four other items of the 
depression scale but such bias affecting the majority of items in a 
scale cannot be detected with the DIF method used here (section 
4.4.2).  
The validation of the HAD Scale (Appendix B and section 4.5.2) 
confirmed that as discussed in paper VI, selective reporting may 
be one of the likely explanations; see further discussion below. 
4.8.3  Discussion 
Originally, we wrote a manuscript reporting general population 
‘norms data’ only. Just before submission of the manuscript the 
analyses for the next paper, the comparison of the general popu-
lation data to low-risk breast cancer patients, were carried out. As 
these analyses revealed the surprising results reported in paper 
VI, submission of the manuscript was deferred until these results 
had been interpreted. Given that the subsequent interpretation 
seriously questioned the use of ‘norms data’ we decided to drop 
the separate publication of general population data and to report 
these data along with the data from low-risk breast cancer pa-
tients (paper VI) instead.  
Breast cancer is probably the disease that has been most exten-
sively investigated by psychosocially interested researchers [114] 
and anxiety and depression are some of the most frequent out-
comes in such studies. The belief that breast cancer patients 
suffer from anxiety and depression is well-established [18]. When 
writing paper VI numerous papers reporting that breast cancer 
patients have anxiety and depression could be identified [115-
128].  
Therefore, the findings in paper VI were extremely controversial. 
We discussed a range of possible explanations of the unexpected 
findings and concluded that the comparison of responses from a 
general population sample against breast cancer patients was 
probably not valid due to primarily selective reporting and re-
sponse shift (paper VI).  
The DIF analyses (Appendix A and section 4.4.2) and the valida-
tion of the HAD Scale (Appendix B, table B1 and B2, and section 
4.5.2) were included in the originally submitted version of paper 
VI but had to be omitted to shorten the paper according to com-
ments from reviewers; brief conclusions from these studies were 
instead used as ‘speculations’ in the interpretation of results 
(paper VI, p. 527-8). Thus, these results do not add new aspects to 
the discussion as they were already taken into account in our 
conclusion. 
The HAD Scale has been widely used in the last few years. In 
paper VI we reported that according to a MEDLINE search up until 
August 1998 there were 267 publications with the HAD Scale in 
the title or abstract. By October 2006 the number was 1,800 
publications, and 83 of these concerned breast cancer.  
However, only one other study in primary breast cancer including 
a general population sample has been identified. An Australian 
study also used the HAD Scale and replicated our findings of 
higher levels of anxiety and depression in a general population 
sample than in a cross-sectional study of breast cancer patients 2-
43 months after diagnosis [63, 129]. Furthermore, they carried 
out DIF analyses. Osborne et al. carefully discussed their findings 
taking our discussion and conclusions into consideration. They 
ended up with two options, (1) ‘The present study and that of 
Groenvold, each with a reasonably strong experimental design, 
have demonstrated that women with breast cancer tend to have 
lower anxiety and depression than population women. This ob-
servation remains to be explained.’ and (2) ‘An alternative expla-
nation is there may be mechanisms whereby women diagnosed 
with breast cancer may interpret all or most items on the HADS 
from a different reference point to women without breast can-
cer.’ [63]. 
Thus, in contrast to our more unequivocal conclusion stating that 
the results obtained with the HAD Scale in a general population 
sample are not directly comparable with results from breast 
cancer patients (i.e. Osborne’s option 2), Osborne et al. were 
open to the possibility that breast cancer patients may be experi-
encing less anxiety and depression. 
At the present point in time it is probably not possible to fully 
resolve this discussion. In my view, there is strong arguments 
suggesting that the HAD Scale may not be a valid method for 
comparing anxiety and depression in breast cancer patients 
against that of general population samples. To further clarify this 
question it would be highly relevant to carry out further valida-
tion of the HAD Scale when applied to general population sam-
ples.  
4.8.4  Conclusions 
• This study made the unexpected finding that breast cancer 
patients had lower levels of anxiety and depression than 
women selected at random from the general population.  
• After careful considerations we concluded that this finding is 
probably incorrect.  
• The most likely explanation is that the use of the HAD Scale 
to compare the two groups of women, who are in markedly 
different situations, may not be valid. Several potential 
sources of bias have been identified, including the wording 
of particular HAD Scale items, the phenomenon ‘selective 
reporting’, and the response-shift problem. 
• Further validation of the HAD Scale, particularly in healthy 
respondents and among participants in general population 
surveys, is needed.  
• Intuitively, general population samples are attractive in the 
interpretation of HRQL from patients because they allow es-
timation of ‘excess morbidity caused by the disease com-
pared to controls’. However, before such use can be recom-
mended, the comparability of HRQL data from patient 
populations against general population samples must be fur-
ther evaluated. 
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 4.9  Impact of chemotherapy on quality of life (paper VII) 
4.9.1  Participation 
Control group (the premenopausal patients in DBCG 89 protocol 
A). Of the 199 low-risk breast cancer patients contacted, 181 
were alive and recurrence-free two years postoperatively, and 
148 of the 181 patients (81.8%) had completed all six question-
naires. 
Chemotherapy group (the premenopausal patients in DBCG 89 
protocols B (arm 1) and D (arm 1). Of the 242 patients invited to 
participate, 204 were alive and recurrence-free two years post-
operatively, and 159 of these 204 patients (77.9%) completed all 
six questionnaires. 
The women in the chemotherapy group and the control group 
were not significantly different with regard to age, marital status, 
number of children, employment status, or social class. The pa-
tients in chemotherapy differed from the control group by having 
breast cancer with less favourable prognosis (paper VII, Table 1). 
4.9.2  Results – HRQL in the chemotherapy period 
Table 2 in paper VII summarises the results, and Figs. 1 and 2 in 
paper VII present the longitudinal comparison of HRQL. Based on 
the literature we hypothesised that patients in chemotherapy had 
a worse quality of life on 30 variables. Worse HRQL was defined 
as significantly (p<0.01) worse scores at two or three points in 
time during chemotherapy. Twenty-three of these hypotheses 
were confirmed.  
Confirmed hypotheses 
Figs. 1 and 2 (paper VII) present the mean scores over time in 
both groups. There were many large differences between groups 
– the differences of 15 points for cognitive function, 17 for social 
function, 20 on overall health status/quality of life, 28 for fatigue, 
and 27 for nausea and vomiting exceed the 10 point difference, 
which has been suggested to represent a clinically meaningful 
difference on the EORTC QLQ-C30 [130]. Similarly, large differ-
ences were seen in Fig. 2 for hot flushes/sweats, anticipatory 
nausea, energy, (ir)regular bleedings, weight gain, hair loss, sexual 
interest, and vaginal dryness.  
Table 2 in paper VII also shows the differences in frequencies of 
‘symptoms’/ ‘impairments’ for the variables for which our hy-
potheses were confirmed. Again, many of the differences were 
relatively large, for example 43% compared to 16% reported that 
their cognitive function was below the chosen threshold; 80% 
compared to 31% were fatigued, and half of the patients had 
developed some degree of anticipatory nausea. 
The results concerning psychological distress were mixed. Con-
trary to expectation, the EORTC emotional function and the HAD 
anxiety scales did not show significant differences between 
groups, whereas patients in chemotherapy were significantly 
more depressed according to the HAD depression scale.  
The results concerning sexuality were also mixed. The hypothesis 
that patients in chemotherapy had less sexual interest was con-
firmed but the frequency of sex was not significantly lower in the 
chemotherapy group. Many patients in chemotherapy reported 
vaginal dryness.  
Hypotheses not confirmed 
Significant differences were not seen for financial difficulties, 
employment, or full-time work. The expected difference in vagi-
nal flux was also not found. 
4.9.3  Results – HRQL after the chemotherapy period  
Specific hypotheses were not put forward concerning the HRQL 
assessments after the patients in chemotherapy had completed 
their treatment, i.e. for the assessments at 9, 15, and 24 months. 
For seven variables significantly poorer HRQL was seen in the 
chemotherapy group at all three ‘off-chemotherapy’ assessments: 
hot flushes/sweats, anticipatory nausea, irregular bleedings, hair 
loss, sexual interest, vaginal dryness, and weight gain. Significant 
differences in the same direction were found at some of the 
assessments for cognitive function (at nine months), difficulties 
sleeping (9, 24 months), financial difficulties (15 months), 
amenorrhea (15, 24 months), and urinary incontinence (9, 24 
months) (paper VII, Figs. 1 and 2). 
4.9.4  Results – staff survey 
In this part of the study, the staff survey was used not to generate 
hypotheses but to elucidate the health care professionals’ knowl-
edge and experiences. The upper half of the middle column of 
numbers in Table 3 in paper VII shows the proportion of respon-
dents who did not expect a difference between groups but where 
such difference was found (and was hypothesised based on the 
literature review). For example, 13 of 35 staff members (37%) 
responding to the first question answered that there was no 
difference between patients in chemotherapy and patients not in 
chemotherapy in their ability to work and do household jobs. If 
the results from the HRQL study are viewed as the truth (at least 
for the variables where a difference was hypothesised and con-
firmed) then the staff members not expecting such differences 
between groups can be viewed as being wrong. Thus, almost two 
thirds of the respondents failed to recognise that patients in 
chemotherapy may be dissatisfied with their appearance. Other 
marked discrepancies concern cognitive function, social function, 
and weight gain1.  
4.9.5  Discussion – challenges in reviewing the literature for ‘ef-
fects of chemotherapy’ 
A large amount of literature concerning adjuvant chemotherapy 
and HRQL is available. For example, a PubMed search using the 
search words ‘breast neoplasms AND adjuvant AND chemother-
apy AND quality of life’ resulted in 337 references (1 February 
2007). Before discussing our results against the literature some 
points about the challenges of reviewing such research will be 
made. 
When results of a study like ours are to be interpreted a key 
question is: what is the current knowledge concerning effects of 
breast cancer adjuvant chemotherapy on HRQL? ‘Effects’ imply 
causality. Randomized, double blind trials may be optimal for 
detecting ‘effects’ but are not available. Blinding is not possible 
for obvious reasons, and few studies randomizing patients be-
tween chemotherapy and no treatment have involved HRQL 
assessment. This means that optimal data elucidating the impact 
of chemotherapy on HRQL are sparse. 
A review of the available literature was undertaken with two 
aims: 
1) If possible, to formulate clear inclusion criteria characterizing 
eligible studies, i.e. studies that could appropriately claim to 
describe ‘effects of chemotherapy’. 
                                                                        
1
 The results for financial difficulties should not have been presented in 
the section of Table 3 (paper VII) dealing with confirmed hypotheses 
because the hypothesis was not confirmed. 
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2) To extract the results from the eligible studies: what ‘effects’ 
had been reported? 
The formulation of methodological inclusion criteria proved diffi-
cult. Many studies were ineligible for obvious reasons but many 
could make reasonable claims about likely effects of chemother-
apy. Few studies were ideal, and relying on these would exclude 
most of the literature. Therefore, the ‘middle group’ of ‘reason-
able’ studies had to be scrutinized and these proved to be het-
erogeneous. 
The basis for statements of effect can be summarized as follows: 
• Within-patient change over time, e.g. an increase in the 
intensity of a symptom from a pre-treatment assessment to 
an on-treatment assessment. Advantages of such studies in-
clude that compared to other designs the risk of confounding 
may be smaller. An important disadvantage is that the pre-
treatment (‘baseline’) assessment is rarely a true baseline 
because patients may already be severely affected by the di-
agnosis and other treatment (typically surgery). Therefore 
the change from pre-treatment to on-treatment is likely to 
under-estimate effect and can lead to false-negative conclu-
sions.  
• Comparisons of groups of patients varying as to exposure to 
chemotherapy. In some cases multivariate analyses have 
been used to control for possible confounders, in other cases 
patients were matched with ‘controls’. Most studies were 
cross-sectional but some were longitudinal.  
• Studies of chemotherapy patients only. Most of such studies 
cannot be used because one does not know whether prob-
lems are caused by chemotherapy. However, there may be 
exceptions, e.g. when patients have been carefully inter-
viewed throughout the treatment and have been asked to 
report the symptoms they experienced due to the treat-
ment. The study by Love [131] is a good example; its results 
appear reasonably robust despite the lack of a control group. 
• Studies comparing two chemotherapy regimens. Unless, as 
described above, the study reports a comparison with a 
baseline assessment, the evidence that can be drawn from 
such studies depends on whether differences are found be-
tween groups. When no differences are found, no evidence 
as to chemotherapy effects can be extracted unless it is evi-
dent that the results differ from what is ‘normal’ (e.g., if 50% 
of the patients in both groups report vomiting). Studies find-
ing differences between groups may be useful. For example, 
if two durations of chemotherapy are compared, the period 
where one group is on treatment and the other group is off 
treatment may provide valuable information. Particularly if it 
is a randomised trial, such a design may provide relatively 
solid evidence concerning effects of chemotherapy because 
the risk of confounding is minimal. However, it is also evi-
dent that such a design has its weaknesses because both 
groups have had chemotherapy and thus its sensitivity and 
ability to describe the course of problems/symptoms over 
time is limited. 
In addition to the problems related to definition of clear criteria 
defining whether sufficient evidence for effect is available, a 
number of other difficulties are encountered in reviewing the 
literature. Chemotherapy regimens vary as to drugs, drug doses, 
drug administration (e.g. intravenous vs. oral), intervals between 
cycles (e.g., weekly, three-weekly, four-weekly) and number of 
cycles (and thus duration of treatment), etc. Many articles do not 
describe the nature of regimens sufficiently. Furthermore, pa-
tients treated according to different regimens may be included in 
the same study but separate results per regimen are not pre-
sented. Again, if strict requirements are used, many articles will 
be excluded.  
Another concern is the HRQL methods used. Were they suffi-
ciently validated? Were they comprehensive? As documented in 
section 4.2 most, if not all, instruments used are not comprehen-
sive: they assess subsets of the relevant HRQL aspects only.  
A long list of additional criteria describing the ‘usual’ epidemiol-
ogical criteria concerning the conduct of the studies could be 
made and used in the selection of studies, e.g. criteria describing 
the representativity of the samples, possible sources of bias, etc.  
Thus, the available studies are extremely heterogeneous. If strict, 
uniform inclusion criteria were applied, a large proportion of the 
studies would be excluded. Thus one has to choose between 
making a ‘strict’ review of very few papers using well-defined 
inclusion criteria (e.g., including the papers investigating a par-
ticular treatment regimen only or including only papers with a 
very strong design in terms of causality) and making a more inclu-
sive review of a broader range of papers. 
Based on these observations it was decided to carry out the re-
view ‘manually’ without strict methodological criteria. Instead 
each paper was individually reviewed and articles fulfilling the 
following overall question were included ‘does this study provide 
reasonably solid evidence concerning the presence (or absence) of 
HRQL effects of commonly used chemotherapy regimens?’  
The only relatively strict criteria used were that studies of breast 
cancer adjuvant chemotherapy were excluded if  
• They reported ‘cases only’ – unless other characteristics of 
the studies (e.g., a change over time) made inference about 
a ‘chemotherapy effect’ plausible. 
• Patients were treated with regimens other than CMF, CEF, 
CAF, AC, etc. Thus, studies of taxanes were excluded but a 
few studies of mixed regimens (with a small proportion of 
patients treated with taxanes) were included. Studies of high 
dose chemotherapy were also excluded. A single exception 
was made concerning a study including several HRQL vari-
ables; these patients were treated with NCF (mitoxantrone 
instead of M or E or A) [132] 
If subgroups of patients treated with drugs having specific, well-
known side effects (such as neuropathic side effects of vincristine) 
were included in a study, such side effects were omitted when 
extracting results from the study.  
When studies judged to be ‘borderline’ were encountered, the 
originality of the findings was also considered. If, for example, 
similar results had been found in several studies that should 
definitely be included in the review, the threshold for including a 
study was higher than if it reported new findings. 
Another point noted during the review was that many studies 
used several extensive questionnaires in parallel but placed their 
focus on positive findings. Such possible publication bias is well 
known [133, 134], and in a review like this there are at least two 
mechanisms that may exaggerate such bias towards identifying 
positive effects only. First, for practical reasons it is virtually im-
possible to extract all the negative findings, which have often not 
been reported in detail. Second, when negative results are found, 
the power of the study to detect differences between groups is 
crucial. Negative findings in small studies having low power are of 
little interest. The present review of the literature should there-
fore be seen in the light of there being a risk of false-positive 
findings.  
Finally, the delineation of ‘HRQL’ must also be considered. In 
general, only patient self-reported data concerning the patients’ 
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experiences were included. ‘Toxicity ratings’ made by the physi-
cians in many clinical trials were not included. Similarly, side 
effects such as neutropenia, infections, cardiotoxicity, second 
malignancies, etc. were excluded. However, a few exceptions 
were made for relatively ‘objective’ issues such as weight gain 
and amenorrhea, which were included in our questionnaire but 
could equally well be measured objectively or assessed by a phy-
sician.  
4.9.6  Discussion – HRQL in the treatment period  
Tables 4 and 5 represent the results of a review undertaken as 
described in section 4.9.3: have similar results been found in 
other studies? First, each of the findings of our study will be dis-
cussed in relation to the literature – in the order they are listed in 
Table 2, paper VII. Table 4 is a graphical summary of these find-
ings. The terms (names of multi-item scales and the words used in 
single items) used in our study will be used, but it will be pointed 
out when only partially overlapping terms were used in the other 
studies. This will be followed by a discussion of HRQL aspects 
investigated in other studies that were not assessed in our study 
(Table 5).  
Physical function (PF) 
We did not hypothesise an effect on PF but found slightly lower 
PF in the chemotherapy group at three months. A similar effect (a 
decrease from the pre-treatment assessment) was observed after 
standard CEF chemotherapy and (more pronounced) after dose 
intensive CE [141].   
Role function (RF) 
RF assesses limitations in relation to work and household jobs, 
and we found a clear difference between groups during chemo-
therapy. Impact on the RF scale was also observed in the afore-
mentioned international trial [141] and in a small German study 
[151]. Similar results have been reported in some of the first 
studies from the United States [164, 165] and Canada [142], and 
again recently from Canada [168], although the latter study em-
ployed the FACT-G functional scale, which, in addition to work, 
household jobs, etc. includes sleep, acceptance of illness, enjoy-
ment of life, and overall quality of life [175]. In interviews with 21 
women selected from the same study [168] it was reported that 
fatigue, nausea, and cognitive problems interfered with the ability 
to work full-time; about 30% were able to work part-time during 
chemotherapy [148].  
Emotional function (EF) 
Contrary to expectation we did not find a difference between 
groups on the EF scale (whereas we found increased depression 
according to the HAD Scale). This contrasts with an American 
interview study where 10 of 21 patients reported emotional 
problems due to chemotherapy [138] and a German study, which 
found a almost dramatically reduced EF scale score of 50 in pa-
tients in combined chemotherapy and radiotherapy compared to 
68 (endocrine therapy and radiotherapy) or 62 (radiotherapy 
alone) [151]. This latter study is limited due to small numbers of 
participants (N=41 in the chemotherapy group) but this does not 
explain the low mean scores. EF scores in our chemotherapy 
group were not below 75.  
Whereas the EORTC EF scale used in the studies quoted above 
includes tenseness, worries, irritability, and feeling depressed, a 
Canadian study reported reduced emotional wellbeing according 
to the FACT-G (sadness, coping with illness, hope, nervousness, 
worry about dying, and worry that the condition gets worse) 
[175]. Two large International Breast Cancer Study Group (IBCSG) 
trials convincingly showed an effect of CMF on mood (a scale 
ranging from ‘happy’ to ‘miserable’) and emotional wellbeing (the 
28-item Befindlichkeits-Skala) [156]. Lowered mood associated 
with chemotherapy was also found in a later trial from the same 
group randomising between CMF and tamoxifen [140]. It is possi-
ble that this ‘mood scale’ is conceptually closer to the EORTC 
overall quality of life scale (which showed clearly scores in the 
chemotherapy group, see below) than to the EF scale. A small 
study reported higher psychological distress (Psychological Ad-
justment to Illness Scale [176]) in relation to chemotherapy [154]. 
Two early American studies reported impaired mood [158] and 
described that patients in chemotherapy experienced nervous-
ness, irritability, tearfulness, etc. [164, 165]. A Swedish study, 
however, found no effect of chemotherapy on anxiety or depres-
sion as measured by the HADS Scale [167]. 
These somewhat conflicting results may suggest that the methods 
used in our study (particularly the EORTC emotional function 
scale and the HAD anxiety scale) may not capture the psychologi-
cal consequences of chemotherapy (whereas the overall QL scale 
did). However, the concept ‘psychological consequences’ may not 
be sufficiently precise. This term, along with others used here and 
elsewhere, e.g., psychological distress, (effect on) mood, etc. 
need further clarification.  
Along with the other results, our findings of no difference be-
tween groups in anxiety but a small difference in depression 
suggest that while chemotherapy is clearly distressing, it relatively 
rarely leads to major psychological distress (the incidence of 
depression was 9% in chemotherapy patients compared to 5% in 
controls). This may seem paradoxical but may be explained by the 
fact that the treatment may be experienced as meaningful – as a 
way of fighting the risk of recurrence.  
Cognitive function (CF) 
We found lower (self-reported) CF in the chemotherapy group 
during treatment (and at three months after completion of che-
motherapy). The scale comprises two items on the ability to 
concentrate and memory, and this was the only scale showing 
differential item functioning (DIF): most of the difference re-
flected concentration difficulties; the difference in memory prob-
lems was much smaller (section 4.4.3). A difference in the EORTC 
CF scale was also found in a German study [151]. An early study 
also based on self-report found impaired ability to concentrate 
and ability to write following CMF [142]. A Canadian study found 
moderate to severe cognitive impairment in 15 of 31 patients in 
chemotherapy compared to four of 36 healthy controls [143]. In a 
recent American study patients in chemotherapy reported more 
forgetfulness, difficulty concentrating, and being easily distracted 
[152]. Australian patients named ‘trouble concentrating’ as the 
sixth most troublesome aspect of chemotherapy [149]. A recent 
Canadian study found that 16 of 100 patients in chemotherapy 
compared to four of 100 controls had moderate to severe cogni-
tive dysfunction [168]. A sub-group of 21 patients from the study 
was interviewed in detail about their perception of the impact of 
chemotherapy on cognitive function: ‘Patients reported changes 
in short-term memory, concentration, verbal fluency, processing 
speed and to a lesser degree planning and visual-spatial abilities. 
Almost all patients (20 of 21) reported difficulty with recent 
memory. Participants described increased forgetfulness (of 
names, words, places, and appointments) and slower memory 
retrieval.’ [148]. In contrast, a Swedish study found no effect of 
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chemotherapy on self-reported cognitive function [167]. Cogni-
tive function is further discussed below in the part of this section 
dealing with possible chemotherapy effects after treatment. 
Social function (SF) 
As expected, we found that SF (physical condition or medical 
treatment interfered with family life or social activities) was con-
siderably lower in the chemotherapy group. This was also found 
in a small German study [151]. Relatively small, early studies have 
found that CMF affected family and marital relationships [164, 
165] and family life and social life [142]. 
Global physical condition/quality of life (QL) 
Our study showed markedly lower scores for ‘overall physical 
condition and quality of life’ during chemotherapy; the same was 
found in a recent German study [151] and in the international 
study of CEF, where overall QL dropped from baseline [141]. One 
of the first studies of HRQL, from Canada, also found worse 
‘global quality of life’ in patients receiving CMF [142], and a re-
cent, large, randomised study comparing CMF to tamoxifen found 
poorer ‘subjective health’ in the chemotherapy group [140].  
Fatigue 
Fatigue, nausea, and hair loss are the most well documented 
HRQL consequences of chemotherapy. Increased fatigue after 
chemotherapy was found in all studies assessing fatigue. We 
showed a marked impact on fatigue (80% reported ‘a little’ or 
more compared to 31% in the control group). Some of the studies 
investigated fatigue in detail. A recent American study [136] used 
a diagnostic interview to identify cancer-related fatigue according 
to four proposed ICD-10 criteria (duration, impact, cancer-related 
aetiology, and that fatigue is not primarily a consequence of a 
psychiatric condition) [177, 178]. The overall prevalence of can-
cer-related fatigue in breast cancer patients undergoing adjuvant 
therapy was 26%, and with an OR of 2.23 it was higher in patients 
receiving chemotherapy [136]. A Dutch study investigated the 
course of fatigue during and after chemotherapy [146]. Increasing 
fatigue during chemotherapy was found, whereas another study 
reported that the level of fatigue was constant [157]. Australian 
breast cancer patients identified fatigue as the second most 
troublesome aspect of chemotherapy [149]. A study of mixed 
cancer patients (44% received adjuvant chemotherapy for breast 
cancer) showed that while 86% had experienced tiredness only 
8% had expected this symptom after chemotherapy [131]. Sur-
prisingly, a Swedish study found no effect of chemotherapy on 
fatigue [167]. 
Recent Danish research is evaluating whether physical exercise 
reduces fatigue; encouraging results have been found [179]. A 
recent Cochrane review concerning exercise in breast cancer 
adjuvant therapy found a non-significant improvement of fatigue. 
The authors concluded that additional research was needed to 
clarify the effect of exercise [180]. 
Nausea and vomiting (NV) 
All studies assessing nausea and vomiting after chemotherapy 
found this. In addition to the studies reported here many articles 
reporting results of antiemetic treatment in breast cancer adju-
vant therapy have been published. The issue is therefore not 
whether patients experience NV but to what extent. The medical 
treatment and prevention of NV (antiemetics) has been strongly 
improved the last years following the launch of the drug ondanse-
trone in the beginning of the 1990s [181, 182] Additional drugs 
have been developed, and combinations with corticosteroids 
have proven effective [182-185]. As a result, the problem of NV 
has decreased (and thus, the problem today is probably not as 
pronounced as shown in paper VII), and the relative importance 
of this side effect of chemotherapy has probably diminished. This 
is an important achievement that can be seen in the light of the 
situation described in the interviews of the initial pilot study 
(paper I): of 12 patients in chemotherapy, eight reported frequent 
vomiting and constant nausea for 48 hours or more (up to 10 
days) following each treatment; of the remaining four patients, 
only one did not vomit but still suffered from severe nausea.  
However, the problem of nausea and vomiting is still important. 
For example, a study with 49% breast cancer patients enrolled 
patients in 2001-2002; patients received antiemetic treatment 
according to guidelines; 37% had acute nausea and 52% had 
delayed nausea after moderately emetogenic chemotherapy. The 
study also showed that nausea affected several aspects of the 
patients’ daily lives [186].  
Pain 
No difference in pain scores was observed between groups in our 
study but pain in relation to chemotherapy has been reported in 
other studies [132, 141, 169] and in a recent review [173]. The 
nature of pain is usually not described but could be mucositis 
(e.g., sore mouth as found in our study) or problems with needle 
injections, which has been rated as the 9th most troublesome 
aspect of chemotherapy [149]. In addition to sore mouth, a 
French study evaluating NCF chemotherapy (corresponding to 
CMF with mitoxantrone instead of cyclophosphamide) reported 
headache (44%), stomach pain (38%), muscular pain (30%), and 
articular pain (28%). Each of these was found distressing by at 
least 40% of the patients experiencing it; stomach pain being 
described as distressing by 71%. However, the patients also re-
ceived tamoxifen, which has been associated with muscular and 
articular pain [132]. 
Dyspnoea 
We did not hypothesise a difference in dyspnoea but found this; 
36% of the patients in chemotherapy compared to 12% in the 
control reported ‘a little’ or more dyspnoea at five months (Table 
2, paper VII). A relatively old Dutch study found that 30% of pa-
tients in adjuvant chemotherapy compared to 5% of controls 
reported shortness of breath [170]. A more recent American 
study reported that patients in chemotherapy had more dysp-
noea than those not in chemotherapy [137], and an increase in 
dyspnoea scores was also seen during standard dose CEF [141]. 
Only one of 36 participants in our staff survey expected that 
patients in chemotherapy had increased levels of dyspnoea (Table 
3, paper VII). 
Trouble sleeping 
In our study 70% of patients on chemotherapy compared to 35% 
in the control groups reported ‘a little’ or more trouble sleeping 
(Table 2, paper VII). Similar results have been found in several 
studies (Table 4), and Australian patients rated trouble sleeping as 
the 8th most troublesome aspect of chemotherapy [149]. There 
may be several mechanisms involved in sleep disturbances; one 
of which is insomnia due to hot flushes and sweats resulting from 
the chemotherapy-induced menopause observed in many 
premenopausal women [187].  
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Loss of appetite 
Loss of appetite was seen in 45% of our patients receiving chemo-
therapy compared to 8% in the control group, and has been 
                                                                        
2
 This study evaluated NCF chemotherapy; tamoxifen was also 
given. 
found in many previous studies (Table 4). It seems closely linked 
to nausea and vomiting.  
Constipation 
We did not anticipate constipation but found this in 52% of the 
chemotherapy group compared to 12% of the controls. Only one 
of the other studies reviewed has addressed this symptom, and 
Table 4  
 
‘Effects of chemotherapy’ during the treatment period. Summary of results extracted using the categories of paper VII. Results that could not be 
included in the categories are shown in Table 5. 
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Berglund, 2001 [139]                                   
Bernhard, 2004 [140]      □           □                  
Bottomley, 2005 [141]                                   
Boyd, 1988 [142]  □  □ □ □                          □   
Brezden, 2000 [143]                                   
Burwell, 2006 [144]                              □ □    
Camoriano, 1990 [145]                                   
De Jong, 2004 [146]                                   
Demark, 1993 [147]                                   
Downie 2006 [148]                                   
Duric, 2005 [149]    □                               
Fairclough, 1999 [150]                                   
Fetting, 1998                                   
Galalae 2005 [151]                                   
Ganz, 2004 [152]                                   
Goodwin, 1999 [153]                                   
Hoskins, 1997 [154]   □                                
Hughson, 1986 [155]                                   
Hurny, 1996 [156]   □              □                  
Jacobson, 1999 [157]                                   
Knopf, 1986 [158]                 □                  
Land, 2004 [159]                              □ □    
Levine, 1988 [160]                                   
Love, 1989 [131]                                   
Lu, 2007 [161]      □                             
Macquart, 1997 [132]2                                   
Malinovszky, 2006 
[162]                                 
  
McArdle, 1981 [163]                                   
Meyerowitz, [164, 165]   □ □  □                              
Montgomery, 1997 
[166]                                 
  
Tchen, 2003 [168]  □ □                                
Tierney, 1991 [169]                                   
Van Dam, 1980 [170]                                   
Reviews                                   
NIH Cons. 2000 [171]                                   
Shapiro, 2001 [172]                                   
Moore, 2007 [173]                                   
Partridge, 2001 [174]                                   
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found it in 19% of the patients [131]. Constipation is a well-known 
side effect of ondansetron [188], which was used frequently as an 
antiemetic. 
Diarrhoea 
As expected, diarrhoea was more frequent in the chemotherapy 
group where 35% reported at least ‘a little’ diarrhoea compared 
to 12% in the control group. EORTC QLQ-C30 diarrhoea scores of 
around 28, that is considerably higher than in our study, were 
observed following standard dose CEF [189]. Increased frequency 
of diarrhoea was also reported in a German study [151]. In an 
American study 37% experienced diarrhoea after chemotherapy 
[131], and in a French study the prevalence was 17% [132].  
 Financial difficulties 
The expected differences concerning financial difficulties were 
not found. The hypothesis was based on an American study [164, 
165] first published in 1979, which reported direct costs (most 
insurances policies did not cover all costs), lost income, lack of job 
mobility, and adverse effects on employment status [165]. How-
ever, later studies concerning the treatment phase have not 
addressed this issue. Taken together with the lack of differences 
concerning work, our results suggest that while some patients 
may have been on sick leave during treatment, the Danish em-
ployment system secures full wages during temporary absence 
for most patients, and thus the chemotherapy seemed to have no 
major economic consequences. Furthermore, the chemotherapy 
did not seem to affect the patients’ employment situation, at 
least not in the short term (see below).  
Anxiety and depression (HAD Scale) 
We did not find the expected increase in anxiety whereas patients 
in the chemotherapy group were more often depressed according 
to the HAD Scale (9% vs. 5%). A Swedish study found no effect of 
chemotherapy on HAD anxiety or depression [167]. A study fo-
cused on anxiety did not find higher anxiety in women random-
ised to chemotherapy [190]. A small group of patients may thus 
become clinically depressed, whereas for the vast majority – 
while distressing – the treatment is not associated with psychiat-
ric morbidity. Psychological distress was further discussed in the 
section on emotional function above.  
Energy 
As shown in Table 4 several studies have assessed fatigue, 
whereas ‘lack of energy’ has not been the term used to communi-
cate the findings, except in an interview study [138]. Energy can 
be seen as the opposite of fatigue; thus, the discussion in the 
section on fatigue (above) also applies to energy. One important 
observation made in our study was that, although significantly 
lower than in the chemotherapy group, the proportion of women 
not undergoing chemotherapy who reported lower energy than 
before the operation was fairly high (e.g., 40% at five months).  
Weight gain 
Weight gain (here defined as an increase of at least 2 kg) was 
frequent in both groups but clearly more frequent in the chemo-
therapy group where 55% of patients reported weight gain at 5 
months (compared to 30% in the no treatment group). Again, this 
result shows the importance of a control group to avoid attribut-
ing all changes to chemotherapy. Many other studies have re-
ported weight gain based on patient self-report or measured 
objectively. In 1990, a study describing weight gain was published 
along with a review of 12 similar published studies. In their study, 
the authors found that weight gain was associated with increased 
risk of recurrence and death [145]. Subsequent research has not 
clarified this issue: while obesity is associated with poorer prog-
nosis, it is still unclear whether weight gain also worsens progno-
sis [191]. Weight gain seems to be a related to the duration of 
chemotherapy, to onset of menopause (weight gain being more 
frequent in patients becoming postmenopausal from chemother-
apy), to reduced energy expenditure [192], and to reduced physi-
cal activity [191, 193, 194]. A recent study proposed that reduced 
thyroid function following chemotherapy might also contribute 
[195]. 
Hair loss/wearing a wig 
Hair loss and alopecia following chemotherapy are well docu-
mented, and included in most studies of HRQL (Table 4). Hair loss 
has been named the most troublesome [149] or the second most 
significant/problematic side effect of chemotherapy [138]. Com-
plete alopecia is common following anthracycline-containing 
chemotherapy (i.e., epirubicine in CEF, adriamycin in CAF, CA) 
whereas hair loss after e.g. CMF is less severe [172, 174]. In an 
American study published in 1989, hair loss was experienced by 
89% but only 44% had expected this [131]. Few HRQL studies 
have assessed whether patients wear a wig; in our study only 8% 
of patients in CMF chemotherapy reported wearing a wig. 
Anticipatory nausea 
Anticipatory nausea is a well known though not routinely as-
sessed phenomenon experienced by 53% of the patients in che-
motherapy in our study (compared to 3% of controls). It is 
thought to develop through a classical conditioning process, and 
has been carefully studied by psychologists [135, 166]. The prob-
lem tends to increase during the treatment period (Fig. 2, paper 
VII) [166], and is ideally prevented through effective treatment of 
nausea and vomiting. Psychological [196] and pharmacological 
[197] intervention have been shown to have some effect.  
Sore mouth 
This symptom was seen in 27% of the patients in chemotherapy 
compared to 5% of the control group. The symptom has been 
assessed in a few other HRQL studies [132, 142, 169]. One study 
reported mouth sores [131] and similarly, studies based on physi-
cian-rating of toxicity usually evaluate stomatitis [174]. Mouth 
soreness/stomatitis is a reflection of the well known consequence 
of cytotoxic therapy, mucositis [171, 174].  
Hot flushes/sweats 
These menopause-related symptoms were reported by 86% of 
the patients in chemotherapy compared to 25% of the (premeno-
pausal) controls (Table 2, paper VII). It would have been ideal to 
investigate the symptoms separately as has been done in other 
studies, but we chose to combine them to save space. An Ameri-
can study reported that at the end of primary treatment 61% 
reported hot flushes, and this symptom as well as night sweats 
were more frequent (percentages not reported) in patients who 
had undergone chemotherapy [152]. Another American study 
reported hot flushes in approximately 40% of the women [131] 
after chemotherapy. In a British study patients reported increases 
in night sweats, daytime sweats, and hot flushes after standard 
chemotherapy [162]. In a small, Canadian interview-based study 
about half of the patients reported being awakened by hot 
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flushes [148]. Vasomotor symptoms (hot flushes, feeling warm, 
and sweats) were also found in a Swedish study [167]. 
Given that many premenopausal patients become postmeno-
pausal as a result of chemotherapy (see below) the menopausal 
symptoms are certainly not surprising. Our study showed that the 
menopausal symptoms start shortly after initiation of chemother-
apy (Figure 2, paper VII). A parallel increase was observed in 
sleeping difficulties (Figure 1, paper VII), which may, of course, 
have other causes as well. 
Urinary incontinence 
This symptom was added to the questionnaire as a possible 
menopausal symptom following advice from a gynaecologist 
(paper I). During chemotherapy up to 43% of the patients in che-
motherapy (vs. 25% in the control group) reported at least ‘a 
little’ incontinence. None of the other studies has assessed this 
symptom but two studies have reported ‘bladder problems’ being 
much more frequent after CMF than AC [159] and that ‘urinary 
problems’ were present in 12% of patients after different kinds of 
chemotherapy [131]. Therapy-related bladder problems may be 
directly to cytostatics (e.g. a toxic effect of cyclophosphamide on 
the bladder is well known and necessitates the use of the preven-
tive agent when high-dose treatments are given), whereas indi-
rect effects via endocrine changes are longer-term issues. Given 
that we have not identified other studies fully confirming our 
observation, additional research about the occurrence of urinary 
incontinence is needed. 
Vaginal dryness 
In our study, 42% reported at least ‘a little’ vaginal dryness’ com-
pared to 15% of controls. The three articles listed in Table 4 did 
not report percentages. Vaginal dryness is associated with meno-
pause and negatively affects sexual function [187].  
Vaginal flux 
We added this symptom to the questionnaire following inter-
views where it was reported by four of 14 patients (paper I). 
However, the symptom was not seen more frequently in the 
chemotherapy group, a finding consistent with a Swedish study 
[167]. The symptom has not been studied in the other papers 
reviewed (Table 4). 
Amenorrhea 
It is well established that chemotherapy leads to amenorrhea in a 
significant proportion of premenopausal women [153]. The likeli-
hood of amenorrhea increases steeply with age [153, 187, 198] as 
it depends on the follicular reserve [187]. Our analysis of this 
association in premenopausal women treated with chemotherapy 
(paper VIII) showed that 25% of women below 40 years, 57% of 
women aged 40-44 years, 90% of those aged 45-49, and 100% of 
women aged 50 years or above became amenorrhoic. These 
results fit a graphical model of the relationship between age and 
amenorrhea closely [153]. Amenorrhea after chemotherapy has 
been reported to be permanent [199] but there may be excep-
tions where menses return after amenorrhea [187]. In addition to 
amenorrhea in direct relation to chemotherapy, young women 
who preserve their menses may experience premature meno-
pause [187]. 
 
Irregular bleedings. Irregular bleedings were experienced by 86% 
of patients in chemotherapy compared to 30% of controls. This 
symptom was not assessed in the other studies (Table 4).  
Frequency of intercourse and interest in sex 
Our study suggested that chemotherapy reduced sexual interest 
but not frequency: 19% of patients in chemotherapy reported no 
interest in sex (vs. 7% in the control group). Contrary to expecta-
tion no difference was seen in frequency of intercourse (Table 2, 
paper VII). Several studies have reported that sexual function is 
affected by chemotherapy [139, 144, 152, 159, 162, 164, 165, 
168]. The largest decrease in sexual function has been observed 
in patients who become postmenopausal after chemotherapy 
[144, 187, 200]. 
 
 
 
Table 5  
 
Results from studies reporting ‘HRQL effects of chemotherapy’ other 
than those included in Table 4, listed alphabetically according to first 
author. In all reported cases reduced wellbeing was associated with 
chemotherapy. 
 
HRQL effects 
 
Physical wellbeing, satisfaction with sex life [137] 
Physical wellbeing [140] 
Anger, recreation [142] 
Nail problems [138] 
Menopausal symptoms (a 13-item subscale of the FACT-ES), detailed 
description of the nature and consequences of cognitive impairment 
during chemotherapy [148] 
Thought of actually having treatment (3rd most troublesome), altered 
sense of taste (5th most troublesome), problems with needle injec-
tions (9th most troublesome) [149] 
Physical side effects (BCQ) [202] 
Systemic side effects (a subscale of the EORTC QLQ-BR23 Breast Cancer 
Module including items on dry mouth, food and drink tasting diffe-
rent than usual, painful, irritated or watery eyes, hair loss, feeling ill 
or unwell, hot flushes, headaches) [151] 
Pain with intercourse [203] 
‘Health problems stand in the way of activities’ scale [154] 
Physical wellbeing, perceived adjustment/coping [156] 
Change in bowel pattern, mobility [158] 
Increased production of gas, knowing you must come to clinic to receive 
treatment; drowsy after chemotherapy; tearfulness; runny, dripping 
nose; burning, watery eyes [160] 
Eye problems, restlessness, weakness, mood swings [131] 
Physical wellbeing scale (sleep, energy, pain and physical discomfort, 
eating, sexual functioning, sensory function, capability of daily living) 
[161] 
Headache, stomach pain, muscular pain, articular pain, skin rash, 
weight loss, cystitis [132]3 
Sexual pleasure, sexual discomfort, aches and pains [162] 
Nervousness, irritability, tearfulness, flu-like symptoms [164, 165]  
Sickness, sore eyes, heartburn, taste change [169] 
Spiritlessness, shivering [170] 
 
 
                                                                        
3
 This study evaluated NCF chemotherapy, tamoxifen was also 
given. 
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Satisfaction with appearance 
Hair loss and other consequences of chemotherapy may obvi-
ously affect body image, which may already be impaired due to 
breast surgery. In our study 65% of the patients in chemotherapy 
compared to 46% in the control group reported a score of 5 or 
less on a 7-point scale for satisfaction with appearance (Table 2, 
paper VII). A previous study has reported impaired feeling of 
attractiveness [142], and a Swedish study reported poorer body 
image associated with chemotherapy [167]. The other studies 
reviewed did not assess this issue. Body image is included in 
currently used instruments such as the EORTC QLQ-BR23 Breast 
Cancer Module [201]. 
Employment and full-time work 
As discussed in the section on financial difficulties (above) we did 
not find any association between chemotherapy and work. 
Other findings 
Obviously, parts of the findings in the literature could not be 
categorised according to our ‘system’ because HRQL aspects 
other than those assessed in our study had been investigated. 
These findings are listed in Table 5.  
Some findings could not be included in Table 4 because the terms 
used were less specific (or, at a more global level) than in our 
study, e.g., ‘physical wellbeing’. Such results do not add to the 
description provided in Table 5. The same is the case when overall 
results from multi-item scales measuring several symptoms are 
presented. The findings that chemotherapy was associated with 
higher scores for 13 menopausal symptoms in the FACT-ES, for 
eight symptoms in the systemic side effects scale of the EORTC 
QLQ-BR23, or for seven different HRQL aspects combined in a 
physical wellbeing scale do not necessarily imply that chemother-
apy had an effect on all individual items (unless separate analyses 
of the items or an overall DIF test showing no DIF was reported). 
In contrast, other results add potentially important information. 
First, some specific issues not included in Table 4 have been re-
ported: altered sense of taste [132, 149, 169, 204], nail problems 
[138]; increased production of gas [160]; runny, dripping nose 
[160]; eye problems [131, 132, 160, 169]; flu-like symptoms [164]; 
headache, stomach pain, muscular pain, and articular pain [132] 
(the latter may also have been caused by tamoxifen); and heart-
burn [169]. Eye problems and altered sense of taste were each 
reported in four studies, and eye problems are likely manifesta-
tions of mucositis/conjunctivitis. The remaining findings must be 
viewed as preliminary. Second, additional aspects of some of the 
issues already included in Table 4 have been reported. This in-
cludes psychological aspects (e.g., anger, perceived adjust-
ment/coping, being tearful, mood swings) and aspects of sexual-
ity (e.g., satisfaction with sex life, pain with intercourse).  
Finally, the ‘thought of actually having treatment’ (the third most 
troublesome aspect of chemotherapy) and ‘knowing you must 
come to clinic to receive treatment’ are probably good expres-
sions of the mental burden associated with repeated treatments 
[149]. Similar findings were made in our pilot study (paper I) 
where the repetitive character of coming to treatments and be-
coming sick was mentioned as very distressing.  
As discussed in the section on emotional function above, the 
psychological experience and distress experienced by patients in 
chemotherapy seems insufficiently investigated, at least in the 
literature reviewed here. The contrast between our finding of no 
impairment of emotional function after chemotherapy and the 
distress reported in various ways (e.g., the ‘thought of actually 
having treatment’) calls for conceptual clarification. ‘Emotional 
function’ is conceptually closely linked to anxiety and depression, 
and while it is certainly important to investigate psychologi-
cal/psychiatric morbidity, it seems extremely relevant also to 
investigate patients’ experience of chemotherapy in more detail. 
Such research could have important consequences. First, it would 
clarify whether additional issues need to be added to the meas-
urement tools currently used in order to obtain a sufficient de-
scription of the HRQL impact of chemotherapy, which can form 
the basis for comprehensive information to future patients. Sec-
ond, increased understanding of the patients’ experiences may 
also be valuable for the clinical management of the problems. 
Table 5, which reports the findings not fitting into the categories 
used in our study, thus shows that: 
• Relatively few ‘new’ topics were identified, and most of 
these were reported in only one or a few reports. Issues that 
have been reported in one study only are of uncertain im-
portance, whereas altered taste and eye symptoms are rele-
vant topics to include in future studies. 
• Some HRQL aspects have been assessed differently in the 
studies reviewed (e.g., by asking in a more overall or a more 
specific way, or by focusing on different sub-dimensions of 
the HRQL aspect). This highlights a need for further research 
into the nature of the HRQL aspects assessed, a finding that 
is particularly obvious concerning the psychological aspects.  
• It seems surprising that so few HRQL aspects not included in 
our study have been identified. Our questionnaire was con-
structed in 1991. One could have expected that the exten-
sive research published subsequently had identified many 
previously unknown effects of chemotherapy. This has, how-
ever, not been the case. Two interpretations can be made of 
this. The first is that ‘almost everything was known at that 
time’. The second is that the subsequent research has failed 
to identify the topics we overlooked. 
The conclusion drawn in the last section above can be contrasted 
against the picture shown in Table 4: despite the fact that it can 
now be concluded that it was possible to compose a reasonably 
‘complete’ questionnaire several years ago, all the subsequent 
studies have assessed subsets of the issues identified at that time 
only. The second most comprehensive study published was Love’s 
study4. Another relatively complete though small study (39 pa-
tients in chemotherapy) used the EORTC QLQ-C30 and the breast 
cancer module QLQ-BR23 [151]. Of course, many studies may not 
have attempted to carry out a comprehensive assessment but still 
it appears surprising and problematic that most studies claiming 
to investigate chemotherapy effects have assessed so few. 
This line of thought raises the question whether it is at all rele-
vant to assess many different aspects of HRQL? And if all are not 
relevant, which should be included? As always, such questions 
about research methodology can be answered only when the 
aims are taken into account. HRQL studies may have descriptive 
aims in order to be able to provide comprehensive information to 
future patients. In such studies, the question is whether there are 
any of the topics in Table 4 patients do not want information 
about. If studies of HRQL are carried out to improve the care of 
patients, the main issue is to identify and monitor the symptoms 
or problems that can be prevented or ameliorated through inter-
                                                                        
4
 Love’s study was actually conducted prior to our study but was 
excluded from our initial review because it included lymphoma 
patients and many different chemotherapy regimens. 
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ventions, and the selection of topics may be guided by the oppor-
tunities for prevention or treatment. If studies have a compara-
tive aim, as in trials comparing treatment alternatives, valid com-
parisons demand that all HRQL issues that may differ between 
treatments are included [33]. Based on these considerations it is 
clear that all studies need not assess all 23 issues found to be 
affected in chemotherapy patients in our study (+ potential issues 
reported in other studies, e.g., physical function, emotional func-
tion, pain, constipation, anxiety, and additional psychological, 
sexual, and work-related issues). However, unless specific reasons 
for restricting the focus can be given it seems difficult to choose 
among the many issues in Table 4.  
It is therefore recommendable that future research more explic-
itly considers content. Researchers should present arguments and 
clear criteria for the composition of questionnaires. This study 
shows that the EORTC QLQ-C30 along with the DBCG 89 Ques-
tionnaire or the QLQ-BR23 cover the vast majority of HRQL issues 
associated with CMF chemotherapy.  
In summary,  
• In our study we tested 30 hypotheses about associations 
between adjuvant chemotherapy and HRQL and confirmed 
23 of these; 22 of these 23 findings have been found in other 
studies as well, and can be viewed as well documented. The 
exception is urinary incontinence, which must be viewed as a 
preliminary finding.  
• In addition, we found that patients in chemotherapy may 
experience dyspnoea and constipation. Dyspnoea has been 
found in a few other studies. Constipation may be fully or 
partially explained by antiemetic therapy.  
• Other studies have found additional variables to be associ-
ated with chemotherapy. Changes in taste and eye problems 
have been found repeatedly, whereas other findings must be 
viewed as preliminary because they have been reported in 
only one study. 
• It can therefore be concluded that there are about 27 symp-
toms/problems that are likely effects of adjuvant chemo-
therapy (the exact number depends on the concepts used: 
the number may be increased by splitting up symptoms or 
reduced by collapsing them). 
• The psychological aspects of chemotherapy do not appear 
fully clarified. In particular, the methods used in our study 
may not provide a sufficient evaluation. 
• The questionnaires used in most other studies have had 
inadequate content.  
If these findings summarised above are contrasted with publica-
tions reviewing the HRQL effects of chemotherapy, it is clear that 
these reviews are missing many findings. As shown in the lower 
part of Table 4, each of the four authoritative texts is missing 
many well-documented symptoms and problems [171-174]. 
4.9.7  Discussion – HRQL after the treatment period 
Most of the literature concerning the relationship between adju-
vant chemotherapy and HRQL after the treatment period consists 
of cross-sectional studies of ‘survivors’, typically 2-10 years after 
their diagnosis. As the time horizon in most such studies is longer 
than the present study, many of the results are not directly rele-
vant in the discussion of our results for the period 9-24 months 
after start of treatment (i.e., 3-18 months after completion of 
chemotherapy). However, as symptoms found e.g. five years after 
treatment are likely to be present in the previous years as well, 
some findings from the long-term studies are relevant. 
Overall, our results and other research show that some symptoms 
and problems disappear or diminish, and that others persist. 
Thus, a main finding in our data was the dramatic reduction in the 
number and magnitude of differences between patients in che-
motherapy and the control group. Most of the problems associ-
ated with chemotherapy had diminished or disappeared at the 
nine-month assessment (three months after chemotherapy com-
pletion). This is clinically important. If Figs. 1 and 2 (Paper VII) are 
visually compared, Fig. 1 shows a general tendency towards dis-
appearance of differences between the groups from five to nine 
months, whereas Fig. 2 shows evidence of persistence of prob-
lems in the chemotherapy group for many areas. The reduction of 
impairments in Fig. 1 is pronounced in most of the upper eight 
panels, which are the functional scales, fatigue and nau-
sea/vomiting. The gastrointestinal symptoms lack of appetite, 
constipation, and diarrhoea were also reduced to the level of the 
control group. In contrast, Fig.2 shows that higher levels of hot 
flushes/sweats, anticipatory nausea, irregular bleedings, amenor-
rhea, reduced sexual interest, vaginal dryness, and weight gain 
persisted in the chemotherapy group throughout the two years. 
This difference between Figs. 1 and 2 probably reflects that the 
EORTC QLQ-C30 (Fig. 1) is a broad and general HRQL question-
naire and therefore mainly elucidates the acute toxicity and func-
tional impact of chemotherapy, whereas Fig.2 is the specific DBCG 
89 Questionnaire, and includes several items measuring the hor-
monal consequences of chemotherapy. 
The pattern of relatively quick resolution of chemotherapy toxic-
ity and functional impact is consistent with other prospective 
studies [140, 141, 150, 156, 159]. 
 The other main finding concerns the symptoms/problems that 
persist. Many ‘breast cancer survivor studies’ have investigated 
patients at various time points but a large part of these studies 
have not investigated chemotherapy separately. They have re-
ported cross-sectional studies of breast cancer patients in gen-
eral, and do not make it possible to separate effects of diagnosis, 
surgery, and radiotherapy from chemotherapy. The following text 
will concentrate on studies that had designs that made it possible 
to elucidate the effect of chemotherapy. 
An early, American study consisted of interviews with 27 women 
who were 21 months after chemotherapy [205]. This study is 
mentioned here because patients were directly interviewed 
about their perception of effects of chemotherapy. The patients 
reported trouble sleeping, weight gain, hair loss (still), anticipa-
tory nausea, amenorrhea, and loss of energy. The mean time it 
had taken before they ‘returned to their old selves’ was 6.4 
months [205]. 
In an American interview study with 18 participants six months 
after chemotherapy patients reported hair problems (N=18), 
fatigue (N=15), weight gain (N=8), menopausal problems (N=7), 
emotional problems (N=6), and nail problems (N=6). The order of 
importance was weight gain (most important), emotional prob-
lems, reproductive/menopausal problems, and fatigue [138]. 
A Swedish randomised trial comparing adjuvant chemotherapy 
and radiotherapy with follow-up 2-10 years after treatment found 
that the only difference indicating higher symptomatology in the 
chemotherapy group was smell aversion (patients randomised to 
radiotherapy were found to have decreased stamina, more symp-
toms related to operation scar, and higher anxiety) [206]. 
A small cross-sectional, American study (N=25 in the chemother-
apy group) found that patients who had undergone chemother-
apy seven years earlier had more fatigue, weight gain, hot flush-
es, vaginal dryness, mood swings, dyspareunia, and difficulty 
reaching orgasm than other breast cancer patients [207]. 
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A much larger American study (mean three years after diagnosis) 
found no differences in most aspects of HRQL (SF-36) when com-
paring breast cancer patients to healthy women but found higher 
levels of hot flushes, joint pains, and headaches, and sexual dys-
function [203]. The relationship to chemotherapy was investi-
gated for sexual dysfunction only, and an association with chemo-
therapy was found [203, 208]. The study also reported that 
among women below 50 years sexual dysfunction was most 
frequent in those who had stopped menstruating [203]. In cross-
sectional analyses from the same study, patients treated with 
chemotherapy had more weight gain, vaginal dryness, poorer 
sexual function, and more pain with intercourse [209]. 
The levels of energy were investigated in the same breast cancer 
data compared to a general population sample and to baseline 
data from the Breast Cancer Prevention Trial. The ambiguous 
result was that breast cancer survivors had slightly better energy 
than women in the general population sample but lower energy 
than participants in the prevention trial. Among breast cancer 
patients, fatigued patients were more likely to have been treated 
with chemotherapy [210].   
A more recent American study (mean 10 years after treatment) 
found lower scores for overall quality of life and on a social sub-
scale (interference with activities at home, financial burden, 
sexuality) in a subgroup of patients who had received chemother-
apy [211]. 
A Canadian study followed patients in chemotherapy and healthy 
controls for two years, and found no difference in total FACT-G 
score after one year but persisting fatigue (FACT-F) and meno-
pausal symptoms (FACT-ES) [212]. 
A prospective American study followed patients for five years and 
found a lasting effect of standard dose chemotherapy on meno-
pausal symptoms (sweats, hot flushes, vaginal dryness) and on 
sexual pleasure and discomfort but not frequency of sexual activ-
ity [162]. 
A recent Swedish study found that chemotherapy was negatively 
associated with return to work 2-3 years after diagnosis [213] 
whereas no such association was found in two American studies 
[214, 215].  
A relatively small French study found no effect of chemotherapy 
(compared to no chemotherapy) at a mean of 9.6 years after 
chemotherapy [216]. 
In an analysis from the Nurses’ Health Study women diagnosed 
with breast cancer treated with chemotherapy reported a higher 
level of sexual dysfunction and a larger decline over time in the 
SF-36 scales role emotional and vitality compared to other wom-
en diagnosed with breast cancer [217]. 
A recent Korean study showed markedly poorer HRQL in breast 
cancer survivors compared to a general population sample, e.g. in 
most EORTC QLQ-C30 scales, but none of these was associated 
with chemotherapy [107]. 
A recent Danish study compared the SF-36 scores of breast cancer 
survivors (N=1,316) 5-15 years after their diagnosis against age-
matched reference data from the large Danish Health and Mor-
bidity Survey. There were almost no differences between breast 
cancer patients and healthy women. The breast cancer patients 
reported less pain, better general health, but worse mental 
health; however, these differences were very small. In other 
scales, younger breast cancer patients reported slightly poorer 
HRQL than healthy controls whereas the opposite was seen for 
older women. Remarkably, among breast cancer patients no 
associations were found between past chemotherapy and any of 
the subscales [218]. 
The issue of possible long-term effects of chemotherapy on cogni-
tive function needs separate attention due to the importance of 
this relatively newly described consequence of treatment and 
because, despite much recent research, the results are still con-
troversial [219-222]. Studies reporting short-term effects were 
listed in section 4.9.6.  
In 1995, an American study investigated 28 breast cancer patients 
who had completed adjuvant chemotherapy 1-12 months previ-
ously, and made preliminary findings suggesting cognitive im-
pairment [223]. Three years later, a Dutch study reported that 
32% of breast cancer patients treated with high-dose chemother-
apy had cognitive impairment compared to 17% of patients 
treated with standard-dose and 9% of control patients [224]. 
Another study of standard dose CMF chemotherapy from the 
same group found that 31% of the patients reported problems 
with concentration and 21% problems with memory compared to 
6% and 3% of controls, respectively. Impaired (‘objectively’ meas-
ured) cognitive function was found in 28% of chemotherapy 
patients compared to 12% of controls [225]. As in other studies 
[226, 227], self-reported and measured cognitive function were 
uncorrelated [225]. An American study of breast cancer and lym-
phoma survivors 5 years after diagnosis found poorer cognitive 
function in those treated with chemotherapy [228]. Another 
American study questioned the results from the previously pub-
lished cross-sectional studies. They investigated 84 breast cancer 
patients before chemotherapy, and found that 35% experienced 
cognitive impairment [229]. However, when following up a sub-
group of 18 of these women, more than half of them (11) experi-
enced further decline [230]. Two metaanalyses produced some-
what different conclusions but both found evidence of effect of 
chemotherapy on cognitive function [231, 232]. The most recent 
included 16 studies of which nine involved breast cancer patients 
and concluded that the evidence of effect was seen also in the 
subgroup of breast cancer studies [232]. The three newest, pro-
spective studies have reported conflicting results. In an American 
study, seven of 28 patients declined in two or more domains from 
pre- to post-test [233]. A Dutch study compared high-dose-
chemotherapy (N=28), standard dose chemotherapy (N=39), no 
chemotherapy (N=57), and healthy controls (N=60). Only patients 
in high-dose chemotherapy deteriorated in cognitive function 
[234]. A British study followed 85 women allocated to chemo-
therapy as well as controls. No difference in the proportions 
experiencing decline in cognitive function was found [235]. A 
parallel paper from the same study reported interview data. Four 
weeks after completion of chemotherapy, 77 patients (83%) 
reported memory problems and 73 (78%) concentration problems 
but one year later, there was no longer any difference when 
compared to a control group [227]. Finally, the most recent addi-
tion to the literature is a pilot study showing promising results for 
a cognitive-behavioural intervention program against chemother-
apy-related cognitive dysfunction [236]. 
 
To summarise, the results of the studies of the impact of chemo-
therapy on HRQL after the treatment period are relatively com-
plex. Looking mostly at the largest, newest, and most well-
designed studies, there seems to be little or no effect on the 
general aspects of HRQL as measured by the SF-36, the FACT-G, 
or the EORTC QLQ-C30. In contrast, symptoms such as anticipa-
tory nausea, weight gain, and not least endocrine effects (e.g., 
hot flushes/sweats, irregular bleedings/amenorrhea, vaginal 
dryness), disturbed sleep, and sexual dysfunction are well docu-
mented. Concerning cognitive function, there seems to be little 
doubt that many patients experience problems and that in some 
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patients objective measures support this. However, the fre-
quency, severity, and nature of cognitive problems remain un-
clear, as do their relationships with types and doses of chemo-
therapy. 
 
4.9.8  Discussion – staff study 
The results of the staff study proved useful as a means of eluci-
dating the knowledge of the physicians and nurses, although the 
study was not intended for this purpose. The somewhat surpris-
ing result was that the staff did not expect many of the ‘well-
known’ side effects of chemotherapy. The proportions not ex-
pecting these problems were relatively high for role function 
(37%), cognitive function (53%), social function (47%), overall 
quality of life (25%), weight gain (31%), hair loss (25%), dissatis-
faction with appearance (66%), and impaired sexual life (43%). In 
contrast, only one of the 36 participants did not expect fatigue 
and amenorrhea (paper VII, table 3). 
As discussed in paper IV, the results seem to indicate that in 
general the staff understood the exercise correctly – for example, 
nobody appeared to have misunderstood the direction of the 
scale by answering that patients in chemotherapy had fewer 
symptoms than controls. And as stated above, almost all ex-
pected fatigue and amenorrhea. The staff responses can be 
viewed as a description of the ‘maximally possible information 
given to patients’: it is unlikely that the staff informed patients 
about side effects they did not expect to occur. Furthermore, it 
seems unlikely that they had passed on all information they pos-
sessed to the patients. Finally, the participants selected for the 
staff study was the most experienced nurses and physicians. 
Some patients have been in contact with less experienced staff 
who had less knowledge. In other words, the results suggest that 
the oral information given to patients has been incomplete.  
This assumption also seems probable given the results presented 
previously in this chapter: the quality of life studies – which were 
conducted, one must assume, by specialists in the field – have 
been extremely incomplete in their coverage. Many symptoms 
and problems shown long ago to be associated with chemother-
apy were not assessed in later studies. Similarly, the reviews of 
side effects in prestigious journal were also remarkably incom-
plete as illustrated in Table 4 (bottom). Therefore, it is not surpris-
ing that the knowledge of the health care professionals and the 
information given to patients has been incomplete. 
Furthermore, it is well known that not all information given to 
cancer patients is understood and remembered by the patients 
[237, 238]. Thus, there are two aspects of physician-patient 
communication that are far from optimal: the information given 
to patients is incomplete and only parts are remembered.  
The lack of knowledge of side effects by professionals was also 
found in a French study. Macquart-Moulin compared 50 patients’ 
self-report of 17 symptoms throughout chemotherapy against 
physician-ratings using a standardized sheet at the same time 
points. Symptoms were systematically and strongly under-
estimated [132]. For example, 73% of the patients reported nau-
sea but this was noted for 38% only. 
Many other studies have investigated the extent of agreement 
between patients’ assessment of their HRQL and health care 
professionals’ [79, 80, 89], and have generally found low to mod-
erate agreement although in some newer studies the concor-
dance has been better [80].  
The two extremes of the communication process about HRQL 
effects of chemotherapy, at one end the patients’ experience and 
at the other end, their expectations, can be studied by comparing 
experiences against expectations in the same patients. This was 
done in an American study. Many patients did not expect even 
very frequent symptoms. Only 8% expected tiredness whereas 
86% experienced it. The corresponding figures were 44% vs. 89% 
for hair loss, 57% vs. 87% for nausea, 3% vs. 45% for weight gain, 
4% vs. 44% for mouth sores, 7% vs. 37% for diarrhoea, and 3% vs. 
19% for constipation [131]. The authors concluded that there was 
a two-way communication problem: ‘Patients not only fail to 
receive all the necessary information from clinicians, but they also 
fail to provide clinicians with a complete picture of their treat-
ment experience.’ [131]. Similarly, a Scottish study showed that 
most side effects experienced by breast cancer patients were not 
expected by them [169, 204].  
Several studies have indicated that patients want to be carefully 
and completely informed about consequences of treatment [239-
247]. The available research data, as discussed above, indicate 
that this has not been the case. This is an important result. The 
content of oral and written information to patients today should 
be critically reviewed. A logical, next step in the research must be 
further investigation of the preferences of patients for informa-
tion (i.e., which, and how much information is desired at various 
phases of the trajectory, and how should it be given?)(see also 
section 7.2.2.). 
Concerning the use of the staff study to elucidate the staff mem-
bers’ knowledge and information practices it should be empha-
sised that larger and much more detailed studies are needed in 
order to investigate these issues sufficiently.  
4.9.9  Discussion - overall comments 
Today (2007), the results of our study (and many of those re-
viewed) are relatively old. This must be taken into consideration, 
and limits their generalisability to the situation today in two ways. 
First, improvements in supportive care mean that some of the 
problems, particularly nausea and vomiting, must be expected to 
be reduced today. Other changes in treatment or other aspects of 
care may also have taken place, and can of course be positive 
(e.g. better communication skills) or negative (e.g., less time for 
the individual patient). The HRQL of patients treated with CMF 
today may therefore be different, and apart from the likely reduc-
tion in nausea and vomiting it is unknown whether other poten-
tial differences are for the better or worse. It has not been possi-
ble to locate any studies that have replicated the sampling and 
methodology of previous studies, and thus have been able inves-
tigate whether any major changes have taken place during the 
last decades.  
The other major limitation due to time is that while our study 
concerned CMF chemotherapy, other treatments have become 
standard today. The current recommendation in Denmark is three 
series of CE followed by three series of the taxane docetaxel 
(www.dbcg.dk, accessed June 2007). It is the impression from the 
literature reviewed in this section that there appears to be rela-
tively modest differences between the ‘traditional’ regimens such 
as CMF, CAF, CEF, AC, etc., although there are few formal com-
parisons. In contrast, there may be significant differences when 
these regimens – which have been the standard for approxi-
mately 25 years – are compared to new chemotherapeutic stan-
dards including taxanes [248] or other new drugs.  
These limitations should be taken into account when interpreting 
the results and it is recommendable that the present study is 
followed up by new studies of current treatments. 
It should also be remembered that the discussion has been re-
stricted to studies based on self-report (except for cognitive 
function and weight gain). Hundreds of studies could have been 
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added if those reporting physician-rated toxicity were also in-
cluded; this could have added substantially to documentation for 
some side effects. However, the focus here is on patients’ own 
assessments. 
Our review, as presented above, was subsequently checked 
against the systematic literature review carried out by Mandel-
blatt et al. [249]; no missing studies were identified. 
 The use of results from HRQL studies is further discussed in the 
Perspectives section. 
4.9.10  Conclusions 
• Based on the initial literature review and interviews (paper I) 
we hypothesised that 30 different HRQL issues would be im-
paired in patients undergoing CMF chemotherapy compared 
to patients not in chemotherapy; 23 of these hypotheses 
were confirmed (paper VII). Our study and other research 
suggest that additional HRQL aspects may be affected by 
chemotherapy. Thus, there is considerable evidence that pa-
tients in chemotherapy may experience effects on a wide 
spectrum of HRQL issues. 
• Concerning comprehensiveness, our study is clearly the most 
complete; most other studies have assessed surprisingly few 
of the HRQL issues shown in our study to be impaired in pa-
tients receiving chemotherapy.  
• Current review articles on HRQL effects of adjuvant chemo-
therapy mention only relatively few of these topics. 
• These discrepancies may seem surprising given that our 
questionnaire was based on the literature available in 1990. 
Looking back one can say that the nature of quality of life ef-
fects of chemotherapy was almost fully clarified relatively 
early (or, at least few new effects have been identified), but 
this ‘clarification’ was not generally acknowledged. 
• Concerning HRQL after the treatment period, our main find-
ing was that many symptoms and problems had declined or 
disappeared three months after chemotherapy, but some 
persisted: anticipatory nausea, weight gain, endocrine ef-
fects (e.g., hot flushes/sweats, irregular bleed-
ings/amenorrhea, vaginal dryness), disturbed sleep, and sex-
ual dysfunction. These findings are in agreement with the 
literature. Many patients seem to experience cognitive prob-
lems but despite intensive research it is still not clear 
whether or to what extent chemotherapy leads to lasting 
and objectively measurable cognitive dysfunction. 
• The staff study showed that experienced physicians and 
nurses did not expect many of the ‘scientifically well docu-
mented’ consequences of chemotherapy.  
• These findings indicate that knowledge is not just knowl-
edge: there may be large differences between ‘what is 
known in the literature’ and what experts know.  
• It is important for patients to be informed about conse-
quences of a treatment before and during treatment. Both 
written material and oral information is important. The cur-
rent study suggests that the information given to patients 
about chemotherapy should be more comprehensive than in 
current review articles and – probably – than that which has 
been practised in most places.  
• Adjuvant therapy for breast cancer is undergoing quick and 
profound changes and new studies of HRQL consequences 
are needed in order to obtain up-to-date knowledge for fu-
ture patients. 
4.10  Chemotherapy or ovarian irradiation: impact on HRQL 
(paper VIII) 
4.10.1  Participation 
The flow of patients in the DBCG 89 B protocol in Denmark was 
illustrated in Fig. 1 of paper VIII. The majority of patients (540 of 
the 762 in the protocol) were included from Denmark with the 
remaining patients recruited from Sweden and the Netherlands. 
During the inclusion period, 340 patients from Denmark were 
randomised in the protocol; 23 of whom were not reported from 
the DBCG Secretariat to the quality of life office due to adminis-
trative errors. The remaining 317 patients were invited to take 
part in the study. We chose to exclude the 14 patients who de-
cided not to have the treatment they were randomised to from 
the analyses. Had we used the intention to treat principle for the 
analyses, our results for e.g., ovarian ablation would have been 
confounded with results from patients undergoing chemother-
apy. After two years, 260 of the 317 patients were alive and re-
currence-free, of whom 196 (75%) had filled in all six question-
naires, of whom 87 were in the chemotherapy group and 109 in 
the ovarian ablation group. We do not have an explanation of 
why the randomisation during this period was somewhat skewed 
towards ovarian ablation, but in the entire trial almost the same 
numbers of patients were randomised to the two arms (386 and 
376, respectively) [250]. Of the 109 women in the ovarian abla-
tion group 107 had ovarian radiation and 2 underwent surgical 
oophorectomy. 
As described in paper VIII analyses at several levels showed no 
evidence of bias in the patients included in the final analysis 
compared to the Danish patients included in the trial.  
4.10.2  Results 
The comparison of patients randomised to chemotherapy and 
ovarian ablation, respectively, is shown in Figs. 2 and 3 in paper 
VIII. The overall result was that patients in chemotherapy have 
higher levels of symptomatology in the treatment period (the first 
three assessments). The opposite was seen for a few variables 
related to ovarian ablation. There were few differences after the 
treatment period.  
Thus, patients in chemotherapy reported more impairment of 
cognitive5 and social function, more fatigue, nausea and vomit-
ing, dyspnoea, sleep disturbances, loss of appetite, constipation, 
depression, weight gain, hair loss, anticipatory nausea, sore 
mouth, and urinary incontinence, less satisfaction with appear-
ance, and poorer global quality of life. Directly after radiotherapy 
the patients in the ovarian ablation group had more diarrhoea.  
Patients in the ovarian ablation group had more hot flush-
es/sweats and became amenorrhoic more quickly and more 
completely. However, as 77% of the patients in the chemotherapy 
group had stopped menstruating at two years, and only 9% had 
regular bleedings by two years, the difference was relatively 
small. The age-stratified analyses (paper VIII) showed a pro-
nounced age-effect with only a quarter of the patients below 40 
years becoming postmenopausal after chemotherapy compared 
to 57% in the age-group 40-44 years and 90% in those aged 45-49 
years at diagnosis. 
                                                                        
5
 As for the comparison of patients in chemotherapy to patients 
not in chemotherapy, the cognitive function scale was the only 
scale showing DIF: the difference observed for concentration 
difficulties was much larger than for memory problems (section 
4.4.3 and Appendix A).  
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The additional analysis conducted to elucidate whether the exclu-
sion of patients who completed less than all six questionnaire 
affected the results showed that this was not the case (data not 
shown). All conclusions would have been the same if these pa-
tients were not excluded. In contrast, the plots were slightly 
changed if patients with a recurrence were not excluded (data not 
shown): the main difference was that the levels of several symp-
toms increased from 15 to 24 months as a reflection of disease-
related symptoms or treatment. However, all conclusions drawn 
from the comparison of the two groups would have still been the 
same. 
Table 6 summarises the results of the comparison of patients in 
chemotherapy and controls (paper VII) as well as the randomised 
trial comparing chemotherapy to ovarian ablation (paper VIII). 
The mean ages of the groups of patients are similar (between 44 
and 45 years).   
The outcome of the comparison is shown with a single symbol for 
each variable. Table 6 thus shows whether there is a difference 
and in which direction – not the magnitude or duration. A com-
parison of the graphs (Figs. 1 and 2 in paper VII vs. Figs. 2 and 3 in 
paper VIII) shows that, as one would expect, the differences were 
generally larger when chemotherapy was compared to controls 
than to ovarian ablation.  
With these reservations Table 6 shows that most of the differ-
ences were the same (though not necessarily of the same magni-
tude or duration) when chemotherapy is compared to controls 
and to ovarian ablation. However, no differences were seen for 
role function, energy, vaginal dryness, and interest in sex when 
comparing chemotherapy to ovarian ablation. In other words, 
these dimensions must have been affected by ovarian ablation as 
well. Three differences were reversed, i.e. higher scores were 
seen in the ovarian ablation group for hot flushes/sweats, irregu-
lar bleedings, and amenorrhea. Finally, the patients undergoing 
ovarian ablation had higher levels of diarrhoea at the one-month 
assessment whereas at five months the difference was opposite.  
From a medical/clinical point of view, the two main differences 
between chemotherapy and ovarian ablation are the duration of 
the treatment (six months’ chemotherapy compared to daily 
radiation for a week) and their content (cytotoxic or endocrine 
treatment). Table 6 can be seen as an analytical attempt to sepa-
rate the cytotoxic and endocrine effects of chemotherapy: the 
differences seen both when chemotherapy is compared to con-
trols and to ovarian ablation are those that can be attributed 
mainly to cytotoxic, not endocrine effects. The differences that 
are reversed (hot flushes/sweats, irregular bleedings, and ame-
norrhea) are those where the endocrine effect of ovarian ablation 
is stronger than that of chemotherapy.  
Thus, the overall picture is that while the HRQL impact of chemo-
therapy is clearly stronger and more diverse than that of ovarian 
ablation, it is also evident that ovarian ablation has considerable 
impact on important aspects of HRQL due to its endocrine effects 
and due to their consequences for sexuality. 
4.10.3  Discussion 
In this trial no difference was found in the efficiency of the two 
treatments [250]. This is consistent with the other randomised 
trials [199, 251-255]. In contrast, major differences in HRQL were 
detected. Assuming that the treatments are truly equally effi-
cient, ovarian ablation is thus clearly preferable to CMF chemo-
therapy if only ‘symptomatology’ is considered: many symptoms 
were more pronounced during the much longer cytotoxic treat-
ment, and only hot flushes/sweats were worse with ovarian 
ablation. However, the possible preservation of premenopausal 
status and fertility may outweigh the problems associated with 
chemotherapy for some women. Age is an important factor in this 
consideration, as the probability of becoming postmenopausal 
following chemotherapy is strongly age-related. Our results fol-
lowed a graphical model for the relationship between age and 
amenorrhea following chemotherapy [153] closely, and showed 
that while ‘only’ a quarter of the women below 40 years of age at 
diagnosis became postmenopausal following chemotherapy, the 
probability of amenorrhea was 90% in women aged 45-49 years. 
Thus, there is relatively little probability of staying premenopausal 
for a relatively large part of the women (in our study 58% of the 
premenopausal breast cancer patients were at least 45 years old).  
In addition to the results of the present trial there are two addi-
tional factors that must be taken into consideration in treatment 
decisions concerning premenopausal, receptor-positive women. 
First, as discussed in the section on chemotherapy above, CMF 
chemotherapy is no longer the standard chemotherapy. The Early 
Breast Cancer Trialists’ Collaborative Group’s 1998 review [256] 
suggested that anthracycline-containing regimens are more effec-
tive than CMF chemotherapy, and such regimens are now usually 
the standard, sometimes in combination with taxanes [257] 
and/or trastuzumab [6]. This does not affect the conclusions 
concerning better HRQL with ovarian ablation (as the other che-
motherapeutic regimens are probably similar to or worse in HRQL 
impact) but when other regimens are considered more effective 
than CMF, they are probably also more effective than ovarian 
ablation [258]. Although the differences may be small for the 
individual patient, the choice of ovarian ablation may thus be a 
trade-off of probability of cure against quality of life.  
The second factor in the decision-making is that instead of per-
manent ovarian ablation (as in this study) temporary ovarian 
ablation can be obtained through regular (typically monthly) 
injections with goserelin for 2-3 years. No direct comparisons of 
either effectiveness or HRQL impact of permanent and temporary 
ovarian ablation have been made but they are usually considered 
of similar effectiveness [259] and probably have a roughly similar 
HRQL profile in the two- or three-year treatment period. After 
this, the balance must be expected to shift towards an advantage 
for temporary ablation (as discussed below).   
Before proceeding with the discussion of chemotherapy or ovar-
ian ablation it should be briefly noted that there is also a discus-
sion of whether the treatments should be combined. Specifically, 
it has been argued that for women who do not become amenor-
rhoic after chemotherapy it may be advantageous to add ovarian 
ablation [258, 260-263]. 
 While there are no other published studies comparing HRQL 
between chemotherapy and permanent ovarian ablation, the 
results can be compared against those of three studies comparing 
CMF chemotherapy against temporary ovarian ablation by means 
of goserelin for two years [264]. 
de Haes et al.’s international, randomised trial followed patients 
for three years [264]. Consistent with our study the goserelin trial 
found generally better HRQL during the first six months, where 
the chemotherapy group received treatment, but higher levels of 
‘hormonal symptoms’ (hot flushes was assessed along with other 
symptoms as a total scale score) were found in the goserelin 
group during the two years of ovarian suppression. However, at 
three years the latter difference was reversed and the level of 
hormonal symptoms was higher in the chemotherapy group 
(probably because the menopause induced by chemotherapy is 
irreversible) than in the goserelin group, where ovarian suppres-
sion had been stopped one year earlier. Whereas we found no 
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differences in sexual interest, the scores for sexual interest were 
lower in the goserelin group during treatment, but higher at three 
years [264], thus suggesting a benefit from cessation of ovarian 
suppression. 
Bernhard et al.  recently reported a similar trial with similar re-
sults [262]. It showed less nausea/vomiting, better coping, and 
better overall health in the goserelin group but initially (at three 
months) these patients had more pronounced hot flushes and 
lower mood. At three years, many more patients in the chemo-
therapy group had hot flushes and amenorrhea, thus confirming 
the reversibility of the ovarian suppression, particularly among 
younger women [262]. 
Finally, HRQL was assessed in the Swedish participants of an 
international study comparing various endocrine regimens includ-
ing goserelin [139, 167]. Chemotherapy was given to the node-
positive patients. The study thus allowed an indirect (non-
randomised) comparison of patients in chemotherapy with pa-
tients treated with goserelin. Sexual function was impaired to the 
same extent during the first two years, whereas, as in de Haes’ 
study, the assessment one year after goserelin cessation indi-
cated that the effect of goserelin, but not chemotherapy, on 
sexuality was reversible [139]. Vasomotor effects tended to be 
more pronounced during goserelin treatment but declined after 
goserelin was stopped, whereas they persisted in the chemother-
apy group [167].  
Thus, all three goserelin studies found that endocrine symptoms 
were reversible following completion of goserelin treatment. This 
suggests a likely advantage of temporary ovarian suppression 
over permanent ovarian ablation. 
A theoretical study based on quality-adjusted life-years investi-
gated the trade-offs between treatment efficacy and HRQL when 
choosing between chemotherapy, surgical ovarian ablation, and 
medical ovarian suppression [265]. The study tested how differ-
ent combinations of the relative efficacy of treatments and the 
relative utility of side effects would affect treatment decisions. It 
was found that even small differences in treatment efficacy would 
shift the balance towards the most effect treatment irrespective 
of how patients evaluated the side effects of the treatments. The 
magnitude of differences necessary to shift the balance were 
smaller than those detectable in the available trials [265]. Assum-
ing equal efficacy the cut-point for treatment decisions would be 
a relative utility of side effects of 0.95. Perfect health has the 
utility of 1.0. The relative utility value of 0.95 corresponds to a 
utility of chemotherapy side effects of 0.86 (during a six-month 
period) and a utility of ovarian ablation side effects of 0.90 (as-
sumed to last for two years). Thus, if a potential patient would say 
that the utility during chemotherapy was lower than 0.86 (and 
that of ovarian ablation was still 0.90) the model would then 
favour ovarian ablation. In contrast, if the difference in utility 
between treatments were viewed as smaller, the model would 
then favour chemotherapy [265]. Even though relative utility 
values may be difficult (if at all feasible) to use in clinical practice, 
the study nicely illustrates the interplay between effectiveness 
and HRQL of treatments. 
A British study investigated the preferences of 200 healthy, pre-
menopausal women for goserelin and CMF chemotherapy, re-
spectively [266]. The participants were asked to imagine they had 
breast cancer and were given detailed descriptions of the treat-
ments and their side effects. They were informed that the treat-
ment had the same efficacy. Most women (78%) preferred gose-
relin, 11% preferred chemotherapy, and 11% remained 
undecided [266]. This finding is consistent with the decision-
analytic study mentioned in the previous section provided that 
the difference in utility between treatments is seen as significant 
(e.g., more than 5%) [265]. 
These results suggest that there are two main factors to consider 
when informing future patients. First, whether more than one 
treatment option should be presented. Second, if more than one 
option is considered then the alternatives must be determined. It 
is meaningful to present treatment alternatives only if there are 
differences that may be of relevance to the patients. The HRQL 
differences between chemotherapy and ovarian ablation repre-
sent such differences [258, 266, 267] and there may be other 
alternatives. Therefore, there are arguments for presenting ovar-
ian ablation/suppression as an alternative to chemotherapy. 
The evidence presented here thus indicates that adjuvant therapy 
is one of the still relatively rare cases [268], where findings from 
HRQL research could potentially affect treatment decisions. How-
ever, it is controversial whether this will take place. The question 
is: will physicians and/or guidelines present a dilemma (i.e., a 
detailed description of the advantages and disadvantages of 
chemotherapy vs. ovarian ablation/suppression) to patients, or 
will treatment recommendations continue to be unidimensional 
(‘the best treatment is the most effective treatment as measured 
by probability of survival’)?  
While it is easy to argue that patients should have a choice, it is 
certainly not simple to go from unidimensional treatment rec-
ommendations (‘the most effective treatment we can offer you 
is…’) to multidimensional recommendations [267]. Obviously, 
physicians can present only parts of the available scientific evi-
dence concerning the treatment of a condition – otherwise one 
could imagine absurd situations where endless explanations and 
details would only confuse the patient. On the other hand, if 
different valuations of the scientific evidence may lead to differ-
ent treatment decisions, it is more problematic to deny the pa-
tient insight into complexity [267]. For example, for a 47-year-old 
premenopausal women with receptor-positive breast cancer, is 
the added toxicity associated with ‘optimal chemotherapy’ com-
pared to ovarian ablation justified by the increased probability of 
survival? If explained all details most patients will probably think 
so but some might not. In other words, the consequence of pre-
senting one treatment option only is that some patients will 
receive a treatment they would not have chosen had they been 
given a choice. Is it ethically acceptable to deny patients insight 
into a dilemma like this? And conversely, given that most patients 
will probably choose chemotherapy if it is presented as more 
effective, is it ethically acceptable to expose the patients to all the 
statistical information and medical complexity needed to make a 
truly informed decision?  
Obviously, the answers to these questions involve more than just 
the scientific knowledge about treatments – they also depend on 
how the relationship between physicians and patients is viewed.  
Patients’ expectations to the health care system is changing rap-
idly in these years, and more research into the patients’ views 
and expectations as well as public discussion of the medical deci-
sion-making process is needed. 
4.10.4  Conclusions 
• Chemotherapy was associated with more impact on HRQL 
during the six-month treatment period; only hot 
flushes/sweats were more pronounced in the ovarian abla-
tion group. Thus, from an overall, ‘HRQL perspective’ ovarian 
ablation or suppression may be the preferable treatment for 
many patients. This conclusion is in agreement with a study 
eliciting the views of healthy women.  
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• Among younger, premenopausal women, who may preserve 
their premenopausal status (including fertility) by having 
chemotherapy, this concern may be an argument for chemo-
therapy or for temporary ovarian ablation via goserelin, 
rather than permanent ovarian ablation.   
• No studies have directly compared the impact of permanent 
and temporary ovarian ablation. The studies of goserelin 
suggest that vasomotor symptoms and sexual function im-
prove after cessation of goserelin therapy. This is not the 
case in patients who have undergone chemotherapy. There-
fore, the balance between the HRQL impact of chemother-
apy and ovarian ablation may be even more favourable for 
temporary than for permanent ovarian ablation. 
• In addition to HRQL-related concerns, treatment decisions 
clearly involve judgements of the relative efficiency of 
treatments. While the available studies suggest that ovarian 
ablation and CMF chemotherapy are equally effective, other 
studies have provided evidence that alternative chemo-
therapeutic regimens are more effective than CMF.  
• These results suggest that while ovarian abla-
tion/suppression may be preferable for many women be-
cause of less impairment of HRQL, contemporary chemo-
therapeutic regimens may be more effective. The simple 
solution to this situation is to say that efficiency is always 
more important that HRQL, and that patients should there-
fore have one treatment option only. A more difficult solu-
tion is to determine that there is a dilemma and to involve 
patients in the decision.  
• More research into patients’ views and expectations to the 
health care system in cases where medical decision-making 
involves complex trade-offs between efficacy and HRQL is-
sues is needed. 
4.11  Prognostic significance of quality of life data (paper IX) 
4.11.1  Patients 
The analyses were based on 1,588 patients who had complete 
data for all the biological variables and who had completed the 
first questionnaire. The analysis of RFS and OS included 761 and 
698 ‘events’, respectively, i.e., about half the patients had a re-
currence or a second malignancy, or died. 
4.11.2  Results  
The final biological model is shown in Table 2 of paper IX. When 
adding one variable at a time to the biological model the EORTC 
emotional function and fatigue scales predicted both RFS and OS. 
The HADS anxiety subscale categorised 8-21 (probable or definite 
case) vs. 0-7 (non-case) predicted RFS but not OS. In all cases, low 
psychological distress or low fatigue were associated with im-
proved probability of survival. When categorised at the median 
both HADS subscale were just above the level of significance in 
prediction of RFS. The other variables did not significantly predict 
RFS or OS (Table 3, paper IX). 
When added to the biological model in combination fatigue was 
the only variable remaining as a significant predictor of RFS, and 
emotional function was the only variable predicting OS (Table 3, 
paper IX). Addition of social class to the final models did not 
change the results. 
When the same analyses were carried out in the subset of 432 
low-risk patients, the results were the same except that fatigue 
and emotional function had slightly stronger associations with 
RFS and OS. Reflecting the smaller sample, the p-values were ‘less 
significant’. 
4.11.3  Discussion 
Contrary to our expectations prior to the study we found that 
psychological distress and fatigue predicted the risk of recurrence 
and death even when controlling for the relevant clinical and 
biological variables such as tumour size, malignancy grade, lymph 
nodes, etc.  
When interpreting the results it should be noted that the mean 
age of the patients at diagnosis was 52 years, i.e., many patients 
were in an age group, which apart from breast cancer would be 
expected to have a low mortality. Almost half the patients died 
during the almost 13 years of follow-up. The patterns of relation-
ships between the different self-rated variables from two stan-
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dard questionnaires were all in the same direction (fewer prob-
lems, better survival), and the relationships with recurrence-free 
survival and overall survival were relatively similar.  
One might speculate that although, in addition to biological vari-
ables, all treatment variables were included in the analyses there 
might still be some complex mechanism of confounding resulting 
from the fact that treatment was associated with risk of recur-
rence, and treatment was also (weakly) associated with psycho-
logical distress. Therefore, it is notable that when analyses were 
repeated in the subgroup of 432 low-risk patients exactly the 
same results (in fact slightly stronger associations) were found. 
This mechanism of confounding is therefore an unlikely explana-
tion of the findings. 
Many studies have reported associations between HRQL and 
survival in metastatic cancers other than breast cancer [269-278] 
and metastatic breast cancer [279-283]. However, the finding that 
in the presence of symptomatic disease, patients’ perception of 
their own health is related to their survival, is not surprising.  
The relationship between self-rated health and survival is much 
more scientifically interesting in disease-free patients who have 
no symptoms of cancer (e.g., in primary breast cancer), where 
(optimally) all prognostic variables that can be known to patients 
can be accounted for in the analyses. The only other study of 
primary (breast) cancer patients that has found patients’ self-
ratings of psychological distress to be associated with survival was 
Watson’s study, which aimed at investigating whether the pa-
tients’ coping style predicted survival. A group of 10 patients 
having HADS scores above 10 was found to have shorter survival 
than the remaining patients [284]. This finding was not confirmed 
when the analyses were repeated after longer follow-up [285]. 
It is remarkable that our findings are in contrast to five other 
studies carried out in primary breast cancer patients [279, 286-
289]. The Discussion section in paper IX includes a relatively de-
tailed comparison of our study against each of the five other 
studies. Despite many similarities there are also important differ-
ences in relation to the five studies. Several weaknesses in the 
other studies, compared to our study, were identified. Such dif-
ferences may have contributed to the fact that the other studies 
found no predictive effect but still it appears strange that the 
relatively strong and consistent findings from our study were not 
seen in five other studies. 
Could our results be due to some kind of error or bias, e.g., con-
founding? As mentioned above, it was reassuring to see that the 
findings were the same in the subgroup of low-risk patients as in 
the entire study. Could the patients have had some insight in their 
prognosis that was not accounted for in the analyses? Such know-
ledge might have affected their level of psychological distress and 
fatigue. All the information about the prognosis of the disease 
that the patients may have had (e.g., tumour size, number of 
lymph nodes, malignancy of the tumour, receptor status) as well 
as the treatment was included in the biological models. There-
fore, it is unlikely that the predictive ability of emotional function, 
anxiety, and fatigue is mediated via the patients’ knowledge of 
their prognosis. 
More research is needed to clarify whether our findings or those 
of other studies best describe the reality. 
In paper IX we propose that two different theoretical models can 
be used to interpret our results (paper IX, Fig. 2). The first is the 
traditional ‘mind-body model’ suggesting a causal effect of psy-
chological distress on the disease trajectory. The second model, 
which to my knowledge is new, is called the ‘robustness model’. 
According to this model, the causal relations are different. The 
concept ‘robustness’ is proposed as a common explanation of lack 
of psychological distress and fatigue (despite the exposure to 
significant stressors) and increased resistance to breast cancer. 
Clearly, the interpretation of results is markedly different depend-
ing on the choice of models. The first provides support to the 
psychoneuroimmunological line of thought (e.g., [290]). Following 
this model, the disease course might be modified if psychological 
distress or fatigue were reduced.  
If results are interpreted according to the robustness model, 
interventions that reduce psychological distress or fatigue will not 
affect the cancer but – of course – will still be beneficial. Irrespec-
tive of the choice of model, activities that help patients tackle 
their situation are therefore highly recommendable, but only if 
one believes in the first model should such activities be motivated 
with an effect on survival.  
While not fully clarified [291], the psychoneuroimmunological 
theories related to breast cancer have lost some terrain the last 
years. For example, there was great enthusiasm following Spie-
gel’s study suggesting that psychosocial intervention could pro-
long survival in advanced breast cancer [17] but subsequent 
studies could not replicate the findings [292-294].  
4.11.4  Conclusions 
• The levels of fatigue and emotional function about two 
months after diagnosis predicted the risk of recurrence and 
death for the next many years independently of biological 
and clinical prognostic variables. 
• Our results are consistent with a small study of primary 
breast cancer patients, which found an association between 
depression and survival, but are inconsistent with five other 
studies that found no associations between HRQL and sur-
vival in primary breast cancer.  
• It is currently unknown whether the disparate results may be 
explained by differences in design or analysis between our 
study and the other studies. 
• If our results are correct, they can then be interpreted ac-
cording to two different causal models described in this 
chapter, the traditional ‘mind-body model’ or a ‘robustness 
model’ proposed in paper IX. 
5  DISCUSSION OF MATERIALS AND METHODS 
This thesis investigated the HRQL of primary breast cancer pa-
tients. A number of methodological sub-studies were incorpo-
rated to try to achieve the best possible scientific basis for the 
evaluation of HRQL: the questionnaire was composed after a 
literature review as well as a small interview study, and was pilot 
tested before use (paper I), the multi-item scales were evaluated 
for differential item functioning (DIF) (paper II), the validity of 
patients’ self-assessment was evaluated through a new method 
developed for the purpose (paper III), and to consolidate the basis 
for hypothesis testing a framework for incorporation of staff-
expectations in the analyses was investigated (paper IV). These 
methodological sub-studies have been discussed in the previous 
chapters and will not be discussed here. This chapter will take a 
look at the strengths and weaknesses of the materials and meth-
ods used to evaluate the impact of early breast cancer and adju-
vant therapy on HRQL, and to assess whether psychological dis-
tress has prognostic significance. 
5.1  A longitudinal, not cross-sectional design 
It would have been much simpler and less resource-demanding to 
carry out a cross-sectional study, e.g. based on a single assess-
ment of a random sample of patients 0-2 years after diagnosis. 
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Such a study could have allowed a detection of many of the 
common problems experienced by the patients and could have 
identified major differences between groups. For example, many 
of the symptoms and problems associated with chemotherapy 
would probably have been correctly identified if assessments 
during treatment had been obtained. Furthermore, due to the 
simplicity of the design, data could have been collected more 
quickly and more cheaply and with less effort from patients. 
Nevertheless, it would have taken considerable time to recruit 
the sufficient numbers of patients – the current study included a 
large proportion of the eligible patients in Denmark. Analytically 
such a design would have been more complicated and multivari-
ate regression analysis or other techniques would have been 
needed. Thus, as the analysis would have been more demanding, 
some of the savings (time, resources) from the reduced data 
collection would have been lost. However, one could correctly 
argue that some of the findings of the present study could have 
been found through a cheaper and faster study design. 
The most important disadvantages of the cross-sectional design 
are the reduced ability to describe longitudinal patterns, a re-
duced power to detect differences between groups, and an in-
creased vulnerability to bias (furthermore, as described later in 
this chapter, a cross-sectional design would not be suitable to 
utilise the advantages of the randomised design). The analysis 
presented in papers VII and VIII showed pronounced changes in 
some variables over time, and a cross-sectional design would 
have less power to detect such patterns. And even if patterns 
were reasonably well captured in the data it is much more diffi-
cult communicate the results from multivariate models (one for 
each of the more than 30 variables) than to show simple graphs 
of mean scores over time.  
Furthermore, with a given sample size, a cross-sectional design 
would have less ability to detect differences between groups due 
to the increased noise resulting from differences in the time of 
assessment. The graphs in papers VII and VIII show that the pat-
terns are different for different variables and are usually non-
linear. Such patterns would be extremely difficult to capture 
adequately in multivariate models.  
As an example, a large, recent, cross-sectional study of 2,236 
Chinese breast cancer patients found ‘only a marginal association 
of current use of chemotherapy with poorer QOL in the physical 
wellbeing domain, suggesting that while these symptoms may be 
bothersome, they are transient and may not be substantial 
enough to affect the major dimensions of HRQL in our popula-
tion.’ [161]. The difference in the ability to describe the impact of 
chemotherapy of this cross-sectional study compared to our 
longitudinal study is large.  
Finally, a cross-sectional design is subject to an increased risk of 
bias resulting from the reduced ability to separate the effects of 
the individual variables, even when multivariate models are used. 
It is therefore clear that a longitudinal design is much better 
suited to describe patterns of HRQL over time and to detect dif-
ferences between groups. 
5.2  Patient-assessed HRQL rather than physician-assessed toxic-
ity 
Numerous studies have shown that there is poor to moderate 
agreement between patients’ own assessments of their HRQL and 
assessments done by ‘proxies’ such as health care professionals 
or family members [79, 80, 89, 295, 296]. In general, patients’ 
own assessments must be viewed as more valid [22, 79]. The 
difference may be even larger when patients’ assessments in 
HRQL questionnaires are compared against physician-rated ‘toxic-
ity’: the topics covered are only partially overlapping. Toxicity 
ratings such as WHO Common Toxicity Criteria are focused on 
specific, mainly physical symptoms, whereas HRQL instruments 
also include other aspects, e.g., psychosocial aspects. Toxicity 
ratings have a clear and well-established role in clinical trials but 
do not replace HRQL assessments.  
5.3  Questionnaires to patients rather than interviews 
As the present study had the aim to quantify and compare the 
prevalence of a wide range of HRQL aspects (symptoms, prob-
lems, etc) between groups and over time, a quantitative, stan-
dardised methodology was needed. This also allowed direct com-
parisons with published studies.  
It is important to acknowledge that the standardised, quantitative 
methodology used here does not give the possible insights one 
could have obtained from interviews. New knowledge about, for 
example, how patients think about, perceive, and react to treat-
ment and disease could be obtained from interviews, whereas 
such information is almost ignored from a study like this. The two 
phases where a qualitative methodology was applied in this 
study, the initial interviews and in the analysis of data from the 
validation study (paper III), brought forward useful new informa-
tion. 
5.4  Patient participation 
The participation of 90.3% (first assessment) of the patients in the 
clinical study (and thus the basis for papers II, VI, VII, VIII, and IX) 
(Table 3, section 4.3.2) was extremely high for a study of this kind. 
The attrition in the longitudinal analyses reported in papers VII 
and VIII was modest, and as described in the papers it did not 
seem to affect the results. Levels of participation close to 100% 
have been achieved in randomised trials where participation in 
the HRQL was an inclusion criterion, but are rare in studies where 
participation is voluntary. Thus, compared to other studies it is a 
strength that the participation in our study was very high. The 
fact that patients took the time to complete a relatively extensive 
questionnaire at a point in time where they had many other 
things to do probably reflects that they found the study relevant. 
This interest in the study may not only have reduced the risk of 
bias due to non-participation; it may also have contributed to a 
high level of validity of results because patients took the task 
seriously. This assumption is coherent with the impression I got 
from large numbers of comments written in the questionnaires 
and from many telephone calls from patients during the data 
collection: the patients generally saw the study as very important 
and often made additional comments aimed at elaborating their 
responses. 
5.5  Comparisons within randomised trials and between non-
randomised groups  
The advantages of the randomised trial – compared to non-
randomised designs – are well known.  
While the internal validity of randomised trials is usually higher 
than non-randomised comparisons, the external validity may be 
limited if the experimental design leads to selection of a sub-
group of patients that is not representative of the population of 
interest. In the current study it was clearly a strength that the 
comparison of chemotherapy and ovarian ablation took place in a 
randomised trial because this reduced the risk of confounding. 
The disadvantage was that patients who were strongly against 
one of the two treatments (e.g., a young woman wanting to 
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preserve her fertility), probably refused randomisation, and our 
results may therefore not be generalised to such patients. 
The comparisons in papers VI and VII were not randomised, as 
this was for obvious reasons not possible. With respect to internal 
validity, these studies are clearly weaker than the randomised 
trial in paper VIII. This is evidenced in the unclear results of paper 
VI: the study did not clarify to what extent a recent breast cancer 
diagnosis leads to anxiety and depression (however, as discussed 
previously, multiple methodological issues related to the com-
parison of ‘patients’ to persons from a general population sample 
were identified). The weakness is also seen in paper VII, where it 
was not possible to distinguish the effect of chemotherapy from 
that of the difference in prognosis between groups.  
The control group in paper VII was probably highly representative 
of low-risk patients, whereas the patients in chemotherapy were 
those included into two randomised trials. Thus, one may argue 
that the representativity of the patients in the chemotherapy 
group is less optimal than that of the control group. There may be 
selection bias in randomised trials because patients who accept 
randomisation may differ from those refusing randomisation 
(e.g., in the level of trust in the health care system). However, our 
main interest was to elucidate HRQL differences, and most of 
these dimensions are probably not substantially affected by such 
selection: it seems unlikely that the magnitude or course of the 
various symptoms is markedly different in patients accepting 
randomisation compared to those not accepting randomisation. 
However, we cannot know this.  
For these reasons, when designing the study we discussed care-
fully whether to include those patients refusing randomisation. 
The main argument in favour of this was that it would allow us to 
investigate the entire population of patients. In addition, we 
could have found out whether there were differences in the HRQL 
associated with different treatments between those randomised 
and those not randomised. We chose not to include patients 
refusing randomisation for mainly two reasons. First, there was a 
possible ethical problem in approaching patients who had just 
refused participation in a scientific study and once again ask them 
to participate in a different but closely related study. Second, we 
considered it more important to the aims of the study to use the 
available resources to get as large groups as possible within the 
randomised trials. 
However, again, randomised trials are feasible under certain 
circumstances only. The trial reported in paper VIII might be the 
only randomised trial ever conducted comparing chemotherapy 
to permanent ovarian ablation, and therefore it was valuable that 
the opportunity to include an HRQL study was utilised. 
5.6  Timing of assessments 
As discussed above, the longitudinal design with six measure-
ments over two years is superior compared to a cross-sectional 
design. Clearly, one could have included more assessments or 
have selected other points in time but each additional assessment 
costs time for participants, is expensive for the research budget, 
and may increase drop-out. The six points of assessment seem to 
cover the period of acute toxicity and a subsequent ‘normalisa-
tion’ period leading to absence of differences between groups as 
well. Thus, additional assessments seem warranted mainly if one 
is interested in short-term fluctuations as in a recent study of 
fatigue [297]. On the other hand, the graphs of papers VII and VIII 
show that omission of one or more of the assessments would 
have led to loss of information. Further follow-up of the study 
population beyond two years might lead to additional findings, 
e.g., on the duration of persisting symptoms, but the most impor-
tant results seem to be those obtained during the first two years. 
One can argue that a major weakness of the timing of assess-
ments in the present study was that it did not include a ‘baseline’ 
questionnaire completed before randomisation and initiation of 
adjuvant therapy. Articles and textbooks on the methodology of 
HRQL research routinely recommend baseline assessments [25, 
298]. A ‘baseline’ assessment before randomisation can be used 
to investigate whether there are differences in HRQL before 
treatment. Such differences can be accounted for in the analysis. 
Furthermore, a baseline measurement would give additional 
possibilities in the choice of analytic strategies because ‘change 
scores’ rather than absolute scores could be used as outcomes 
[25](p. 236). It may, however, be difficult to ensure completion of 
HRQL forms before randomisation, and ‘baseline’ assessments 
after randomisation are less useful because patients may be 
affected by the outcome of randomisation [25, 156]. 
 There are, however, some problems associated even with ‘base-
line scores’ carried out before randomisation. First, of course, 
while a ‘pre-randomisation assessment’ can in principle be ob-
tained for patients entering a randomised trial, a comparable 
assessment in patients not randomised may not be obtainable: 
patients awaiting information about their adjuvant therapy are in 
a stressful situation, and this will affect their HRQL scores. In the 
current study it would have been difficult to interpret a compari-
son of ‘pre-randomisation’ scores of patients randomised to 
chemotherapy compared to scores from the control group, who, 
obviously, were not randomised. In contrast, within the analysis 
of randomised trials a pre-randomisation may be useful to test for 
possible differences between randomised groups. 
Pre-randomisation assessments are clearly not ‘pre-disease’ 
assessments: the patient is aware that she is ill, is awaiting a 
potentially stressful treatment, and thus is certainly not in any-
thing similar to her normal state. In fact, the post-operative pe-
riod until initiation of adjuvant therapy, where the patient is still 
not fully informed about her disease, treatment, and prognosis, is 
extremely stressful to most patients. Therefore, a ‘baseline’ as-
sessment carried out at this point in time is a measure of the 
fluctuating problems and distress the patient is experiencing. 
It was decided not to include a pre-randomisation assessment in 
the current study mainly for two reasons. First, it was not consid-
ered practically possible to arrange a pre-randomisation assess-
ment in all potential patients in a way that was felt to be appro-
priate towards the participating patients, and would result in 
reasonably complete data. Second, it was not considered vital for 
the validity of the study to have such an assessment. The study 
had its focus on the period during and after initiation of adjuvant 
therapy, not on the period preceding it. The most important, 
planned comparisons were to take place within the randomised 
trials, and the risk of imbalanced randomisation was considered 
small. 
Thus, if feasible, pre-randomisation baseline assessments may be 
useful in randomised trials but would probably not have added 
very much to the validity of the present study.  
Another aspect of the timing of assessments concerns their rela-
tionship to the fluctuations caused by particularly chemotherapy. 
It is well known that side effects of chemotherapy, e.g. nau-
sea/vomiting and fatigue, have cyclic patterns. Nausea and vomit-
ing is typically most pronounced on the day of infusions and 
possibly the following days (with different drugs having different 
temporary patterns). Fatigue is typically a problem for a longer 
period but also tends to improve with time from last infusion. 
Thus, both nausea and vomiting, and fatigue tend to be minimal 
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when the patients come to the hospital for treatment, whereas 
anxiety may be higher at this point in time than for example one 
week earlier.  
Although investigated in a few studies [297], such temporary 
patterns have to a large extent been ignored in HRQL research. 
The reason for this is probably mainly practical: if the selected 
mode of questionnaire administration is to give patients the 
questionnaire in the hospital (and patients come every three to 
four weeks for treatment) then the typical one-week time frame 
employed in the questionnaire elucidates the week before treat-
ment, not the week after treatment (some questionnaires have a 
longer time frame but also a time frame of, e.g., four weeks as-
sesses the week after treatment poorly). It is impractical to ar-
range an extra visit to the hospital or to allow a research assistant 
travel to the patient’s house. And the compliance may be higher 
when patients are asked to complete the questionnaire at once 
than if the patient is to take the questionnaire back home to 
complete. Questionnaires are therefore often handed out when 
the patients come for treatment and are completed at that point 
in time. The logical consequence is that treatment-related prob-
lems are under-estimated.  
It is a strength of our study that it employed a post-based admini-
stration system aimed at obtaining questionnaire completion one 
week after chemotherapy (and at the corresponding point in time 
for patients not in chemotherapy). We have not investigated the 
extent to which this actually took place (and this can be criti-
cized), but although some patients may have delayed the comple-
tion of the questionnaire, our system must have had a better 
ability to capture the treatment-related symptoms than proce-
dures where questionnaires were handed out and completed at 
the hospital. 
5.7  The location of questionnaire completion 
It follows from the discussion above that questionnaires were 
completed at home in our study. The main alternative is comple-
tion at the hospital. Each location has advantages and disadvan-
tages. Advantages related to completion at home include the 
patient having sufficient time, can plan to complete the question-
naire when and how it is most suitable, and, not least, that the 
patient is in her ‘normal state’, not in the often stressful situation 
at hospitals when awaiting treatment or consultation with a 
doctor. The main disadvantage is that the staff is not there to give 
help or to supervise that the assessment takes place as intended. 
Many patients utilized the possibility of calling me by telephone 
while completing the questionnaires, and asked for advice as to 
how to do; typically the questions concerned relatively unimpor-
tant issues but the carefulness exhibited was impressing and 
encouraging. Thus, when completion at home is coupled with a 
‘hotline’, advice can be given. In my view the advantages of com-
pletion at home outweigh its disadvantages in most cases. The 
main problem is that it is logistically demanding to arrange the 
posting of questionnaires and reminders in large, longitudinal 
studies. 
5.8  This approach compared to other approaches to HRQL as-
sessment 
Specific aspects of the research strategy used in this study are 
discussed in other parts of this chapter but it may also be of in-
terest to take a look at the profile of this study compared to other 
studies in the HRQL research tradition. First, one can discuss 
whether there is a single ‘HRQL research paradigm/tradition’ or 
whether there are actually several competing para-
digms/traditions. Many researchers in the field may take the 
latter view arguing that there are markedly different approaches 
being applied. On the other hand, one can argue that there is a 
field of research using the terms ‘quality of life research’, HRQL 
research, etc., which has a number of general characteristics. 
Although there is no generally accepted, single definition of 
HRQL, an excellent review of definitions is given by Ferrans [24], 
and several textbooks describe and give recommendations for a 
wide range of conceptual and methodological issues [25, 299-
307]. Furthermore, guidelines, which to some extent can be 
viewed as expressions of consensus, are being published regularly 
[306, 308, 309] and there exists a scientific society called Interna-
tional Society for Quality of Life Research holding yearly, well-
attended meetings. Finally, the US Food and Drug Administration 
recently issued guidance for the pharmaceutical industry provid-
ing extremely specific and detailed recommendations on the 
methodology of HRQL research [310]. This latter document used 
the term ‘patient-rated outcomes’ (PRO) instead of HRQL, but 
while the PRO concept is more inclusive, most of the content and 
methodology is the same.  
Thus, while one may argue that ‘HRQL research’ represents a 
reasonably well-established research paradigm, there are a num-
ber of ‘internal’ differences where the present study has ‘chosen 
side’. Such decisions can of course be discussed. One important 
line can be drawn between multidimensional research describing 
several aspects of HRQL (as in this thesis), and unidimensional 
assessments. The latter aims at describing quality of life on a 
single axis, e.g., from 0 to 1, and this is a prerequisite for health 
economic analyses such as estimation of quality of life-adjusted 
life-years (QALYs). Such methodology allows for comparison of 
different interventions with regard to the costs per QALY gained. 
Although there have been researchers working to establish links 
between multidimensional and unidimensional measures [311], 
the general view is that results from these lines of research are 
incompatible. In this thesis, this incompatibility can exemplified 
with the comparison of chemotherapy and ovarian ablation: the 
results cannot be translated into figures describing the HRQL of 
the treatments on a 0-1 scale – in fact, as described in the discus-
sion, the relative merits of the treatments depend on the pa-
tients’ values, and thus the outcome of the comparison cannot be 
described in a single figure.  
Thus, it must be acknowledged that results from the present work 
are not relevant for health economic analyses needing quality of 
life data on a single axis. 
Another division within HRQL research is between methods mea-
suring pre-selected dimensions only (as in this thesis) and those 
focused on ‘individual quality of life’. In the latter, newer meth-
odology, the dimensions to be measured vary between partici-
pants [312]. Thus, the first step in the assessment is to identify 
the dimensions to be investigated. This has the clear advantage 
that the individual persons’ values and situation are taken into 
consideration but severely limit the possibilities of comparison 
across individuals and between groups. For this study, a standard-
ised assessment of the same HRQL dimensions in all participants 
was considered mandatory to reach the goals but, obviously, 
addition of individualised information would have been useful. 
It is also important to be aware that there are aspects not usually 
covered by typical HRQL assessments that are viewed as ex-
tremely relevant by patients. A recent example of this came from 
the Danish Cancer Society project ‘Kræftpatientens Verden’ (‘The 
Cancer Patient’s World’) [313]. The qualitative part of that study 
showed that, in general, patients were more interested in discuss-
ing problems and frustrations related to the encounter with the 
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health care system (e.g., ‘service issues’ such as problems related 
to waiting time, information, communication, lack of continuity, 
and psychosocial care) than they were in discussing symptoms 
and disease-related problems [314]. The main reason for the 
patients’ focus on the problems related to the health care system 
was probably that such problems might potentially have been 
avoided, whereas patients saw symptoms and disease-related 
problems as unavoidable consequences. This example illustrates 
that there are important issues that are not covered by traditional 
HRQL assessments, which have profound influence on the pa-
tients’ quality of life, and which certainly need investigation.  
In summary, there is not a single delineation of HRQL research 
that can be termed as most correct; HRQL research represents 
activities aimed at elucidating the patients’ experiences and 
perspectives but the way such research is best carried out de-
pends entirely on the aims. This thesis aims to provide answers to 
certain questions but other questions could have been asked; 
thus different answers about the quality of life of breast cancer 
patients would have been obtained. 
5.9  The statistical analysis strategy 
Several different statistical analysis strategies could have been 
applied in the two descriptive and comparative, longitudinal 
studies (papers VII and VIII). Our study included many variables 
assessed six times over two years. Some (surprisingly few) pa-
tients dropped out during the study or provided incomplete ques-
tionnaires. This situation left us with several decisions concerning 
the level of aggregation at each point in time as well as across 
time. We chose to aggregate very little. As a result we were left 
with many variables (as shown in the figures of papers VII and 
VIII,), and we could compare the variables six times. The ‘rules’ 
we applied in paper VII limited this a little; nevertheless, one can 
argue that we carried out too many significance tests, thus in-
creasing the risk of false positive findings.  
Another important drawback associated with our lack of aggrega-
tion is the complexity of results (as evidenced in excessive num-
bers of graphs), which is clearly a limitation because it makes 
communication of our results time-consuming and complicated. 
However, we can argue that the reality is complex and that it is 
inappropriate to limit this complexity as long as it is not well 
understood. Furthermore, our studies have given insights that 
may be utilised to plan simpler studies in the future, e.g., studies 
with shorter questionnaires or fewer assessment points.  
We could thus have chosen to aggregate variables more than we 
did (e.g., by constructing multi-item scales from the DBCG 89 
Questionnaire) but at the point in time when analyses were 
planned and conducted this would, in my view, not have been 
appropriate. Papers VII and VIII documented that almost all vari-
ables analysed contributed new information. 
 We could have combined information from several assessments, 
e.g. by making ‘area under the curve’ estimations or by modelling 
the data in various ways. Such analyses generally increase the 
power to detect differences between groups and over time and 
may help in simplifying and/or interpreting the results. Such 
approaches are described in good textbooks [25, 315, 316] but 
after careful consideration our decision was to keep analyses as 
simple as possible to preserve the information obtained.  
The sample sizes of our studies (papers VII and VIII) allowed de-
tection of differences in mean scores between groups of about 6-
8 points and up. A clinically important difference in the EORTC 
QLQ-C30 and other similar questionnaires is typically viewed as 
being around 10 on a 0-100 scale, although smaller differences 
may also be relevant [25, 45, 317]. Thus, our approach does not 
seem to have severely limited the ability to detect clinically im-
portant differences. 
Another advantage of simple approaches is that it is easy for 
readers to judge the results and to extrapolate them to compari-
sons with their own data.  
Our preference for minimal aggregation of data thus mainly 
stems from a view of our study as having its main strength in 
description and simple, clinically anchored comparisons (papers 
VII and VIII). In contrast, in studies where HRQL data are primary 
end-points it is of great importance to maximise power and to 
limit the number of end-points. Therefore, in such studies one 
could choose to combine data from more than one assessment, 
to limit analyses to one or a few end-points, or to use more com-
plex statistical models. 
5.10  The data and analysis for prognostic factors 
In addition to the strengths and weaknesses of the data and 
analyses discussed in paper IX a few comments will be made here.  
In general, the quality of the available data must be viewed as 
close to optimal with regard to its completeness and quality: very 
high patient participation, high completeness and quality of clini-
cal and biological background variables, and high quality of out-
come variables (survival was obtained by linking with the Central 
Personal Register, the others had been subject to extensive qual-
ity control because they formed the basis for randomised trials). 
Furthermore, the size of the data set was large.  
As also discussed in the paper, it is controversial whether the 
timing of assessments in our study was optimal. We cannot ex-
clude the possibility that other results could have come from 
assessments at other points in the trajectory but the mechanism 
of such a difference remains unclear. And even if this were the 
case, it would not affect the finding that patients’ self-
assessments about two months after their diagnosis predict sur-
vival for about 13 years. 
We could have included fewer or more than the six variables (plus 
social class) in the analyses. If we had had to focus on one vari-
able only we would have selected the EORTC emotional function 
scale or the HAD depression subscale, and this would have led to 
close to the same results. Of course, we cannot know what the 
results from inclusion of additional variables would have been but 
that could be investigated in the future. The finding of a similar 
effect across a number of variables reduces the risk that findings 
are due to chance. 
The variables can be handled in many different ways in the analy-
ses, i.e., as continuous, categorised or otherwise transformed. 
Our choice of a uniform categorisation (dichotomization at the 
median) across all the six variables reduces the risk of over-
estimation of effect. In contrast, the testing of a variable in more 
than one categorisation (as done for the two HAD subscales in 
order to test them at the clinical cut points as well) can be criti-
cised, but the findings for the HAD scale were not important for 
the paper’s results. 
One can discuss whether our choice of categorisation was the 
right one but there exists no single commonly agreed ‘most ap-
propriate’ way of categorising a variable [97] (p. 205-7). Dichoto-
mization at the median of the distribution of a variable is one of a 
number of common approaches. 
One might argue that we were missing important prognostic 
variables from the biological/clinical model. However, we in-
cluded the commonly used variables and more variables than 
most of the other studies. Furthermore, we included more infor-
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mation about prognosis than patients had been given (i.e., as we 
included the data available, the doctor could not have told the 
patient more, and the vast majority of patients have not been 
given all details). Finally, when we compared the prognostic abil-
ity of a self-rated variable with and without control for the bio-
logical model the results were about the same – in fact, there 
tended to be an increase in predictive power when we adjusted 
for the biological model. This may appear surprising but is not 
uncommon [318]. 
Based on these considerations, our findings – which contradict 
most of the literature – do not appear to be artefacts resulting 
from obvious methodological weaknesses. 
6  CONCLUSIONS 
This thesis has shown that it is possible to carry out a large, pro-
spective study of primary breast cancer patients’ health-related 
quality of life (HRQL) with a very high level of patient participa-
tion, to elucidate the patients’ HRQL in detail, and to produce 
clinically relevant information that can be used in several ways. 
The methodological parts of the study generally supported the 
validity of the questionnaire-based methodology but also identi-
fied limitations, particularly if questionnaires are used to compare 
groups of persons who are in very different circumstances. Fi-
nally, an unexpected result was the predictive ability of patients’ 
self-assessments of their HRQL. 
Referring to the aims, the overall conclusions are: 
1. The questionnaire composed for this study was feasible for 
use in a longitudinal study and was shown to have excellent 
content validity. It made it possible to assess the impact of 
early breast cancer and adjuvant therapy on HRQL in more 
detail than in previous studies. 
2. In general, the multi-item scales included in the question-
naire were adequate representations of the information col-
lected through their items. Thus, despite some findings of 
differential item functioning (DIF), the frequency, magnitude 
and practical importance of DIF in the EORTC QLQ-C30 and 
the HAD Scale were very limited. 
3. To a large extent patients understood and responded to the 
items of the questionnaire in the same way as did the re-
searchers. This indicates that, in general, patients answered 
the questionnaire without frequent misunderstandings or 
other errors in their responses. However, a mechanism that 
in some cases may lead to under-estimation of the levels of 
symptoms and problems (and was termed ‘selective report-
ing’) was identified. 
4. The views and experiences of health care professionals 
involved in the treatment of breast cancer patients did not 
contribute substantially to the handling of analytical prob-
lems related to multiple hypothesis testing. Health care pro-
fessionals’ insight into patients’ HRQL was found to be lim-
ited.  
5. A general population study involving a large group of Danish 
women was conducted, but previously unacknowledged 
problems with the use of such data were identified. These 
problems, which may be at least partially caused by the ‘se-
lective reporting’ mechanism identified in the validation 
study, may invalidate comparisons of data from patients 
against general population data.  
6. Due to the problems identified in relation to comparisons 
between general population data and (breast cancer) pa-
tients, the prevalence of anxiety and depression in newly di-
agnosed breast cancer patients relative to women of the 
general population could not be reliably evaluated.  
7. Many important differences in HRQL were found between 
premenopausal low-risk patients not offered any systemic 
therapy and patients on chemotherapy. 
8. Several important differences in HRQL were found between 
premenopausal patients with receptor-positive tumours 
randomised to chemotherapy or ovarian ablation. 
9. Psychological distress and fatigue were found to carry prog-
nostic information independent of biological variables. 
7  PERSPECTIVES FOR FUTURE RESEARCH 
This thesis has presented an early example of HRQL research. 
Since the conception of the study, extensive experience with 
HRQL research has been achieved. For example, the number of 
PubMed publications indexed with ‘quality of life’ as MeSH term 
in combination with ‘breast neoplasms’ increased more than 
tenfold from 281 in 1990 to 3,205 in June 2007 
(www.pubmed.gov, accessed 6 June 2007).  
This development, where traditional biomedical outcomes are 
increasingly being supplemented by patient-rated outcomes, is 
likely to continue. In addition to the medical background pre-
sented earlier it also builds on political evolutions including in-
creased focus on the patient as a participant in the decision-
making process who needs sufficient information (e.g., patient 
empowerment), and increasing recognition of the importance of 
the consumer-perspective in the development of the health care 
system.  
Breast cancer is probably the disease that has fostered the most 
HRQL research. Of 59,205 publications on ‘quality of life’ (MeSH 
term) in PubMed, more than 5% were related to breast cancer 
(www.pubmed.gov, accessed 6 June 2007). 
Despite this extensive research there are still many methodologi-
cal challenges and considerable controversy and uncertainty as to 
what role HRQL research is to have in clinical trials, medical deci-
sion-making, and clinical practice.  
7.1  Methodological aspects 
7.1.1  The content of questionnaires 
One of the most basic methodological issues in HRQL is the con-
tent of the questionnaires used. As shown in this thesis, most of 
the published research related to breast cancer adjuvant therapy 
has employed questionnaires that did not comprehensively eluci-
date the HRQL associated with even the most commonly used 
types of chemotherapy. The development of breast-cancer fo-
cused supplements to the most widely used standard question-
naires for cancer patients (EORTC QLQ-B23 [201] and FACT-B 
[319]) was an important advance, but as the treatments used for 
adjuvant therapy of breast cancer are rapidly changing, additional 
research is needed to investigate which HRQL aspects are af-
fected by the new treatments. It will be necessary either to revise 
the existing questionnaires or to develop new, supplementary 
questionnaires [268]: like any other aspect of validation, the 
content validation of questionnaires is an ongoing process [320].  
7.1.2  Validation of questionnaires 
In addition to the work needed to secure that the right questions 
are asked, the ongoing work with validation of questionnaires for 
breast cancer research should follow multiple tracks.  
An important line of future research is the application of cognitive 
interviewing techniques to explore respondents’ perception of 
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questionnaire items. These techniques elucidate the cognitive 
processes involved in the completion of questionnaires, and 
include verbal probing by an interviewer, ‘think-aloud’ tech-
niques, etc. [34, 84, 85]. Our validation study (paper III) compar-
ing patients’ and observers’ ratings was one of the first applica-
tions of such techniques in oncology [34]. Cognitive interviewing 
are useful both in the development (i.e., as an extension of the 
traditional pilot testing) and in the validation of existing methods 
[34].  
Whereas DIF analyses were virtually unknown in the HRQL field 
when paper II was published, the relevance of DIF analyses is now 
widely acknowledged. For example, in ‘The ten Ds of health out-
comes measurement for the twenty-first century’, McHorney and 
Cook emphasise the importance of DIF analyses as being one of 
the ‘ten Ds’ [321], and this methodology also forms part of most 
work with item response and computer-adaptive testing (see 
below). We recently presented recommendations for the future 
use of DIF analyses in clinical trials [67]. 
There are several important aspects of the validation and evalua-
tion of questionnaires that have not been touched upon in this 
thesis, e.g., investigation of sensitivity and responsiveness, 
floor/ceiling-effects, and the use of various psychometric meth-
ods such as multitrait scaling and factor-analysis-based methods. 
These issues will not be further discussed but clearly have impor-
tant roles also in future work.  
Investigation of the equivalence of translations of standard in-
struments and of potential cross-cultural differences also remains 
an important area. Our recent applications of DIF analyses are 
relevant examples [65, 66, 74] but other approaches are also 
needed in this emerging area.  
7.1.3  Clinical significance 
It is a paradox that the usual approaches to analysis of standard 
questionnaires involve construction of multi-item scales whereby 
the responses to items that were originally simple and easily 
interpretable (e.g., 34% had ‘Very much pain’), become abstract 
scores. One can rightly ask how a difference in role function of 7 
points on a 0-100 scale should be interpreted. It may be statisti-
cally significant but is it clinically significant and how? Further-
more, any researcher planning an intervention study (e.g., a 
randomised trial) must specify the magnitude of anticipated 
difference between groups or over time, and to do this one must 
make assumptions about the minimal, clinically relevant differ-
ence [20]. These problems have led to extensive research into 
interpretation of scores on HRQL instruments [25, 130, 322-327]. 
While some clarity has been achieved [326, 327] there is still a 
pronounced need for more research. For example, when there 
are a number of different treatments, how should the magnitudes 
of differences on various dimensions be explained to patients? 
This applies to the scenarios discussed in this thesis in relation to 
premenopausal, node-positive and receptor-positive breast can-
cer patients and to many other situations. 
7.1.4  The use of general population studies 
The conclusion in this thesis that direct comparison of HRQL 
scores from breast cancer patients to a general population sam-
ple may be invalid is not generally accepted. This important issue 
needs further investigation. 
7.1.5  Item response theory, item banking, and computer-adaptive 
testing 
The last decade has seen a strong increase in the interest in appli-
cation of modern psychometric methods to HRQL assessment, 
and their importance is now widely acknowledged [20, 328-332]. 
Item response theory (IRT) methods have proven useful in short-
ening HRQL scales with no or little loss of information [333-335] 
and in developing item banks that can be administered using so-
called computer-adaptive testing (CAT) [329-331, 336-338]. With 
IRT and CAT higher measurement precision may be obtained with 
the same number of items administered, the number and nature 
of items may be varied between respondents, and results may be 
compared across studies using different items. Much of the future 
research in HRQL assessment will focus on such methodology as 
witnessed in the large American Patient-Reported Outcomes 
Measurement Information System (PROMIS) [339] and, on a 
smaller scale, in an ongoing, Danish led development of a CAT-
based, interactive version of the EORTC QLQ-C30. 
7.2  Clinical aspects 
7.2.1  HRQL assessment in breast cancer clinical trials 
A systematic review of randomised breast cancer trials evaluating 
HRQL was published in 2003 [268] and was further discussed in a 
subsequent publication [340]. It included literature searches until 
June 2001. The review identified 66 trials of which 46 evaluated 
biomedical interventions and 20 evaluated psychosocial interven-
tions; only 7 trials concerned adjuvant therapy. The authors con-
cluded that the HRQL results did not affect clinical decision-
making in any of the seven trials but also acknowledged that 
other results might come from ongoing studies. They argued that 
in the future HRQL should mainly be assessed in adjuvant therapy 
trials when treatments are expected to have equivalent effect on 
recurrence and survival or when long-term effects (e.g., on cogni-
tive function, menopause) are expected [268].  
In my view this recommendation implies that HRQL is relevant in 
the majority of trials because the relative effectiveness cannot be 
known a priori and because long-term consequences are still 
unknown for most of the new regimens. Furthermore, even when 
survival differences are found, there may be short-term differ-
ences in HRQL, which may influence the overall conclusions from 
trials.  
However, given the importance of appropriate methodology (and 
the frustrations resulting from inconclusive data), HRQL assess-
ment should be done only if there are sufficient resources avail-
able to make the efforts successful. This concerns the entire 
process from planning to publication. It is more the rule than the 
exception that the discussion of possible HRQL assessment is 
started after most other aspects of clinical trials have been set-
tled, and, of course, this severely limits the possibility of truly 
integrating the HRQL assessment in the scientific thinking behind 
the trial. The result is that the potential of HRQL research is un-
der-utilized and this, again, impairs its reputation. 
Therefore, rather than incorporating HRQL assessment into all 
trials, it can be recommended to select those trials where the 
methodology can be sufficient. For such studies it is worthwhile 
to spend the necessary time on questionnaire composi-
tion/development to secure that the relevant HRQL dimensions 
are actually covered. Thoughtful preparation may also optimize 
the utility of HRQL data by using the opportunity to answer addi-
tional, clinically or methodologically relevant questions.  
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7.2.2  The use of HRQL data in clinical decision-making 
In an editorial on the status of HRQL research Levine and Ganz 
noted that ‘it is disappointing that there are relatively few exam-
ples of formal quality-of-life measurement that have influenced 
individual patient decision-making or treatment policies.’ [341]. 
They encouraged ‘the translation of quality-of-life measurement 
into clinical practice to improve patient care’ [341].  
The use of HRQL data in decision-making is insufficiently investi-
gated. HRQL data are often complex (as seen in this thesis) and 
even without HRQL data it is often complicated to inform patients 
about several treatment modalities and options. Various decision-
aids have been developed and may be helpful [342-344], and 
information needs have been explored [244-247, 345]. However, 
it would be relevant to further investigate patients’ priorities 
concerning HRQL information: how detailed and in which form do 
the patients want the information to be given? And to what ex-
tent is it desirable and feasible to present and compare HRQL 
profiles of more than one treatment? 
7.2.3  The use of HRQL assessment in clinical practice 
A number of studies have investigated whether HRQL question-
naires completed by the patient before meeting the doctor may 
improve communication or treatment. The aim of such research, 
where the idea is to use the individual patient’s own data, is thus 
different from the use of published HRQL data (from other pa-
tients) in decision-making as discussed in the previous section. 
Part of the rationale is the discrepancy observed between pa-
tients’ and physicians’ evaluation of HRQL [79, 80, 86], which 
implies that physicians’ insight in the patients’ situation might be 
improved if they had access to the HRQL questionnaires. Ideally, 
such HRQL data might lead to better treatment of symptoms and 
other problems, to better communication, and to higher satisfac-
tion. However, despite relatively extensive research and encour-
aging results it is still not clear how and to what extent HRQL 
questionnaires may best be used in clinical practice [346-352]. 
This is an important, future field of research.  
8  ENGLISH SUMMARY 
The treatment of primary breast cancer usually consists of sur-
gery often followed by adjuvant therapy (radiotherapy, chemo-
therapy, hormonal treatment, etc.) to reduce the risk of recur-
rence. The cancer diagnosis and the treatments may have 
significant impact on the patients’ quality of life.  
This thesis deals with scientific aspects and clinical results of a 
study aimed at assessing the impact of breast cancer (and its 
treatment) on the patients’ quality of life. Studies such as this 
assessing the problems and symptoms experienced by the pa-
tients are often referred to as health-related quality of life (HRQL) 
research. HRQL research deals with subjective experiences and 
raises challenging, scientific questions. Therefore, much attention 
was directed towards methodological issues in this clinically 
motivated project. 
The study was a prospective, longitudinal, questionnaire-based 
investigation of women with newly diagnosed breast cancer 
registered in the Danish Breast Cancer Co-operative Group’s 
DBCG 89 Program. The patients were sub-divided into low-risk 
and high-risk patients. High-risk patients were offered randomisa-
tion in one of three randomised adjuvant therapy trials involving 
chemotherapy, ovarian ablation, and endocrine therapy.  
After a literature study and interviews with breast cancer pa-
tients, a questionnaire was composed that included two widely 
used standard questionnaires (EORTC QLQ-C30 and Hospital 
Anxiety and Depression (HAD) Scale) and a DBCG 89 Question-
naire developed for this study.  
A total of 1,898 eligible patients were invited by post to partici-
pate in the study involving six assessments over a 2-year period, 
and 1,713 patients (90%) completed the first questionnaire. Fur-
thermore, a questionnaire was sent to 872 women selected at 
random from the general population; 608 (70%) responded. 
The multi-item scales of the two standard questionnaires were 
analysed for so-called differential item functioning (DIF) in order 
to investigate whether the (summary) scale scores were adequate 
representations of the information obtained by the individual 
items. The DIF analyses identified a number of cases of DIF, 
which, among other things, contributed to detection of possible 
problems in the HAD Scale. It was concluded that DIF analyses are 
relevant when important analyses based on multi-item scales are 
made. 
A new way to evaluate the validity of questionnaires was devel-
oped. The results from questionnaires completed by patients 
were compared against results from open-ended interviews with 
the same patients rated by observers. The idea was that if results 
were similar, the patients had then probably understood and 
completed the questionnaire items as intended. On the other 
hand, if results from self-assessment and interviews deviated, 
misunderstandings or other errors might have taken place, and 
the study would give insight into possible problems. Of 57 breast 
cancer patients, 46 (81%) were successfully interviewed. In gen-
eral, the agreement between patient-completed questionnaires 
and interviews was excellent, indicating very good validity. The 
median weighted kappa for the EORTC QLQ-C30 was 0.85 (range 
0.49-1.00); it was 0.79 (range 0.65-0.95) for the HAD Scale, and 
0.92 (range 0.51-1.00) for the DBCG 89 Questionnaire. However, 
the study identified a mechanism called selective reporting, which 
may affect results from most HRQL questionnaires: in order to 
provide correct and useful answers some patients do not report 
symptoms they believe are irrelevant to the study, e.g., symp-
toms unrelated to cancer. This mechanism may lead to bias if 
results from patients are compared to results from populations 
reporting their symptoms more completely, e.g., general popula-
tion samples. In contrast, this mechanism has little importance 
when results from different sub-groups of cancer patients are 
compared. 
In this study multiple variables were assessed at multiple points in 
time and we did not have a priori hypotheses for all these poten-
tial comparisons. Therefore, a staff survey involving experienced 
doctors and nurses was conducted in order to generate hypothe-
ses that could be tested in the data from patients. We contacted 
46 health care professionals and 36 (78%) responded. Overall, the 
staff survey did not prove very useful for the intended purpose. 
The main reason for this was probably that the health care pro-
fessionals had limited insight into the patients’ HRQL. A different 
approach to the problem of multiple hypothesis testing proved 
more useful. Hypotheses generated from the initial literature 
review were tested in the comparison of patients in chemother-
apy against patients not in chemotherapy. 
The study of women selected at random from the general popula-
tion showed that these women experienced a considerable de-
gree of ‘morbidity’ according to all three questionnaires. This 
shows that symptoms and problems reported by cancer patients 
may have causes other than cancer, and thus constitutes a good 
justification for the use of data from general population studies 
when interpreting data from cancer patients. 
The levels of anxiety and depression of low-risk breast cancer 
patients were found to be lower than those from the general 
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population sample. After careful consideration we concluded that 
this finding was probably incorrect. The most important explana-
tions were thought to be the wording of some HAD Scale items as 
well as two mechanisms that are not specific to the HAD Scale, 
the ‘selective reporting mechanism’ found in the validation study, 
and the response-shift problem. These findings indicate – in con-
trast to the conclusion above – that the comparability of HRQL 
data from cancer patients and general population data must be 
questioned. However, as this is the first study to raise the prob-
lem, this issue needs further investigation. 
Based on the initial literature review and interviews we hypothe-
sised that 30 different HRQL issues would be impaired in patients 
undergoing CMF chemotherapy compared to patients not in 
chemotherapy; 23 of these hypotheses were confirmed. In addi-
tion, our study and other research suggest that other HRQL as-
pects may also be affected by chemotherapy. Thus, there is con-
siderable evidence that patients in chemotherapy may experience 
effects on a wide spectrum of HRQL issues. 
Most other studies have assessed surprisingly few of the HRQL 
issues shown in our study to be impaired in patients receiving 
chemotherapy. Similarly, current review articles on HRQL effects 
of adjuvant chemotherapy mention only relatively few of these 
topics. 
Concerning HRQL after the treatment period, our main finding 
was that many symptoms and problems had declined or disap-
peared, but some persisted: anticipatory nausea, weight gain, 
endocrine effects (e.g., hot flushes/sweats, irregular bleed-
ings/amenorrhea, vaginal dryness), disturbed sleep, and sexual 
dysfunction. These findings are in agreement with the literature.  
The staff study showed that experienced physicians and nurses 
did not expect many of the ‘scientifically well documented’ con-
sequences of chemotherapy.  
Taken together, our findings suggest that information to patients 
about chemotherapy should be more comprehensive than that 
which has been practised in most places.  
When compared against ovarian ablation, chemotherapy was 
associated with more impact on HRQL during the treatment pe-
riod; only hot flushes/sweats were more pronounced in the ovar-
ian ablation group. Thus, from an overall ‘HRQL perspective’ 
ovarian ablation or suppression may be preferable. However, 
younger women may preserve their premenopausal status (in-
cluding fertility) by having chemotherapy, and this may be an 
argument for chemotherapy or for temporary ovarian ablation via 
goserelin, rather than permanent ovarian ablation.  Furthermore, 
while ovarian ablation/suppression may be preferable because of 
less impairment of HRQL, contemporary chemotherapeutic regi-
mens may be more effective. These results indicate that for some 
patients, the HRQL data and results on treatment efficiency may 
be in conflict. There is no simple, universally correct solution to 
this dilemma. More research into patients’ views and expecta-
tions to the health-care system in cases where medical decision-
making involves complex trade-offs between treatment efficiency 
and HRQL issues is needed. 
Contrary to expectations, the analyses showed that fatigue and 
emotional function predicted the risk of recurrence and death 
independently of biological and clinical prognostic variables. In 
multivariate Cox regression analyses patients who were more 
fatigued or had poorer emotional function had a worse prognosis. 
These results are consistent with one small study, but are incon-
sistent with five similar studies in patients with primary breast 
cancer, which found no such associations. The reasons for these 
important differences are currently unknown. 
In conclusion, this study consisted of methodological and clinical 
investigations of HRQL in primary breast cancer patients. The 
initial questionnaire development resulted in a combination of 
questionnaires that was more comprehensive than in other simi-
lar studies. The results of the methodological studies generally 
supported the validity of the questionnaires but also gave impor-
tant insights into potential scientific problems that are probably 
not restricted to the present study. These insights helped to 
prevent misinterpretations of the clinical data. The study pro-
vided the most detailed description of HRQL during and after 
breast cancer adjuvant chemotherapy to date, and compared 
results of chemotherapy against ovarian ablation. It also provided 
controversial results concerning the prognostic value of HRQL 
data. The combination of a large empirical study and several 
methodological sub-studies thus proved useful and gave new 
results. 
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APPENDIX A. DIF ANALYSES 
This appendix contains results of DIF analyses of the multi-item 
scales of the EORTC QLQ-C30 and the HAD Scale that were re-
moved from papers VI-VIII in order to shorten the papers. 
Materials and methods 
The data are described in papers VI-VIII. DIF analyses are de-
scribed in paper II and section 3.7. 
Results concerning anxiety and depression in breast cancer 
patients compared to the general population (paper VI) 
The DIF analyses of the two HAD subscales in relation to group 
(general population or patient) and age showed no evidence of 
DIF in the anxiety scale. In contrast, there was DIF in relation to 
group in the depression scale mainly for item 10, 'I have lost 
interest in my appearance': at a given level of depression, there 
were much higher scores on this item in the general population 
than in the breast cancer patients (partial gamma = 0.56, p < 
0.0001). Consequently, this item influenced comparisons be-
tween the two groups: depression scores in the general popula-
tion sample were biased upward. When comparing the groups by 
means of the remaining 6 items, the magnitude of the difference 
in mean scores between the two groups (described in section 
4.8.2) was diminished, but still significant (ANCOVA, p = 0.02).  
The depression sub-scale also showed DIF with regard to age for ‘I 
feel as if I am slowed down’ (item 60) and ‘I look forward with 
enjoyment to things’ (item 64). These two items had stronger 
increments in item score with increasing age than the total de-
pression score (age relation: partial gammas 0.33 and 0.42, p < 
0.001, controlling for scale score). 
Results concerning chemotherapy versus no chemotherapy and 
chemotherapy versus ovarian ablation (papers VII and VIII) 
No significant (p < 0.001) DIF was detected in relation to group in 
either study. Specifically, the three cases of DIF in relation to 
chemotherapy described in paper II were not significant in the 
analyses addressing this comparison in paper VII. However, for 
one of these cases of DIF, the cognitive function scale, DIF of 
similar magnitude, but not meeting the p < 0.001 significance 
criterion, was found in the data reported in papers VII (partial 
gamma=0.58, p=0.011) and VIII (partial gamma=0.47, p=0.004). 
Separate analyses of the two items showed that chemotherapy 
had a relatively strong effect on concentration, whereas it had a 
much weaker effect on memory.  
 
 
APPENDIX B. VALIDATION OF HAD SCALE AND DBCG 89 QUES-
TIONNAIRE  
Materials and methods 
The data are from the same study as paper III although the par-
ticipants were the breast cancer patients only. The methodology 
was summarised in section 3.8 (described in full in paper III). 
Results 
Please see Tables B1-4. 
Table B1  
 
Agreement between patients and the observer about responses to the items of the Hospital Anxiety and Depression Scale. Item scores for patients 
and observer, overall agreement (overall), and weighted kappa (kappa) with standard error (SE). 
 
 Mean score  Agreement 
Item Patients Observer  Overall Kappa (SE) 
1) I feel tense or wound up  0.83 0.78  .83 .92 (.03) 
2) I still enjoy the things I used to enjoy  .41 .41  .87 .88  (.07) 
3) I get a sort of frightened feeling as if something awful is about to 
happen  
 
1.26 
 
1.13 
  
.69 
 
.77 
 
(.07) 
4) I can laugh and see the funny side of things  .28 .37  .87 .70  (.10) 
5) Worrying thoughts go through my mind  .80 .93  .67 .77  (.07) 
6) I feel cheerful  .41 .50  .80 .72  (.12) 
7) I can sit at ease and feel relaxed  .76 .67  .61 .71  (.11) 
8) I feel as if I am slowed down  .87 **1.09  .70 .82  (.05) 
9) I get a sort of frightened feeling like ‘butterflies’ in the stomach  .76 .63  .80 .84  (.05) 
10) I have lost interest in my appearance  36 .22  .84 .81  (.09) 
11) I feel restless as if I have to be on the move .65 **.41  .72 .69  (.13) 
12) I look forward with enjoyment to things .39 .54  .80 .65  (.09) 
13) I get sudden feelings of panic .67 .60  .78 .84  (.06) 
14) I can enjoy a good book or radio or TV programme .46 .46  .91 .95  (.03) 
*) Item numbers are those of the HAD Scale, not those used in this study. 
**) Scores of patients and observer significantly different (p = .04 and p = .02, respectively). 
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Table B2  
 
Qualitative comments to the HAD scale items.  
Quotes from patients are in brackets. 
 
 
2) I still enjoy the things I used to enjoy  
Misses a response option ‘more’. Was not in doubt how to answer. 
Might consider not answering. 
 
3) I get a sort of frightened feeling as if something awful is about to 
happen 
This question is generally interpreted in relation to the breast cancer. 
Is considered a question about fear of recurrence or death following 
cancer. 
‘Yes, I know what ‘It’ can imply, but no, it is quite rare that I think of it’. 
The rater was in doubt how to rate this; none of the options seems 
suitable.  
‘Yes, but I am not thinking of that all of the time.’ It is difficult to rate 
this response adequately: It seems wrong to use one of the modifica-
tions (e.g. ‘Yes, but not too badly’) but on the other hand I find it 
difficult to use the most extreme category for this. 
 
5) Worrying thoughts go through my mind 
This question is generally interpreted in relation to the breast cancer. 
‘I perceive options 3 and 4 as identical.’  
Rater: difficult to discriminate between 1 and 2. 
 
8) I feel as if I am slowed down 
‘Yes, due to age’. Everything is fine, perceives it as natural for a 70-
year-old to be ‘slowed down’. 
Rater: The answer does not sound as being correlated to depression 
but rather to tiredness/age. 
 
9) I get a sort of frightened feeling like ‘butterflies’ in the stomach  
The patients recounts that originally she said ‘yes’ to this question 
because she had been tense but in the interview she reaches the 
conclusion that this should be a ‘no’ because it does not take the form 
of ‘butterflies’. 
 
10) I have lost interest in my appearance 
‘Yes, it’s not the same as it once was when you are 68 but I try to be 
clean and tidy. The operation has not meant anything.’ Rater: in doubt 
how to rate this but chose 4, corresponding to no symptomatology. 
 
11) I feel restless as if I have to be on the move 
‘Oh no, during the last week it’s been Easter so it has been less than 
usual because we have had visitors.’ It sounds as if she had originally 
answered more broadly. 
 
12) I look forward with enjoyment to things 
More than before. 
 
14) I can enjoy a good book or radio or TV programme 
Could, but did not have the time. 
Is in doubt as to whether the question concerns the frequency of 
enjoying a book/TV or whether you do enjoy it (every time).  
 
Table B4  
 
Qualitative comments to the DBCG 89 Questionnaire items.  
Quotes from patients are in brackets. 
 
 
1) Has your mouth or your tongue been sore? 
Because the dental prosthesis is chafing. 
Answers ‘a little’ because she has had pain in the throat only. 
 
4) How satisfied have you been with your appearance? 
Had previously stated that she did not like to look at the scar. Here she 
first answers ‘satisfied’ but when asked whether this is her overall 
judgment she answers: ‘No, I thought of the face only. If the scar has to 
be taken into account then ‘somewhat dissatisfied’.’ 
The patient thinks this is a stupid question. If it is meant to be answe-
red by someone who is not dressed then it is ‘at the bottom’, but with 
clothes on it is ‘good enough’. Did not know which of these two opti-
ons she should use when replying. At the end of the discussion she 
agrees with the interviewer to make an overall judgment. 
 
10) At present, do you have less hair than usual? (NB. Referring to the 
thickness, not the length) 
‘Just as thick but only 1-1½ cm. It’s growing out now.’ Wears a wig. 
During the interview the patient realises that it is in the past week vs. 
‘normally’. Answered ‘yes’ originally because the hair has become 
thinner with age. 
 
12) Have you had desire for sexual intercourse? 
Is unchanged compared to before. Thinks it is ‘normal’. Will not call 
this ‘Very much’. 
Answers ‘A little’ in a way that it sounds very positive, as something 
totally OK. This is confirmed by the replies to the next questions where 
the answer in 13 is ‘5-6 times’ and in (the deleted item on satisfaction) 
‘very satisfied’. This pattern has been heard a number of times: ‘Very 
satisfied’ with ‘a little’ desire. In other words, in these cases ‘a little’ 
cannot be interpreted negatively. 
 
13) How frequently have you had sexual intercourse? 
‘What is sexual intercourse?’ The patient chose a very strict definition 
when originally answering but was in doubt. 
 
17) How many hours a week have you worked outside your home 
during the last month? 
The patient takes care of other people’s children at home (child min-
der): what is she to answer? Has 49 regular working hours per week. 
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Table B3 
 
Agreement between patients and the observer about responses to the items of the DBCG 89 Questionnaire. Item scores for patients and observer, 
overall agreement (overall), and weighted kappa (kappa) with standard error (SE).  
 
 
 
Mean score  Agreement 
Item 
 Pa-
tients 
Observer  Overall Kappa (SE) 
 
1. Has your mouth or your tongue been sore? 
  
14 
 
* 21 
  
0.80 
 
.77 
 
(.06) 
2. Have you had hot flushes and/or sweats?  44 49  0.78 .92 (.02) 
3. Have you had nausea when thinking of your treatment?  18 20  0.98 .93 (.07) 
4. How satisfied have you been with your appearance?  68 66  0.48 0.51 (.13) 
5. How has your energy been compared to before your breast operation? (1)  3.3 3.2  0.71 0.83 (.06) 
6. Do you have regular menstrual bleedings?  15 13  0.98 0.91 (.08) 
7. Have you had any menstrual bleedings within the last 12 months?  61 61  1.00 1.00 (.00) 
8. Do you have any difficulties holding your water (urine)?  15 16  0.98 0.97 (.03) 
9. Has your weight changed since the breast operation? (2)  34 33  0.93 0.85 (.09) 
10. At present, do you have less hair than usual? 
(NB. Referring to the thickness, not the length.) 
  
19 
 
17 
  
0.91 
 
0.94 
 
(.03) 
11. These days, do you wear a wig?  11 11  1.00 1.00 (.00) 
12. Have you had desire for sexual intercourse?  44 * 38  0.71 0.82 (.04) 
13. How frequently have you had sexual intercourse? (3)  1.39 1.47  0.85 0.93 (.03) 
14. Have you been bothered by vaginal dryness?  14 15  0.84 0.85 (.05) 
15. Have you been bothered by vaginal discharge?  11 14  0.91 0.88 (.05) 
16. Do you have paid employment?  76 76  1.00 1.00 (.00) 
17. How many hours a week have you worked outside your home during the 
last month? 
 
  
20 
 
19 
  
0.76 - 
 
- 
1 Untransformed score; 1=‘Much less’, 4=‘Unchanged’, 7=‘Much greater’ 
2 Per cent reporting weight gain. 
3 Transformed score; 0=‘Have not had sexual intercourse’, 4=‘7 times or more’ 
*) Scores of patients and observer significantly different (p = .03 and p = .02, respectively). 
 
APPENDIX C. HYPOTHESES CONCERNING PAPER VIII 
 
Table C1 
 
Staff members’ (N=36) expectations concerning the comparison of chemotherapy versus ovarian ablation. For each issue, we asked ‘Which group 
does - all things being equal - have the symptom/problem to the largest extent?’ The issues are ranked according to the number of respondents 
expecting more symptomatology in patients receiving chemotherapy. 
 
Issue 
 
Chemotherapy No difference (2) Ovarian ablation 
     
Nausea and vomiting   28 8 0 
Hair loss  23 13 0 
Fatigue   22 12 2 
Reduced ability to work/do household jobs   14 21 0 
Overall physical condition/quality of life impaired (1)  14 20 2 
Financial difficulties due to disease/treatment  10 26 0 
Interference with family life/social activities   10 24 2 
Reduced ability to concentrate and remember things  10 24 2 
Weight gain   10 19 6 
Reduced ‘physical function’ (being able to take a walk, take care of oneself) (1)  9 27 0 
Reduced ‘emotional function’ (anxiety, depression, etc.)   7 25 3 
Impaired sexual life   6 25 4 
Pain  2 33 0 
Dissatisfaction with appearance  2 31 2 
Hot flushes/sweats   1 11 23 
Irregular bleedings/menostasia   1 11 23 
Dyspnea  
 
 0 36 0 
1 Separate issues covered each of the two items in the scale. The figure is the average of the responses to these two issues. 
2 ‘No difference’ means that no difference between treatments was expected. 
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APPENDIX D. GENERAL POPULATION DATA FOR THE DBCG 89 
QUESTIONNAIRE 
 
 
Table D1  
 
Age-stratified mean values (SD) for the DBCG 89 Questionnaire in the general population sample. Only the 12 items that were meaningful in a non-
cancer population were applied. 
 
 
 
30-39 yrs.  
(N=145) 
 
40-49 yrs.  
(N=138) 
 
50-59 yrs.   
(N=141) 
 
60-69 yrs.   
(N=116) 
 
70-75 yrs.   
(N=68) 
 
All 
(N=608) 
 
 
Sore mouth 
 
4 
 
(14) 
 
5 
 
(17) 
 
11 
 
(24) 
 
9 
 
(22) 
 
6 
 
(14) 
 
7 
 
(19) 
Hot flushes 15 (27) 20 (28) 31 (32) 22 (27) 12 (25) 21 (29) 
Satisfied appearance 64 (24) 62 (26) 60 (25) 61 (28) 62 (23) 62 (26) 
Regular bleedings 85 (35) 77 (42) 16 (37) 2 (13) 3 (17) 43 (49) 
Bleedings 94 (23) 84 (37) 28 (45) 3 (16) 2 (12) 49 (50) 
Incontinence 9 (17) 11 (19) 17 (25) 16 (23) 18 (27) 14 (22) 
Sexual interest 54 (27) 56 (28) 38 (28) 23 (27) 14 (24) 41 (31) 
Had sex last month 82 (39) 81 (39) 63 (48) 39 (49) 19 (40) 63 (48) 
Vaginal dryness 5 (16) 5 (15) 16 (28) 21 (34) 9 (20) 11 (24) 
Vaginal discharge 22 (25) 12 (19) 8 (18) 6 (17) 6 (17) 12 (21) 
Employed full time 49 (50) 49 (50) 37 (49) 11 (31) 0 (0) 34 (47) 
Employed 
 
74 (44) 77 (42) 71 (46) 18 (38) 5 (21) 56 (50) 
